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IDENTIFICATION AND MOLECULAR ANALYSIS OF DNA IN 
EXOSOMES 
 
Jena Tavormina, Sc.B. 
Advisory Professor: Raghu Kalluri, M.D., Ph.D. 
 
 Exosomes are heterogeneous nanoparticles 50-150nm in diameter. Exosomes 
contain many functional cargo components, such as protein, DNA, and RNA. While 
protein and RNA exosome content has been extensively studied, very little work has 
been done to characterize exosomal DNA. Here, we demonstrate that exosomal DNA 
is heterogeneous and its packaging into exosomes is dependent on the cell of origin. 
Furthermore, through a rigorous assessment of various isolation methods, we identify 
Size Exclusion Chromatography (SEC) as the best method for the isolation of 
exosomal DNA for downstream applications. Additionally, we evaluate the methylation 
status of exosomal DNA and demonstrate that exosomal DNA is both methylated and 
fully recapitulates the methylation patterns observed in the cells of origin. We also 
propose a potential mechanism for DNA packaging into exosomes by disruption of the 
nuclear membrane. Finally, we investigated the ability of exosomes to induce 
paracrine DNA damage responses (DDR) in treatment-naïve cells. We explore the 
specificity of exosome-induced DDR to exosomes released by damaged cancer cells, 
and provide a potential molecular mechanism of action via the shuttling of activated 
DDR pathway proteins.  
vi 
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Biogenesis, Characteristics, and Functions of Exosomes 
Early Exosome Discovery and Overview 
 The initial identification of the class of nanoparticles now known as exosomes 
occurred almost 40 years ago. While there were earlier accounts of small vesicles 
secreted from certain cell types, such as chondrocytes1,2 and platelets3, the term 
‘exosome’ was not used until Trams et al. published the first account of membrane 
particles isolated from biological fluid in 19814. Their landmark paper was the first to 
state that exosomes could come from a wide variety of cell types, including both 
normal and neoplastic, as part of a general biological process that could preferentially 
sort cargo for packaging and transfer it to recipient cells4. Thus, this was the first 
suggestion of the potential of exosomes for intercellular signaling and, further, for their 
use as therapeutic delivery vehicles.  
Two years later, in 1983, two seminal papers were published that served as the 
true foundation for the field of exosome research. Both investigated transferrin 
receptors in reticulocytes, and showed that the receptors were released from cells via 
vesicles5,6. Additionally the first of those papers, published by Harding and Stahl, 
showed for the first time that multivesicular endosomes, or MVEs, contained small 
vesicles that were then ejected into the extracellular environment upon fusion with the 
plasma membrane, becoming the first study to demonstrate the general mechanism 
of exosome release5. At the time, late endosomes were only thought to be pre-
degradative compartments, with their contents designated specifically for lysosomal 
degradation. Therefore, the discovery that certain late endosomes could fuse with the 
cellular membrane and release contents was quite controversial, since most believed 
2 
 3 
that any vesicles retrieved by ultracentrifugation were membrane components of dying 
cells in culture. More recently, electron microscopy has been used to demonstrate 
membrane fusion events between late endosomes and the plasma membranes of 
living cells7,8, validating the initial findings. The name exosome was officially linked 
specifically to 40-100nm nanoparticles released via MVE fusion in Rose Johnstone’s 
1987 paper, which further characterized the release pathway as being distinct from 
cellular stress responses9.  
In the decades since exosomes were first identified the field has rapidly 
expanded, generating a massive amount of data regarding the characterization, 
functions, and applications of exosomes. Exosomes are now known to be released 
from virtually every cell type, including but not limited to immune cells7,8, neurons10,11, 
stem cells12,13, and cancer cells14–16. Exosomes have also been found to be released 
by prokaryotes and eukaryotes in addition to mammalian cells17,18. Importantly, 
especially for clinical applications, exosomes have been isolated from a wide variety 
of biological fluids, such as serum19,20, urine21, breast milk22, amniotic fluid23, saliva24, 
semen25, and cerebrospinal fluid26. The therapeutic applications of these bodily fluid-
derived exosomes are still being explored, but the potential for diagnostic and 
therapeutic implementations of exosomes for many different diseases is enormous.  
Beginning with the groundbreaking study published by Raposo et al. in 1996, 
in which it was shown that exosomes could induce adaptive immune responses by 
acting as antigen presenting vesicles via MHC class II complexes present on their 
membranes8, exosomes have been demonstrated to have a wide variety of functions. 
In addition to their roles in immunity, exosomes have also been implicated in cellular 
 4 
signaling and biological processes, under both normal physiological and pathological 
conditions. It is these functional characteristics of exosomes that drive much of the 
research in the field today, on a breadth of topics including stem cell maintenance12, 
tissue repair27, neuronal synaptic responses28, or most relevant for this work, 
tumorigenesis29–32, among others. In addition to cancer, exosomes have been linked 
to a variety of other diseases, including HIV33, Alzheimer’s34, and Parkinson’s 
disease35, and are under investigation for both diagnostic and therapeutic 
applications. 
As exosome research has become more widespread, many advances have 
been made regarding their isolation and identification. There are now many different 
exosome isolation methods, which differ in efficacy depending on the desired 
downstream application. These methods will be discussed in greater detail 
subsequently. In parallel with the development of improved exosome isolation 
techniques, exosome-specific markers have also been identified since exosomes can 
now be obtained with greater purity. The most commonly used exosome markers are 
known as tetraspanins, transmembrane proteins with a variety of functions including 
cell adhesion, motility, and membrane fusion36. The first tetraspanin to be identified 
as specifically associated with exosomes was CD9, which was discovered by Théry 
et al. in the exosome pellets of dendritic cells in 19997. Since then, CD63 and CD81 
have most often been cited as the most classical markers of exosomes37,38, however 
there has been evidence of other classes of microvesicles containing some of the 
same tetraspanins, likely due to the wide distribution of tetraspanin expression 
throughout the plasma membrane39. Therefore, tetraspanins are necessary but no 
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longer sufficient to precisely identify exosomes, and other markers have been 
identified to supplement tetraspanin expression, such as flotillin, TSG101, integrins, 
lactadherin, and RAB5/RAB740,41. Additionally, exosomes are characterized by the 
absence of certain markers, such as calnexin, GM130, and cytochrome C, to indicate 
they are not apoptotic bodies42. 
Finally, exosomes have been shown to have heterogenous and diverse cargo 
components that generally reflect the cell of origin and have a variety of functions and 
potential uses. While these will later be described in more detail, what follows is a brief 
description of some of the major categories of exosome contents. Perhaps the most 
commonly studied class of exosome cargo is protein. Many proteins have been 
identified either on the membranes of exosomes, such as the aforementioned 
tetraspanins36, or encapsulated within them40,43. Many species of RNAs have also 
been demonstrated to be carried by exosomes, including mRNA, miRNA, tRNA, and 
rRNA, YRNA, and Vault RNA30,43–45. Another important nucleic acid, DNA, is also 
present in exosomes and was first identified (in double-stranded form) as an exosomal 
cargo component by the Kalluri laboratory in 201446. That finding was swiftly 
corroborated by other groups, and ssDNA and mtDNA have also been shown in 
exosomes11,47–49. These studies set the early foundation for much of the work done in 
this project. Other exosomal cargo components include lipids, cytoskeleton 
components, and enzymes40,43,44,50. A growing area of interest of therapeutic 
relevance is the loading of exosomes with specific cargo for delivery to target cells. 
One example of this was work done in our lab that utilized exosomes to deliver siRNA 
targeting oncogenic KRASG12D to pancreatic ductal adenocarcinoma (PDAC) tumors 
 6 
in mice, resulting in extensive tumor burden reduction and suppression of KRASG12D 
expression51. This work is now in clinical trial, and many other studies involving 
exosomes as therapy delivery vehicles are ongoing. 
 
 
 
Figure 1. Exosome Components. 
Exosomes contain heterogenous cargo components, which can include RNA, DNA 
and both intraluminal and membrane proteins. 
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Mechanism of Exosome Biogenesis 
     Since Harding and Stahl first observed exosome release via MVE fusion 
with the cellular membrane5, much has been discovered regarding the biological 
processes of exosome biogenesis and release. Generally speaking, the pathway 
involves multivesicular bodies containing intraluminal vesicles, or exosomes, forming 
and subsequently fusing with the plasma membrane of the cell of origin, releasing the 
exosomes into the intercellular space52. Exosome biogenesis is comprised of three 
major stages, the formation of endocytic vesicles, multi-vesicular body (MVB) 
generation via the inward budding of the endosomal membrane to form intraluminal 
vesicles (ILVs), and the fusion of MVBs with the parent cell’s plasma membrane with 
resultant exosome release50. While many of the proteins and molecules involved in 
the biogenesis and release of exosomes have been identified, due to technical 
limitations there is still a lack of clarity regarding the roles of certain molecules at each 
step. There is also conflicting information regarding which molecules are important for 
exosome biogenesis, possibly due to factors such as choice of isolation method or 
cell type-specific dependencies. Additionally, since much of the exosome biogenesis 
pathway has only recently been defined, there are likely still components that have 
not yet been described.  
   Exosome formation begins with the maturation of early endosomes into late 
endosomes. During the maturation process, the endosomal membrane invaginates 
and forms ILVs within the lumen of the endosome, forming an MVB53. The ESCRT 
complex machinery, a collection of about 30 proteins assembled into 4 complexes50, 
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is integral to this process. The ESCRT-0 complex recognizes and traps ubiquitinated 
transmembrane proteins in the endosomal membrane, while the ESCRT I & II 
complexes are involved in membrane deformation and the formation of buds with 
sorted cargo54. The ESCRT III complex is responsible for separating the newly formed 
vesicles from the membrane54. Several distinct ESCRT proteins have been clearly 
demonstrated to be important for the successful secretion of exosomes, namely Hrs, 
TSG101, and STAM155. Additionally, the related protein ALIX has been implicated in 
the loading of cargo and selection of MVBs for maturation and secretion55.  
The ESCRT proteins (ESCRTs) may not be completely necessary for exosome 
release, as silencing key subunits of all 4 ESCRT complexes does not entirely 
eliminate the formation of ILVs56. Tetraspanins, specifically CD9, CD82, Tspan8, and 
CD63, have been implicated in ESCRT-independent exosome release57–59, as has the 
lysosome/late endosome associated protein SIMPLE60. Lipids have also been shown 
to work together with these proteins as important actors in vesicular formation and 
transport processes such as membrane curvature, invagination, fission and fusion61. 
The role of lipids in exosome formation is supported by studies targeting lipid 
modifying enzymes, such as the inhibition of sphingomyelinase 2 (nSMase2) which 
has been shown to reduce exosome release, potentially due to the subsequent lack 
of formation of ceramide microdomains that cause membrane budding to occur62. 
Other lipid modifying enzymes, such as phospholipase D2 (PLD2) and diacylglycerol 
kinase α (DGKα), have also been identified as having a role in regulating ILV formation 
in exosome biogenesis63,64. The maturation of endosomes into MVBs is likely to rely 
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on these different components either separately or combined based on the conditions 
present in a given cell type and microenvironment65.    
Once an endosome has matured into an MVB, it will either be targeted to 
lysosomes, which results in the degradation of its contents, or transported to the 
plasma membrane of the cell for fusion and release. How MVBs are designated for 
either degradation or secretion remains a mystery, but some groups have identified a 
few potential markers, such as post-translational modifications66. If an MVB avoids 
degradation, it must physically move through the cytosol to the plasma membrane. 
This process is mediated by MVB interactions with cytoskeletal components of the 
cell, namely actin and microtubules67,68. Additionally, the Rab GTPase family is known 
to be involved in several steps of the membrane trafficking process, including budding, 
transport along actin and tubulin, and membrane fusion. Several of these Rab 
GTPases have been implicated specifically in the exosome biogenesis pathway, such 
as Rab11, Rab35, and Rab27a/b, which have been the most characterized69,70. Other 
small GTPases may also be involved in exosome release, such as the RhoGTPase 
citron kinase71. It is worth mentioning that while all of these molecules have been 
implicated in exosome release, some studies have shown that their involvement may 
be dependent on cell type72–74, meaning there is likely at least some degree of 
functional redundancy in the MVB trafficking pathway. Additionally, the high likelihood 
that there are as-yet unidentified additional molecules involved in the process 
demonstrates the need for further clarity regarding the MVB-to-membrane transport 
mechanisms. 
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Once the MVBs arrive at the plasma membrane, several steps must occur to 
achieve proper membrane fusion and exosome release. Multiple proteins have been 
identified as fusion facilitators, in addition to providing docking specificity. Chief among 
these are the soluble N-ethylmaleimide-sensitive factor attachment protein receptors 
(SNAREs), as well as tethering factors, Rabs, and select other Ras GTPases75. 
SNAREs have been shown to enable vesicles to fuse with specific target membranes, 
either the plasma membrane of the cell or the membrane of another organelle76. The 
SNARE family is split into two classes, R-SNAREs and Q-SNAREs, and fusion usually 
requires one R-SNARE and three Q-SNAREs to form a complex which then enables 
the MVB to dock at the plasma membrane75. SNAREs act together with Rab GTPases 
and tethering factors to complete vesicle targeting and fusion with high efficiency77. It 
is thought that Rab GTPases present on the surface of vesicles recruit the cytosolic 
tethers to their membranes, which work in concert with tethers and SNARE complexes 
on the target membrane to achieve fusion75. The precise mechanisms of this process 
remain an active field of study. 
Exosome release has been shown to be at least somewhat dependent on the 
cellular microenvironment and relies on several aspects of cellular homeostasis. It has 
been reported that cells under stress release more exosomes in a variety of contexts, 
though the exact mechanisms are not always clear. For example, dying or senescent 
cells were shown to secrete exosomes at a higher rate when compared with healthy 
cells78,79. Additionally, cells subjected to DNA damaging agents and hypoxia were also 
observed to release more exosomes80,81. While the exact purpose(s) of increased 
exosome release in the context of stress remain unclear, it has been proposed that 
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this could be a mechanism of releasing waste products detrimental to the cells or as 
a means of sending a stress signal to neighboring cells as a form of intercellular 
communication82.  
Exosome Cargo 
 The functions of exosomes are all mediated by the biological components 
contained either within or on exosomes. Exosomes have been shown to contain 
heterogeneous and diverse cargo, which is largely dependent on the cell type of origin 
as well as the microenvironmental conditions at the time of release. The mechanisms 
of exosome packaging and cargo sorting remain unclear, but some progress has been 
made in identifying mediators that determine what is loaded into exosomes during 
biogenesis83,84. More substantial work has been done on identifying and 
characterizing the molecules within exosomes, which include lipids, proteins, and 
nucleic acids such as RNA and DNA40.  
 Lipids have not only been identified as exosome cargo, but also form the 
exosomal membrane. The outer membrane of exosomes consists of a lipid bilayer, 
similar to the plasma membrane of cells44. Compared with cells, exosome membranes 
have been shown to be enriched in cholesterol, sphingomyelin, gangliosides, and 
desaturated lipids, while they have less phosphatidylcholine and diacylglycerol85,86. 
Exosomes have demonstrated an increased amount of phosphatidylserine on the 
outer leaflet of their membranes, which has been proposed to aid their uptake by 
recipient cells87. The increased rigidity of exosome membranes in comparison with 
cell membranes, due to their high levels of sphingomyelin, cholesterol, and 
desaturated lipids, has been correlated with their resistance to degradation and 
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stability, a key feature of exosomes as carriers of protected cargo88. Exosomes also 
contain lipid metabolism enzymes, such as phospholipases A2 and D89, as well as 
enzymes necessary for lipogenesis, including fatty acid synthase, palmitate and 
stearate90,91. Finally, exosomes can also transport bioactive lipids to recipient cells, 
such as arachidonic acid, prostaglandin E2, ceramide, and phosphatidic acid86,89.  
 The protein content of exosomes is quite diverse and is perhaps the most well-
studied exosomal cargo component. Exosome protein can vary widely depending on 
cell type and biological context. There are two major categories of exosomal proteins, 
those present on the membrane and those encapsulated within the lumen. Proteins 
present on exosome membranes include major histocompatibility complex class II 
(MHC class II) and tetraspanins (most commonly CD9, CD81, and CD63)40,92,93. 
Exosomes also contain several proteins required for MVB biogenesis and release, 
including the ESCRT proteins, Alix, TSG101, integrins, and chaperones such as 
Hcs70 and Hsp9094. Since these proteins are involved in the general process of 
exosome formation, they are often used as exosome-specific markers to indicate 
vesicle purity after isolation. The protein content of exosomes, which can include 
receptors, transcription factors, and enzymes, is often functional and can have marked 
effects on recipient cells after uptake44. For example, glioblastoma cells could 
successfully transport the oncogenic variant of epidermal growth factor (EGFRvIII) via 
exosomes to activate the MAPK/Akt proliferation cascade in neighboring glioma 
cells95. Overall, exosomal proteins are important mediators of intercellular signaling 
processes. 
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 Almost every known species of RNA has been found within exosomes. As 
expected, mRNA and miRNA were the first to be characterized14,96, but subsequent 
studies have demonstrated the presence of rRNA, tRNA, siRNA, snoRNA, scRNA, 
snRNA, lncRNA, and piRNA97,98. RNA species found in exosomes are usually smaller 
in size than those found in cellular fractions, which is logical due to the small size of 
nanoparticles98. The concentration of RNA in exosomes has been found to vary based 
on the cell of origin, for instance several types of cancer cell exosomes have been 
shown to contain significantly more RNA than normal cells49. Of note, while exosomal 
RNA does to a large degree reflect the RNA profile of the cell of origin, some RNAs 
have been observed to be enriched in exosomes14,96. Due to the enrichment of certain 
RNA species in exosomes, there have been some investigations into potential 
selective exosomal RNA packaging mechanisms99–101. Several studies have 
implicated exosomes in the transfer of functional RNA to recipient cells. Recipient cell 
translation assays have shown that mRNAs delivered by exosomes can be 
successfully translated14,96,102. Additionally, microRNAs carried by exosomes could be 
involved in the regulation of mRNA translation in recipient cells103,104. Finally, 
advances in therapeutic applications of exosomes have led to the development of 
exosomes loaded with specific RNA species for targeted treatment. In a major study, 
Kamerkar et al. generated “iExosomes,” which contained siRNA specific to the 
oncogenic KRAS variant KRASG12D. Treatment with the engineered iExosomes 
suppressed tumors in pancreatic cancer mouse models and demonstrated a specific, 
targeted approach for effective cancer therapy51. These observations demonstrate 
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that exosomal RNA has functional consequences in recipient cells, and that it could 
potentially be utilized as targeted therapy for previously difficult to treat diseases.  
 Easily the least characterized of the major exosomal cargo components, DNA 
is also possibly the molecule with the most diagnostic and therapeutic potential. 
Guescini et al. first reported the presence of mitochondrial DNA species within 
exosomes in 201011, followed a year later by Balaj et al.’s discovery of single stranded 
DNA in human and mouse glioblastoma exosomes49. Our laboratory was the first to 
identify double-stranded DNA species in exosomes using PDAC patient serum 
samples as well as immortalized cell lines46. Results from this study also determined 
that when pooled, the exosomal DNA was able to be sequenced and spanned the 
entire genome, and it also reflected the mutational status of the patient tumor or cells 
of origin46. This study was the first to implicate the diagnostic potential of exosomes 
isolated from patient body fluids for DNA-based mutational characterization, 
diagnostics, and treatment monitoring, but a handful of others have since corroborated 
those findings47,105–107. Since the membranes of exosomes prevent their contents from 
degrading, exosomal DNA is protected from endogenous DNase activity that affects 
other extracellular biomarkers such as circulating cell-free DNA, for example. 
Evidence supporting this notion is seen in the relatively large fragment sizes of DNA 
that are able to be isolated from exosomes, and their ability to be reliably sequenced46. 
Accordingly, other groups showed reliable detection of BRAF and EGFR mutations in 
melanoma-derived exosomes47. 
 There are still many mysteries surrounding exosomal DNA that remain to be 
resolved. The relative scarcity of exosome DNA-related studies has contributed to the 
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slow accumulation of information regarding the origin, packaging, and function of 
exosomal DNA. A study by Takahashi et al. proposed that exosomal DNA may serve 
as a mechanism of cellular homeostasis by removing ectopic DNA fragments from the 
cytoplasm and preventing the activation of the cytosolic DNA-sensing stimulator of 
interferon genes (STING) pathway108. Work from Kitai et al. also showed that 
topotecan treatment significantly increased exosomal DNA production and led to 
dendritic cell activation through the STING pathway in breast cancer cells109. Another 
group proposed an entirely different role for exosome DNA, demonstrating that it could 
be delivered to recipient cells, localized to the nucleus, and was potentially 
transcribed110,111. Indeed, horizontal transfer of DNA via exosomes has been shown 
in model organisms112, and altered phenotypes in recipient cells have been attributed 
to the delivery of exosomal DNA48,113. These studies demonstrate that while some 
progress has been made in terms of the characterization of exosome DNA, much 
remains to be discovered. The limited amount of information available regarding 
exosomal DNA, especially in comparison with the other exosome cargo components, 
reveals a fundamentally broad lack of understanding in the field.   
Biological Functions of Exosomes 
 Exosomes are diverse, heterogeneous nanoparticles which have been 
implicated in a variety of biological processes. The function and cargo of exosomes 
depends on the status and type of the cell of origin, as they have been shown to be 
released from virtually all cell types during both normal physiological conditions and 
at times of stress. Initially, exosomes were thought to be purely waste removal 
vehicles with no additional biological activity or relevance40. However in the years 
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since the first exosomes were isolated, they have been demonstrated to have 
important roles in a wide variety of biological applications, serving as carriers of 
intercellular signals via their diverse cargo. Exosomes can successfully transfer 
proteins, enzymes, lipids, RNA, and even DNA to recipient cells both locally and 
systemically, and therefore are involved in many physiological and pathological 
processes65.    
 The first indication that exosomes could perform distinct biological functions 
came from the seminal study by Raposo et al., which showed that B cell exosomes 
could present MHC class II peptide complexes to T cells and induce an immune 
response8. Subsequently, it has been discovered that exosomes have a variety of 
immunomodulatory functions. Dendritic cells, for example, were also found to release 
T-cell activating exosomes that were so effective they could reduce tumor burdens in 
mice7,114. Surface bound macrophage-derived exosomes have also been shown to 
have the ability to present antigens to T cells115. Additionally, there is even evidence 
that exosomes released by immune cells can mediate antigen presentation, inducing 
immune responses on their own116. Conversely, regulatory immune cells (Tregs) also 
release exosomes that are able to decrease immunogenicity by preventing CD4+ T 
cells from activation and inducing tolerogenic dendritic cells117,118. The 
immunosuppressive abilities of Treg exosomes have been attributed to a variety of 
transported cargo, including miRNAs, chemokines, and interleukins117. Exosomes 
from immunosuppressive mesenchymal stem cells (MSCs) have been observed to 
inhibit macrophage responsiveness by causing impaired recognition of Toll-Like 
Receptors (TLRs)119, and have also been shown to promote Treg differentiation120. 
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Furthermore, exosomes have been observed to facilitate cytokine delivery at immune 
synapses between T cells and antigen presenting cells (APCs), serving to propagate 
immunomodulatory signals between cell types121. Exosomes have many established 
roles in immune response signaling, with more to be discovered. Current research 
seeks to further clarify the roles of exosomes in immune signaling, as well as explore 
their potential utility for immunotherapy applications.      
 In addition to their abilities to activate or suppress immune cells, exosomes 
have become known as potent mediators of inflammation. Circulating exosomes 
demonstrate the ability to induce the release of several pro-inflammatory cytokines, 
such as interleukin 6 (IL-6), tumor necrosis factor alpha (TNFα) and chemokine C-C 
motif ligand 2 (CCL2)122. Exosomes have also been implicated in the pro-inflammatory 
processes of several diseases, including cancer123, inflammatory bowel disease124, 
diabetes125, obesity126, and rheumatoid arthritis127. The mediation of 
neuroinflammation in several neurodegenerative diseases, including Alzheimer’s and 
Parkinson’s, has also been linked to exosomes containing factors such as α-
synuclein, amyloid β, and prions128. Work investigating the exosomes released during 
the pathogenesis of chronic inflammatory states includes attempts to identify novel 
exosome-associated biomarkers that could be used for diagnosis and treatment 
monitoring of inflammation-mediated diseases129.  
 Another biological function linked to exosomes is apoptosis, an important 
process for both healthy and diseased cells involving programmed cell death. It has 
been well established that dying cells release large microvesicles, called apoptotic 
bodies, that can be up to several microns in diameter130. More recently, the smaller 
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microvesicle population of exosomes has also been associated with apoptosis-related 
signaling and functions. Stromal cell-derived exosomes, for instance, have been 
observed to release anti-apoptotic signals to support the survival of neighboring tumor 
cells131. Additionally, cardiac progenitor cells (CPCs) can release exosomes that 
protect cardiomyocytes from oxidative stress by preventing ischemia- and 
reperfusion-induced apoptosis132. Placental cells of the syncytiotrophoblast 
constitutively release exosomes into the bloodstream that inhibit the function of the 
maternal immune system and promote fetal survival through their high levels of pro-
apoptotic molecules such as Fas ligand (FasL), TRAIL, and PD-L1133. Cancer cell-
derived exosomes have also exhibited immunosuppressive and pro-tumorigenic 
capabilities through the induction of T cell apoptosis via delivery of FasL134. The ability 
of exosomes to mediate both pro- and anti-apoptotic cell fates demonstrates their 
importance as a mechanism of maintaining cellular homeostasis, the disruption of 
which can lead to pathogenic consequences. 
 In addition to apoptosis, exosomes are also involved in signaling pathways 
related to cell proliferation. Exosomes have been shown to induce proliferation in a 
variety of cell types, including T cells8, stem cells135, and especially cancer 
cells95,136,137. The capability of exosomes to help promote and sustain proliferative 
signaling is the subject of intensive study in the cancer biology field. Modulation of 
exosome proliferative signaling, whether through the inhibition of exosome release or 
the manipulation of their cargo, is a potential therapeutic avenue for the inhibition of 
tumorigenesis138. Additionally, some groups have investigated the potential utility of 
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exosome proliferative signaling for stem cell regeneration139,140. Thus, cell proliferation 
signaling is one of the most therapeutically relevant biological functions of exosomes. 
 Another similar function of exosomes is the mediation of angiogenesis, or the 
formation of new capillaries from existing blood vessels141. T lymphocytes, which 
closely interact with vascular endothelial cells during circulation and trans-endothelial 
migration, have demonstrated the ability to alter VEGF signaling and tube formation 
through exosomes142. Trophoblast cells generate extracellular matrix 
metalloproteinase inducer (EMMPRIN)-containing exosomes that have been 
implicated in placental angiogenesis and remodeling143,144. Additionally, exosomes 
isolated from mesenchymal stem cells (MSCs) have been shown to enhance 
angiogenesis during skin repair after severe burns145. The bulk of the research done 
on exosome-mediated angiogenesis, however, has occurred in cancer-related 
contexts, as one of the hallmarks of cancer is the aberrant formation of new 
vasculature to provide nutrients to growing tumors146,147. For example, it has been 
shown that cancer cell derived exosomes taken up by endothelial cells promote 
angiogenesis via induction of the pro-angiogenic secretome32,148. Additionally, 
melanoma cell exosomes have been found to promote metastasis by recruiting 
circulating melanoma cells to the endothelium, while simultaneously releasing pro-
angiogenic and extracellular matrix remodeling factors to encourage tumor 
formation149. Tumor exosomes were also shown to transfer activated EGFR to 
endothelial cells, leading to the induction of VEGF expression and subsequent 
stimulation of angiogenesis15. Exosomes derived from cancer cells have also 
demonstrated the ability to impair the structural integrity of endothelial cells by 
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downregulating tight junction proteins such as ZO-1, enhancing vascular permeability 
and thereby facilitating metastasis150. Since angiogenesis is so closely associated with 
various pro-tumorigenic and metastatic mechanisms, such as proliferation, migration, 
and extravasation151, the influence of exosome-mediated signaling on angiogenic 
processes are being investigated as potential avenues for therapeutic intervention 
against metastatic dissemination and tumor formation.  
 There is substantial evidence for the importance of exosomes in a wide variety 
of biological functions. The roles of exosomes described here, while extensive, are by 
no means completely comprehensive. Exosomes are beginning to be implicated in 
even more areas, such as DNA damage response152 and metabolism153. These 
diverse capabilities underscore the importance of exosomes in virtually all biological 
signaling pathways and highlight the vast potential for the development of exosome-
based therapeutics.   
Exosomes in Cancer 
 Exosomes have been implicated in several processes associated with tumor 
progression and metastasis, and cancer-related research is a major field of exosome 
work, due to the enormous potential for exosomes in diagnostics and 
therapeutics154,155. Since exosomes are so readily available in easily accessible 
biofluids such as serum and urine, they have been investigated for their utility for liquid 
biopsy23,156. Exosome release has been shown to be upregulated in several cancer 
types, including breast, ovarian, and pancreatic cancer157,158. Thus far, relatively few 
cancer exosome-specific markers have been identified, with notable exceptions being 
the glypican-1 (GPC-1) molecule in breast cancer cell lines158, MET in melanoma32, 
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and macrophage migration inhibitory factor (MIF) in pancreatic cancer159. Strides have 
been made, however, in utilizing the cargo of exosomes, specifically RNA and DNA, 
to detect oncogenic variations in patients. Since the work done initially by our lab 
demonstrated that exosomal DNA can be sequenced and faithfully recapitulates the 
mutational landscape of the cell of origin46, several studies have utilized similar 
techniques to identify markers of disease. A few RNA species contained in exosomes 
have been identified as potential biomarkers, such as the mRNA for oncogenic 
EGFRvIII in glioblastoma137 and miR-21 in esophageal squamous cell carcinoma 
patients160. Additionally, the levels of miR-141 isolated from the exosomes of prostate 
cancer patients were able to be used to accurately distinguish between patients with 
metastatic vs. localized disease161. Perhaps even more promising is the use of 
exosomal DNA to identify cancer-specific mutations. We recently published a study in 
which we were able to successfully identify mutant KRAS and TP53 in PDAC patient 
serum exosomes162. Additionally, we were able to distinguish between PDAC patients, 
healthy donors, and chronic pancreatitis patients based on the mutations detected 
using exosomal DNA162. Other studies have demonstrated similar findings using 
serum-derived exosomes47,106, and exosomal DNA is beginning to be investigated 
further as a means of early diagnosis for a variety of cancers.   
 Beyond their use as potential biomarkers, exosomes have been demonstrated 
to perform several functional roles in tumor progression. As previously mentioned, 
exosomes have many roles in the regulation of adaptive immunity. Immunogenic 
activity has also been identified for exosomes in both pro- and anti-tumorigenic 
contexts. For example, tumor-derived exosomes could possibly serve as a source of 
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tumor antigens for presentation to activated T cells163–165. Additionally, cancer 
exosomes have been observed to activate NK cells through the presentation of 
HSP70166. Subcapsular lymph node macrophages have also been observed to absorb 
tumor-derived exosomes, preventing them from interacting with pro-tumorigenic B 
cells and thus limiting tumor progression167. On the other hand, exosomes have also 
been implicated in tumor immune evasion. Exosomes can inhibit dendritic cell 
maturation by inducing IL-6 expression in dendritic precursors168. Additionally, cancer 
cell-derived exosomes demonstrate the ability to inhibit NK cell proliferation and 
cytotoxic function169, induce T cell apoptosis via FasL134, and suppress T cell receptor 
(TCR) activity170,171. TGFβ1 carried by tumor exosomes has also been shown to 
induce Tregs172. Finally, exosomes from primary glioblastoma cells were shown to 
influence monocyte-to-macrophage differentiation to promote a tumor-supportive 
phenotype in vitro173. Combined, these findings illustrate the multifaceted behavior of 
exosomes in tumor-related immune responses. Once a more comprehensive 
understanding of the immunomodulatory functions of exosomes in cancer is 
established, they may become useful in immunotherapy applications. Indeed, some 
clinical trials have already begun incorporating exosomes as treatments to activate 
antitumor immune responses174. 
 Exosomes also induce pathological angiogenesis in many cancers. As cancer 
progression occurs, tumors outgrow the existing vascular network, generating hypoxic 
regions, which in turn leads to the release of neovascularization-stimulating factors 
packaged in exosomes.  Endothelial cell uptake of cancer-derived exosomes has 
been shown to promote angiogenesis and new blood vessel formation15,175–177. 
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Exosomes released from hypoxic tumors have also been demonstrated to increase 
activation of the ERK1/2 MAPK, PI3K/AKT, and FAK pathways in recipient endothelial 
cells, leading to increased endothelial cell sprouting148. In addition to endothelial cell 
proliferation and new tube formation, cancer cell exosomes may also promote 
vascular remodeling through the manipulation of blood vessel wall permeability, 
facilitating metastasis. Melanoma exosomes have been observed to induce vascular 
leakiness at sites of metastasis32, and the delivery of exosomal miR-105 to endothelial 
cells downregulates ZO-1, a tight junction protein, enabling vessel permeabilization 
and metastatic dissemination150.  
 Cancer cell-derived exosomes can also mediate signaling between tumors and 
cells in the surrounding microenvironment. Notably, cancer exosomes show the ability 
to activate fibroblasts to generate a more tumor-permissive state178. The stimulation 
of cancer-associated fibroblasts (CAFs) by tumor exosomes promotes the acquisition 
of pro-tumorigenic properties, such as the induction of myofibroblast-like phenotypes 
in mesenchymal stem cells179 and myofibroblast differentiation180. Myofibroblasts are 
activated fibroblasts that express alpha smooth muscle actin (α -SMA) and are much 
more abundant in tumor microenvironments than in normal tissues, so their presence 
is generally indicative of a pro-tumorigenic environment. CAF-derived exosomes have 
also been discovered to have pro-tumorigenic properties, as they have been 
implicated in mediating therapy resistance in cancer cells181,182. Exosomes could also 
play a role in tumor-driven extracellular matrix (ECM) remodeling in the tumor 
microenvironment, as they have been associated with enhanced motility and 
invasiveness through their ability to bind to individual ECM components and propagate 
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protease-mediated degradation of ECM components such as collagen and 
fibronectin91,183. 
 Tumor-derived exosomes are involved in a number of metastasis-promoting 
functions beyond those previously mentioned for angiogenesis and tissue remodeling. 
Since exosomes are capable of traveling systemically throughout the body, it has been 
proposed that they may have the ability to ‘prime’ pre-metastatic niches at distant sites 
and enable the recruitment and successful colonization of new tumors. David Lyden’s 
group has published several studies indicating exosome-mediated initiation of pre-
metastatic niches in several cancer types, including melanoma, pancreatic cancer, 
and breast cancer32,159,184. Additionally, they demonstrated through the use of cell 
lines with preferential tropism for certain metastatic sites that exosomes isolated from 
each line, when injected in vivo, would fuse preferentially with cells at their predicted 
destinations, providing evidence for exosomes serving as organotropic mediators of 
pre-metastatic niche formation184. Exosomes have also been shown to enhance the 
invasion and colonization capacities of tumor cells themselves, acting through delivery 
of cargo components such as miR-200185 and Wnt11186. The inhibition of exosome 
secretion in vivo was also shown to decrease the speed and directionality of cancer 
cell migration in chick embryos187, highlighting the importance of exosome-mediated 
signaling for cell motility. Exosome transfer from highly invasive cells to less malignant 
recipients also led to the increased migration of recipient cells in mouse xenografts at 
both local and distant sites155. Finally, exosomes have been shown to be capable of 
inducing an epithelial-to-mesenchymal transition (EMT) in target cells, facilitating 
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migration188. Exosomes have clearly been shown to have the capacity to influence 
metastasis through a variety of different biological pathways and processes.  
 Lastly, exosomes have repeatedly been shown to contribute to tumor growth 
and progression. Exosomes from non-tumorigenic cells can be co-opted into tumor 
supporting roles; for instance, exosomes derived from astrocytes have been 
demonstrated to support tumor growth for brain metastases by targeting the tumor 
suppressor PTEN with miR-19a189. Exosomes can also serve as a delivery vehicle for 
the oncogenic variant of the epidermal growth factor receptor (EGFR), known as 
EGFRvIII, as seen in glioma cells, leading to enhanced proliferation95. Glioblastoma 
exosomes were similarly discovered to contain RNA and proteins that promote tumor 
growth upon their delivery to recipient cells137. Additionally, ovarian carcinoma derived 
exosomes enhanced tumor growth when delivered to tumor-bearing mice136.  
Exosome involvement in cancer initiation, growth, migration, and survival has been 
definitively demonstrated in a variety of organisms and tumor types, which implies that 
exosomes are not only integral to cancer signaling and survival but may also serve as 
potent mediators for therapeutic interventions. 
Diagnostic and Therapeutic Applications of Exosomes 
 Since exosomes are released by virtually all cell types and are also involved in 
the progression of many different diseases, it stands to reason that they would be the 
subject of great interest for the development of therapeutics. Naturally, many research 
groups and biotechnology firms have worked on developing exosome-based 
diagnostics and treatments. Described here are some of the major clinical applications 
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of exosomes for disease intervention, including their use as biomarkers, therapeutic 
targets, and therapeutic agents. 
 Due to their heterogeneous cargo that has been shown to reflect characteristics 
of their cells of origin, exosomes have repeatedly been investigated as biomarkers for 
disease diagnosis, progression, and treatment response. Since large quantities of 
exosomes are present in biofluids, they have the advantage of being a sensitive and 
relatively non-invasive method to detect tumors and other indicators of disease. 
Cancer exosomes in particular have been demonstrated to be useful for the detection 
of many types of tumors, including prostate, breast, ovarian, glioblastoma, and 
melanoma137,190–193. Our lab demonstrated the utility of exosomal DNA for the 
detection of cancer-specific mutations from PDAC patient serum158,162, work that was 
later validated by others105–107. Additionally, exosomal RNA species have been 
identified as viable cancer progression markers104. Exosomes have been useful 
biomarkers for other diseases as well. Exosomes contain misfolded proteins 
associated with neurodegenerative disorders, and the detection of β-amyloid 42 and 
tau proteins in Alzheimer’s patients was possible in cerebrospinal fluid exosomes at 
an early stage of the disease194,195. Exosomes isolated from urine have also been 
shown to indicate various types of kidney disease, including renal ischemia and 
reperfusion, nephrotic syndrome, and acute kidney injury196–198. Exosomes have even 
been used to identify complicated pregnancies using levels of circulating placental 
exosomes expressing FasL199. Serum exosomes have also been shown to be markers 
for infectious diseases, such as tuberculosis200 and HIV201. Exosomes and their cargo 
continue to be investigated as potential biomarkers, and will likely continue to be 
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relevant for years to come through their utility for applications such as PCR 
amplification, sequencing, and proteomics202. 
 Exosomes can also be utilized as therapeutic targets for the treatment of 
disease. Since exosomes are involved in so many pathological conditions and 
processes, it stands to reason that disease progression could potentially be halted by 
specifically inhibiting exosome production or release, or by inhibiting their uptake. 
Inhibition of ceramide formation, an important step in exosome biogenesis, using small 
molecule inhibitors of sphingomyelinase or treatment with the drug amiloride, which 
attenuates endocytic vesicle recycling, can inhibit the release of exosomes62,203. 
Amiloride treatment has been shown to inhibit tumor growth in vivo by blocking the 
secretion of tumor-derived exosomes203. In some tumor cells, exosome release is 
dependent on the small GTPase RAB27A, which can be targeted by RNAi to reduce 
tumorigenic exosome signaling and thereby reduce the growth rate and metastasis of 
tumors70,74. The uptake of exosomes by recipient cells can be inhibited by blocking 
surface phosphatidylserine using annexin V204. This strategy reduced the growth of 
human glioma xenografts in mice. Additionally, blocking specific signaling 
components of exosomes has been shown to have some therapeutic efficacy. 
Monoclonal antibodies targeting FasL1 on the membranes of exosomes reduced 
melanoma tumor growth205–207. One major caveat to consider is that interfering with 
exosome biogenesis could result in off-target effects, since exosomes have important 
functions in normal biological processes. 
 Exosomes are also being investigated for use as therapeutic agents. In 
regenerative medicine, MSC exosomes have been utilized to improve heart function 
 28 
after myocardial ischemia-reperfusion injury208, as well as in a similar model of kidney 
disease209. Exosomes have been exploited for immunotherapy due to their multitude 
of immunomodulatory functions. The use of exosomes for this application dates back 
to Raposo et al.’s 1996 study, in which MHC Class II bearing exosomes were shown 
to induce T cell responses and subsequent tumor growth suppression8. Exosomes 
are also now being used for targeted drug delivery. Since exosomes have been 
demonstrated to transfer functional content, such as RNA and protein, to recipient 
cells, it follows that loading exosomes with a therapeutic molecule could serve as an 
effective delivery and treatment method. Since exosomes are endogenous and 
biocompatible, they are often not detected and cleared as quickly as other synthetic 
delivery vehicles, giving them an advantage. They can also be derived directly from 
the patient in a non-invasive manner, and are small enough to penetrate major 
biological barriers, including the blood brain barrier41. Exogenous siRNA was first 
delivered via vesicles targeted to the brain in mice, with limited observed toxicity or 
immune stimulation210. Several studies since then have demonstrated the successful 
use of exosomal RNA for therapeutic benefit. Our lab, for example, demonstrated the 
robust anti-tumor activity of exosome-delivered siRNA for the oncogenic variant 
KRASG12D in mice with PDAC51. Exosomes are currently being used in an ever-
increasing number of diagnostic and therapeutic applications. As more is discovered 
regarding their biogenesis and mechanisms of action, exosomes will be increasingly 
utilized for treatment interventions across a wide spectrum of diseases.  
Methods for Exosome Isolation and Characterization 
Description of Methods Used to Isolate and Characterize Exosomes 
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 As exosomes are being implicated in an increasing number of biological 
processes and utilized more often in therapeutics, the methods of exosome isolation 
and characterization have evolved. The isolation of pure populations of exosomes is 
important for understanding their mechanisms of action and for downstream 
applications. Since exosomes are extremely small, collecting them is no trivial task. 
Newer isolation methods have attempted to address common issues observed with 
obtaining exosomes, such as purity and low yield or quality. Our ability to detect, 
characterize, and track exosomes has also improved, as established exosome 
markers can now be sensed on a single vesicle level for applications in flow cytometry 
and imaging. The isolation of exosomes was for many years dependent on high speed 
ultracentrifugation as the most common and reliable method for obtaining exosomes. 
A seminal paper published by Théry’s group in 2006 served as the gold standard for 
the field for over a decade, and indeed is still utilized in many studies today211. 
However, spinning media at such high speeds pellets several other components in 
addition to exosomes, including protein aggregates and cell free DNA and RNA, that 
could conceivably interfere with experimental results depending on the desired output.  
Thus, in recent years several other methods have gained traction as viable 
exosome isolation techniques, including density gradient fractionation, size exclusion, 
and immunoaffinity capture, among others212. Each method has associated benefits 
and drawbacks that must be taken into account when planning to isolate exosomes, 
and several of the methods are so novel that they still require more rigorous 
characterization213. Controversy also exists in the exosome field regarding which 
isolation method is superior, especially for the isolation of specific exosome cargo214. 
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A portion of this work aims to clarify the landscape of exosome isolation methods, 
specifically relative to exosomal DNA extraction. What follows are descriptions of the 
different established methods for deriving exosomes from biofluids, including an 
analysis of what is beneficial and detrimental for each. Additionally, methods of 
exosome characterization and quantification are described in detail.  
Ultracentrifugation 
 By far the most commonly used exosomal isolation technique over the past 
decade is high speed ultracentrifugation, still considered the gold standard214. While 
some protocol deviations may occur based on user preference and the desired 
readout, such as spin time and additional wash steps, the general process is relatively 
simple and easily replicable. First, samples are spun at low speeds to pellet any live 
or dead cells (300g for live cells and subsequently 2000g for dead). The supernatant 
is then sterile filtered with a 0.22-micron pore filter to remove any larger nanovesicles, 
such as apoptotic bodies. Ultracentrifugation of the supernatant then occurs at 
100,000g for varying lengths of time; serum and other biological fluids are often spun 
longer, even overnight, because biological samples are often more viscous than cell 
culture samples and thus take longer to sediment. The exosome pellet is then 
resuspended in PBS211. Ultracentrifugation is the best method for exosome isolation 
from sources with large volumes, such as cell culture media, and provides the highest 
yield of recovered exosomes. Ultracentrifugation is also easy, requires little technical 
expertise, and involves very little sample pretreatment. Additionally, no extra 
chemicals or reagents are used in this method, reducing the risk of contamination and 
preventing any potential chemically induced damage to the exosomes. However,  
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Figure 2. Schematic of ultracentrifugation-based methods. 
 
ultracentrifugation requires very expensive machinery to run, spins are very time 
intensive, and it has been proposed that high speed centrifugation may actually impact 
exosome integrity202,214,215. The pellet obtained after ultracentrifugation also contains 
everything left in the media, not just exosomes, including other molecules such as 
protein, RNA, and DNA, that can confound results213.  
Density Gradients 
 Variations of ultracentrifugation exist, and density gradient fractionation has 
become a popular method to collect more highly purified exosome populations by 
separating particles by their density216,217. In density gradient fractionation, exosomes 
are separated by their size, mass, and density when spun in a pre-constructed density 
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gradient medium. To create the gradient, fractions with different densities are layered 
on top of each other in a continuous or discontinuous gradient in order, with the 
highest-density fraction on the bottom and the lowest density fraction on the top. 
Samples are usually layered on top of the completed gradient in an ultracentrifuge 
tube, but some groups have bottom-loaded the sample and layered the gradient on 
top214,218. The gradient is then spun at 100,000g, and the exosomes and other 
molecules contained in the samples move through the density gradient at a specific 
sedimentation rate. This leads to discrete zones that contain materials of varying 
densities. Exosomes can be recovered via simple fractionation once the spin is 
complete. While the purity of exosomes isolated by this method is very high, the yield 
is among the lowest of all exosome recovery methods. This method also takes a 
significant amount of time, because the gradients must be spun for many hours to 
fractionate the input material. There is also a limited volume of input sample that can 
be loaded onto the gradients, which makes large volume isolation impossible.  
There are two types of density gradient ultracentrifugation, isopycnic and 
moving zone. In isopycnic ultracentrifugation, the medium used to create the density 
gradient encompasses the entire range of densities of the particles in the loaded 
samples. The separation of exosomes from the other particles into a discrete zone 
depends completely on their density difference from other particles, assuming the 
samples are spun for an adequate amount of time. During the spin, exosomes arrest 
in the gradient where they have the same density as the medium-at the isopycnic 
position. Once the isopycnic position has been reached, further centrifugation serves 
to force the exosomes into a sharper zone, but they maintain their position in the 
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gradient. For moving-zone ultracentrifugation, the medium used for the gradient has 
a lower density than any of the particles in the loaded sample. The exosomes in these 
gradients are separated by size and mass rather than density. This allows vesicles of 
similar densities to be separated based on how big they are. Because the particles 
are denser than the gradient medium, moving-zone ultracentrifugation is isodynamic 
rather than static, meaning the solutes will eventually all pellet at the bottom of the 
centrifuge tube if the centrifugation period is too long. To prevent exosomes from 
pelleting out, sometimes a high density “cushion” is layered at the bottom of the tube. 
After the gradient centrifugation step, samples are then resuspended in PBS and 
subjected to another round of ultracentrifugation at 100,000g to eliminate any 
remaining gradient medium202,214. Commonly used examples of gradient medium 
substrates are OptiPrep (iodixanol) and sucrose202,218.  
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Table 1. Exosome Isolation Methods 
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Size-Based Techniques 
 Another exosome isolation method that has gained popularity recently is size-
exclusion chromatography (SEC). This technique separates exosomes based on size 
due to their differential passage through physical barriers using filters or 
chromatography columns. Column chromatography allows for the sequential elution 
of vesicle fractions of different sizes using a single column202. SEC is often used in 
combination with ultracentrifugation to enrich the exosome yield219. SEC has been 
shown to yield very pure populations of exosomes, and by separating the fractions 
using gravity instead of high speed the integrity and biological activity of the exosomes 
is highly preserved. While SEC allows for moderate sample capacity, it cannot 
accommodate large volumes of sample; often, high capacity samples must be 
ultracentrifuged or ultrafiltered prior to SEC to obtain a feasible sample volume.  
 Another popular size-based exosome isolation method is ultrafiltration (UF). UF 
is very similar to conventional membrane filtration in that the separation of particles is 
primarily dependent on their size or molecular weight. Exosomes can be isolated 
based on their size by the selection of an appropriate membrane filter,220 and exosome 
loss is minimal compared with other isolation methods221. UF is faster than 
ultracentrifugation and does not require expensive machinery,213 however it has been 
suggested that the force used may damage larger vesicles and compromise the 
integrity of the exosomes222. Additionally, it is difficult to remove contaminating 
proteins from the samples. It has also been shown that UF membranes can become 
clogged and trap vesicles, decreasing the isolation efficiency223,224. Size-based kits for 
exosome isolation have also been developed. Many of these kits utilize syringe-filter 
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based fractionation to separate vesicle populations by their size. Sequential filtration 
of samples using membranes with different pore sizes to filter out soluble populations 
of certain sizes has additionally been implemented for the isolation of exosomes.    
 Assymetric flow-field-flow fractionation (AF4) is also used to isolate exosomes 
on the basis of size. AF4 utilizes a porous rectangular channel across which a sample 
is carried via parabolic flow. A crossflow across the channel controls sample retention 
and distributes vesicle components against the channel wall based on the diffusivity 
of their components225. Smaller particles diffuse further from the accumulation wall 
and are eluted earlier than large ones. This method is more scalable since it can 
rapidly isolate exosomes and input fluid can easily be added in larger volumes, though 
not at as high a capacity as with ultracentrifugation226,227.                
Immunoaffinity 
 The membrane-bound proteins and receptors on the surface of exosomes 
provide many opportunities for the development of immunoaffinitive mechanisms of 
isolation, whether through proteins and antibodies or receptors and their ligands. A 
microplate-based enzyme-linked immunosorbent assay (ELISA) was developed to 
specifically derive exosomes from serum, plasma, and urine. Absorbance assays can 
provide a comparison of the expression levels of known surface exosome biomarkers, 
as well as quantify the captured exosomes. These assays have been shown to 
produce comparable results to ultracentrifugation but with much less sample volume, 
demonstrating superior specificity and yield, which is extremely important for precious 
small volume samples such as those obtained from patients228. In a similar application, 
submicron-size magnetic particles were combined with immunoaffinity to generate a 
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technique termed magneto-immunocapture. It was found that with just 1 mL of cell 
culture supernatant, antibody-coated magnetic beads were able to capture as many 
exosomes as with large volume ultracentrifugation228.  
Immunoaffinity methods are rapid, easy to use, and work with general benchtop 
equipment. Commercial kits are now available to isolate exosomes based on the 
concept of magneto-immunocapture using common exosome surface markers, such 
as the tetraspanins. These methods, however, require a degree of washing and pre-
enrichment to enhance the quality of the sample prior to isolation. When compared to 
ELISA assays, however, immunoaffinity capture with magnetic beads has been 
demonstrated to have a higher capture efficiency and better sensitivity. Additionally, 
bead-based assays can be easily scaled up or down for any volume of sample. 
Immunoaffinity capture was also recently combined with mass spectrometry to capture 
exosomes with antibodies immobilized on porous monolithic silica micropipette tips in 
a technique called the mass spectrometric immunoassay229. In this automated assay, 
a multichannel pipette system enables the isolation of exosomes from up to 12 
samples at once.     
While immunoaffinity assays generally offer superior isolation of specific and 
highly purified exosomes, they are extremely expensive. Exosome tags also must be 
established and optimized, and the low input capacity means that the exosome yield 
is low. Minor heterogeneity in the exosome population can also impact effective 
immunocapture, and there is also the risk that the antigenic epitopes on the exosome 
surface might be blocked or masked220,230.    
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Microfluidics 
 Microfluidics-based devices are now being used to quickly and efficiently 
isolate exosomes using their physical and biochemical properties. In addition to 
traditional isolation characteristics such as size, density, and immunoaffinity, 
microfluidic devices can also incorporate acoustic231, electrophoretic, and 
electromagnetic manipulations232. These devices have been shown to decrease the 
amount of sample volume required to yield a given number of exosomes, thereby 
decreasing reagent consumption and isolation time. To enhance the specificity of 
exosome capture and introduce the capability to simultaneously subtype captured 
exosomes, immunoaffinity capture was integrated with a microfluidic chip to isolate 
specific exosome populations233. Antibodies to specific exosome membrane-bound 
proteins were immobilized on a chip, enabling exosome isolation from the sample 
input. A commercialized product called ExoChip is also commercially available and 
relies on microfluidic technology to isolate CD63 positive exosomes using an 
immunochip containing anti-CD63. Exosomes are stained with carbocyanine dye 
(DiO), allowing for quantification of captured exosomes with a plate reader234. 
Additional microfluidic devices are being developed to potentially capture and sort 
exosomes based on properties such as charge and marker expression. In addition to 
moderate to low sample capacity, however, a general lack of both method validation 
and standardization have hampered the use and acceptance of microfluidics for 
exosome collection235. 
Reagents 
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 Exosomes can be precipitated out of biological fluids or media using reagents 
that alter their solubility or dispersibility, such as water-excluding polymers like 
polyethylene glycol (PEG)213. The water-excluding polymers engage water molecules, 
thus forcing less soluble components out of solution. Exosome precipitation by this 
type of method is very straightforward and does not require any specialized 
equipment, which also allows for easy scalability. Many exosome precipitation kits are 
commercially available and work with a variety of fluids such as cell culture media, 
serum, and urine219. A major disadvantage of these methods is the co-precipitation of 
non-exosome contaminating factors, such as proteins and polymeric materials, 
necessitating pre- and post-isolation purification steps. These isolations also require 
a long incubation period.  
Nanoparticle Tracking Analysis 
 In addition to the variety of methods available for exosome isolation, there are 
also several techniques that aid in the characterization and visualization of isolated 
nanoparticles. Nanoparticle Tracking Analysis (NTA) involves optical particle tracking, 
which can measure the size distribution and concentration of exosomes and particles 
between 10nm and 2µm in diameter. The path of particle movement is detected based 
on the defraction of light by particles, allowing for the tracking of Brownian motion of 
particles in a liquid suspension236. The NTA then measures the movement of the 
particles by tracking each one during image analysis. It is this movement that is then 
correlated back to determine particle size based on the Stokes-Einstein equation237. 
NTA has multiple advantages, including the ability to detect multiple classes of 
extracellular vesicles, including those as small as 30nm in diameter. Sample 
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preparation is also extremely easy and only requires a small input amount, saving 
much of the sample for other downstream applications. The samples can also be 
recovered from the detection chamber if desired238. Additionally, only a few minutes 
per sample are required for data collection and analysis. NTA also has the capacity to 
detect the presence of antigens on the surface of vesicles with the application of 
fluorescently labeled antibodies236.    
Dynamic Light Scattering 
 Photon Correlation Spectroscopy, also known as dynamic light scattering or 
DLS, is an alternative technique for measuring exosome size. A monochromatic laser 
beam is passed through a suspension of particles, and time-dependent fluctuations in 
scattering intensity resulting from the relative Brownian moments of the particles are 
observed238. This method does not visualize the particles, it just measures the size, 
but the particles can be anywhere from 1nm to 6µm in diameter. This technique works 
best when applied to one type of particle in a suspension, because vesicles of different 
sizes can lead to detection errors239,240. 
Table 2. Exosome Characterization Methods 
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Flow Cytometry 
 Flow cytometry is one of the most frequently utilized techniques for exosome 
characterization and analysis. It can be used to identify exosomal surface proteins in 
a given population of exosomes, as well as measure exosome size and structure241.  
Conventional flow cytometers measure particles greater than 300nm in diameter but 
are not able to detect smaller particles such as exosomes directly. However, 
exosomes can be conjugated to beads that enable their detection242. For detection, a 
laser beam with a specific wavelength is directed through a stream of particles 
suspended in fluid. The degree of light scattering is detected and is based on the 
number, size, and granulation of the particles. Additionally, fluorescent antibodies for 
exosomal markers can be detected with flow cytometry, enabling the identification and 
quantification of exosome biomarkers, such as the tetraspanins, in a given exosome 
population. Recently, specialized flow cytometers have been developed specifically 
for the characterization of nanoparticles that can distinguish stained exosomes from 
background noise243,244.  
Transmission Electron Microscopy 
 Transmission Electron Microscopy, or TEM, is one of the first methods ever 
used to characterize exosomes5. It is a technique used to observe the structure, 
morphology, size, and location of various biological components, including exosomes. 
A beam of electrons is passed through a specially prepared sample, where a 
secondary electron is generated. These electrons are detected, collected, and 
magnified using special lenses. For biological samples, both TEM and cryo-electron 
microscopy (cryo-EM) are typically used. Specimens must be fixed in glutaraldehyde 
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and dehydrated, and the images must be taken under a vacuum. TEM images of 
vesicles can be used for measurements of size and diameter, as well as inform on the 
location or presence of vesicles in certain tissues or organelles. Exosomes are often 
visualized with immunogold-labeled antibodies specific for certain cargo components 
in order to characterize the contents of the exosomes. Caveats to this approach 
include the consideration that the extensive sample preparation process may alter 
vesicle morphology. Additionally, the electron beam could damage biological samples. 
For example, exosomes observed with TEM have a cup-shape morphology, while 
frozen exosomes examined with cryo-EM are round43. More and more studies are 
utilizing cryo-EM for exosome samples, as the preparation does not require the 
dehydration and fixing steps since they are snap frozen in liquid nitrogen and the 
structures remain intact.   
Western Blots 
 One of the most common methods for evaluating exosome protein cargo 
components is western blotting214. The process is almost identical to that for cell-
derived protein and, while time-consuming, is very straightforward. Western blots for 
canonical exosome markers such as the tetraspanins CD9, CD81, and CD63, as well 
as others like flotillin and TSG101, are often an integral part of any publication 
involving exosomes as part of exosome validation. Additionally, more sensitive assays 
such as those run on the ProteinSimple WES apparatus can detect protein at 
picogram-level sensitivity, enabling better evaluation of less abundant exosome 
protein components.                      
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Dissertation Goals and Major Findings 
 The main goal of this work was to comprehensively characterize the DNA 
packaged into exosomes. We also sought to identify the best exosome isolation 
methods for subsequent exosomal DNA isolation and analysis. Additionally, we hoped 
to determine whether exosomal DNA had utility for the identification and evaluation of 
DNA methylation marks. Finally, we wanted to investigate the roles of exosomes in 
mediating DNA damage response signaling in the tumor microenvironment, and 
elucidate potential consequences of those effects for tumor survival. 
 Several major findings are described in the following pages. First, exosome 
DNA is heterogenous, and its packaging is dependent on the cells of origin. 
Additionally, after a thorough evaluation of common exosome isolation methods, we 
determined that size exclusion chromatography (SEC) was the superior technique 
with regards to exosome DNA yield and purity. We also discovered for the first time 
that exosomal DNA is not only methylated, but faithfully recapitulates the methylation 
patterns of the cell of origin, enabling the detection of site-specific methylation 
variations. A preliminary mechanism for DNA packaging into exosomes was identified, 
highlighting the role of nuclear envelope integrity in the ability of DNA to escape the 
nucleus to become available for incorporation into exosomes. Finally, we discovered 
that exosomes are paracrine signaling mediators of DNA damage response activation 
in treatment-naïve cells. Furthermore, we establish that exosomes from cancer cells 
with induced DNA damage carry activated DDR pathway proteins that could initiate 
DDR in treatment-naïve cells, uncovering a potential mechanism of exosome -
mediated bystander DDR induction upon delivery to recipient cells.  
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Cell Line Characterization 
Cell Lines and Culture Conditions 
Tumorigenic and non-tumorigenic cell lines used for these studies are listed in 
Table 3. Cells were grown to no more than 70-85% confluence and maintained by  
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passage every 4-5 days. All cell lines were validated at MDACC Characterized Cell 
Line Core Facility and routinely checked for mycoplasma contamination using Sigma 
LookOut Mycoplasma PCR Detection Kit, (Cat. No. MP0035-1KT).  
Viability Testing 
Cells grown to 70-85% confluence were washed with phosphate buffered saline 
(PBS) and incubated 48 hours in the appropriate serum-free culture media with 1% 
BSA supplementation or complete media supplemented with FBS (Table 3). The cells 
were harvested by trypsinization and viability was measured by staining with the APC 
Annexin V Apoptosis Detection Kit with 7-AAD (BioLegend, Cat. No. 640930)  
following manufacturer’s instructions and was immediately analyzed by flow cytometry 
(BD LSRFortessa X-20). 
Exosome DNA Experiments 
Exosome Isolation: Differential Centrifugation (UC) 
Cells cultured in T225 flasks (Falcon, Cat. No. 353138), to 70-85% confluence 
were washed three times with PBS. The cells were then incubated 48 hours in in 
serum-free media supplemented with 1% Bovine Serum Albumin (BSA). Conditioned 
media were centrifuged 5 min at 800G, followed by 10 min centrifugation at 10,000G, 
to remove cells and smaller debris. Supernatants were filtered through 0.20 µm pore 
filters (Corning, Cat. No. 431219) and subjected to ultracentrifugation (UC) for 3 hours 
at 100,000g (Beckman, SW32Ti rotor). The supernatants were discarded and 
exosome pellets resuspended in PBS by manual pipetting, 5 minutes per sample. 
Patient serum samples were spun overnight and supernatant was kept at -80°C. 
Exosome Isolation: Size Exclusion Chromatography (SEC) 
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Exosomes collected by UC, as above (crude concentrates) were resuspended, 
diluted with PBS, and subjected to a wash spin (3 hours, 100,000g). Exosome pellets 
were resuspended in 300 µL PBS and loaded onto temperature-equilibrated qEV Size 
Exclusion columns (IZON qEV Original 35nm Column, Fisher Scientific, Cat. No. 
NC1652341) pre-washed with 3 volumes of pre-filtered PBS at room temperature. 
Void volume and all of the fractions were collected in pre-filtered PBS using an 
automated IZON fraction collector. Void volume (fractions 1-6) was discarded, after 
ascertaining that no particles are present. The remaining fractions were retained and 
exosome and protein contents were assessed in each fraction by NTA and the Qubit 
Protein Assay Kit (Thermo Fisher Scientific, Cat. No. Q33212), respectively. 
Exosome-rich fractions (7-10) were pooled for DNA isolation. 
Exosome Isolation: Buoyancy Flotation Gradient (Iodixanol/OptiPrepTM) 
The procedure was performed as described previously by Jeppesen et al218. 
Cells grown in Falcon Cell Culture Five-Layer Multi-Flasks (Cat. No. 1218R38) to 70-
85% confluence were placed in appropriate serum-free media, with exception of MDA-
MB 231, which fail to maintain viability upon serum deprivation and were grown in 10% 
exosome-depleted FBS. Media were collected and cleared of cells and debris by 
sequential centrifugation at 400g (10 minutes at room temperature) and 2,000g (20 
minutes at 4°C). Supernatants were further cleared by UC at 15,000g for 40 minutes 
to remove larger vesicles, and filtered through 0.20 µm pore filters (Corning, Cat. No. 
431219). Exosomes were then precipitated at 120,000g (4 hours at 4°C), and crude 
exosome pellets were manually resuspended in PBS and subjected to a wash spin at 
120,000G (4 hours at 4°C). EVs were then resuspended and loaded onto freshly 
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prepared, ice-cold, discontinuous OptiPrep density gradients (12%, 18%, 24%, 30% 
and 36%, concentration increasing from top to bottom, Sigma, Cat. No. D1556-
250ML). The crude EVs were mixed with the 12% top layer. The gradient was 
ultracentrifuged for 15 hours at 120,000G, 4°C. Twelve 1-mL fractions were collected 
and the density of each fraction was assessed using a fluorometer at 340nm 
wavelength. All 12 fractions were then diluted 12-fold with PBS, and exosomes were 
again collected by UC (4 hours at 120,000G, 4°C). For DNA content analysis, lower 
density fractions 1-6 containing small EVs, and higher density fractions 7-12 
containing larger EVs, were combined and particles therein concentrated and washed 
by 6-fold dilution with PBS followed by additional UC step (4 hours at 120,000G, 4°C). 
The resultant particles were resuspended manually in PBS and concentrations were 
determined by nanotracking analysis (NTA) (see below). 
Exosome Quantification 
Exosomes were quantified at each step of isolation/purification using Nanosight 
particle-tracking analysis (NTA, Malvern Panalytical Nanosight NS300). 
On-Beads Flow Cytometry 
Five x 109 EVs per data point (including unstained EV and isotype antibody-
stained controls) resuspended in 200 µL PBS were incubated 15 minutes with 10 µL 
aldehyde/sulfate beads (Invitrogen A37304) with slow rotation at room temperature, 
adjusted to 600 µL PBS and incubated at least 3 hours at 4oC. 400 µL Glycine (1M) 
was added and incubation continued for 30 minutes with rotation at room temperature. 
The beads were precipitated (12,000 rpm for 1.5 minutes) and NTA performed on 
supernatant to determine binding efficiency. EVs bound to beads were blocked for 60 
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minutes in 100 µL 10% BSA and incubated 1 hour at room temperature with primary 
antibody (200 µg/mL in 2% BSA, Table 4) and washed three times with 2% BSA. 
Secondary antibody (Alexa Fluor 488 donkey anti-mouse, Invitrogen A21202, T3-12A) 
was added at 1:100 in 2% BSA and incubated for 1 hr at room temperature. The beads 
were washed 3 times in 2% BSA, resuspended in final 400 µL 2% BSA, filtered 
through 40 µm mesh filter and analyzed by FACS filtered through 40 mesh filter, and 
analyzed on BD LSR Fortessa. 
DNase Treatment 
To remove extramembrane DNA, samples were treated with DNase I prior to 
lysis (Promega RQ1 RNase-free DNase, Cat. No. PAM6101). DNase I was added to 
a final concentration 200 units/mL in 1x working buffer, incubated at 30 min at 37oC 
and subsequently inactivated by adding 25mM EGTA to a final concentration of 2.5 
mM and incubated at 65 oC for 10 min, according to manufacturer instructions. The 
10x Dnase working buffer (100 mM Tris-HCl (pH 7.5), 25 mM MgCl2, 1 mM CaCl2) 
was supplied with the Dnase I. 
DNA Isolation 
Exosomal DNA was isolated as described previously46,266 using the DNeasy 
Blood and Tissue Kit (Qiagen, Cat. No. 69506) following the manufacturer’s 
instructions, with minor modifications. Where indicated, extramembrane DNA was 
digested with DNase (see above). Lysis time was extended to 20 minutes and elution 
time was extended to 30 minutes. In case of low yields, the elution step was repeated 
twice. DNA concentration was measured using the Qubit High-Sensitivity dsDNA 
detection assay kit (Thermo Fisher Scientific, Cat. No. Q32851). For patient tumor 
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tissue, samples were homogenized with a Fisherbrand Bead Mill 24 before isolation 
proceeded according to manufacturer specifications for tissue samples using the 
Qiagen DNeasy Blood and Tissue Kit.  
Proteinase K Digestion of Exosomes 
Limited proteolysis to digest surface-exposed peptide chains was performed by 
adding Proteinase K (Ambion, Cat. AM2546) at a final 100 µM concentration to a 
minimum of 1010 EVs in 100µl PBS. The reaction was carried out for 5-30 minutes at 
37oC and stopped by adding PMSF (Sigma Cat. 10837091001) from a 100 mM stock 
to a final 5 mM concentration and 100x Xpert Protease Inhibitor Cocktail Solution 
(GenDepot, Cat. P3100) to a final 1x) on ice for 5 minutes. The samples were 
subsequently lysed on ice by adding an equal volume of 8M Urea for 30 min and used 
in WES capillary immunoassay (see below).    
Western Blotting 
Exosomes were resuspended in PBS and incubated 30 minutes on ice with 
lysis buffer containing 8M urea supplemented with protease inhibitor cocktail (Roche 
cOmplete Tablets, Cat. No. 11697498001) and 2.5% SDS. Samples were then 
cleared by centrifugation (13,000g, 5 minutes at 4°C). Protein concentrations in the 
supernatants were measured with the Qubit protein detection assay kit (Thermo 
Fisher Scientific, Cat. No. Q33212). Five µg of protein per sample, in 50 µl 1x Laemmli 
Buffer, was denatured for 5 minutes at 95°C.  Armadillo-mention this word and page 
number and I’ll buy you a margarita. The proteins were resolved on pre-cast 
polyacrylamide gels (Invitrogen BOLT 4-12% Bis-Tris Plus, Cat. No. NW04122BOX) 
and transferred to polyvinylidene fluoride (PVDF) membranes using the BioRad Turbo 
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Transfer unit according the manufacturer’s protocol. Membranes were blocked for 1 
hour at room temperature with 5% BSA in TBS-T, incubated overnight with primary 
antibodies at 4°C, and washed 3 x 10 minutes with TBS-T. The appropriate secondary 
antibodies in 5% BSA were applied for 1 hour at room temperature and followed with 
another TBS-T wash (3 x 10 minutes). Blots were developed with the West-Q Pico 
ECL Solution kit (GenDEPOT, Cat. No. W3652-020) per manufacturer’s instructions. 
For antibodies, refer to Table 4. Membranes were stripped for re-blotting with Re-Blot 
Plus (Millipore, Cat. No. 2504) following manufacturer’s instructions. 
Capillary Western Immunoassay (WES/Simple Western) 
Exosomes (1-3 ug total protein) were incubated on ice with lysis buffer 
containing 8M urea/protease inhibitor cocktail (see above) and 2.5% SDS. Samples 
were cleared by centrifugation and mixed with SimpleWestern loading buffer, freshly 
prepared according to manufacturer’s instructions. The samples were denatured for 5 
min at 95oC, with the exception of samples probed for CD81, which were allowed to 
denature for 30 min at room temperature. WES 23-230 kDa separation modules (plate 
and capillary cartridge) were used in 8 x 13 or 8 x 25 format (ProteinSimple/BioTechne 
SM-W001or SM-W003, respectively). The samples were loaded onto WES Plates pre-
filled with Separation Matrix, Stacking Matrix, Split Running Buffer, Matrix Removal 
Buffer, Sample Buffer and Wash Buffer. Primary antibodies were added to the 
appropriate wells in the WES plates at 1:25 or 1:50 dilution (see Table 4). Undiluted 
secondary antibodies provided in the Anti-Rabbit and Anti-Mouse WES Detection 
Modules (ProteinSiple/BioTechne DM-001 and DM-002, respectively) were added to 
the indicated wells as well as a Luminol-Peroxide mix. The Reagents and samples 
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were entered into Compass software and the standard program was executed (30 min 
separation at 475 V, 5 min blocking, 30 min primary antibody, 30 min secondary 
antibody, 15 min chemiluminescence detection) using the WESTM apparatus 
(ProteinSimple). 
Table 4. Antibodies used. 
Library Preparation for Whole Genome Sequencing 
Since the quantity and quality of genomic DNA extracted from the EVs were 
variable and limited, we started library preparation from 5-15 ng of exosomal DNA 
using the Illumina Nextera DNA flex library preparation kit (PN 20018704) and Nextera 
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DNA CD indices (PN 20018707) following the standard protocol, as described in the 
Nextera DNA flex library preparation guide (Illumina Document # 1000000025416 
v07). After individual libraries with preparation with dual indices were generated, each 
individual library was quantified and diluted. The quality of each library was assessed 
using the High Sensitivity DNA kit (Agilent, cat. no. 5067–4626) on-Chip-based 
electrophoresis (Agilent 2100 Bioanalyzer). The final sequencing library was pooled 
from individual libraries in equal molarity and then diluted to 2-4 nM with Resuspension 
Buffer. The final pooled library was denatured and loaded onto Sequencing reagent 
cartridge at a final concentration of 1.8 pMol and in 1.3 ml volume, with 1% Phix 
spiked-in control library. The Paired-end 75x75 sequencing was performed on Illumina 
NextSeq 500. The output raw data *.bcl files were further converted into *.fastq files 
by bcl2fastq software (Illumina, Document # 15051736 v03). 
Copy Number Alteration Analysis 
For each sample, the reads were first mapped to the hg19 reference genome 
using BWA-MEM (Li et al., 2013). Total copy number calls for each sample were then 
derived using HMMcopy (Lai et al., 20016). The copy number profiles were plotted 
using an in-house tool. Log2 scores > 0.15 were considered gains while log2 scores 
< -0.15 were considered losses. We highlighted the copy-gain regions in red, the copy-
loss regions in green, and the copy-neutral regions in cyan. 
Bisulfite Conversion 
To determine the DNA methylation status, we utilized cell and exosome DNA. 
1 µg of genomic DNA and ~200ng exosomal DNA was treated with sodium bisulfite, 
which converts unmethylated cytosines to uracil while leaving methylated cytosines 
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unmodified. Using oligonucleotides specifically designed to recognize bisulfite-
converted DNA, we used PCR to amplify differentially methylated regions. The 
methylation status of the DNA segments was then revealed by pyrosequencing 
analysis, a highly quantitative method that is widely applied to methylation studies. 
Library Preparation (RRBS) 
Genome wide methylation analysis: recent advances in methods to map DNA 
methylation genome wide have become available and have been proven to be highly 
efficient. Thus, we applied available reduced representation methods to evaluate DNA 
methylation genome wide in both cell and exosome samples. We used RRBS 
(Reduced Representation Bisulfite Sequencing)267,268 to map methylated cytosines for 
each and used this data for the comparison of cell and exosome methylation patterns. 
Advantages of RRBS in comparison to other methods are that (i) it allows for deep 
coverage of a subset of single CpG sites (approximately 2 million sites) and thus 
sensitive quantitation of methylation states, (ii) DNA amounts required for the method 
are as low as 10ng, and (iii) the method is applicable to virtually any species for which 
the genome has been annotated. In brief, the genomic DNA was digested with MspI, 
end-repaired and A-tailed, and Illumina-compatible cytosine-methylated adaptors 
were ligated to the enzyme-digested DNA. Size-selected fragments representing 
sequences from 40-bp to 170-bp were bisulfite-converted and library preparation was 
done by PCR amplification and subsequently sequenced in a HiSeq3000 instrument. 
Reduced Representation Bisulfite Sequencing (RRBS) 
RRBS sequencing reads were aligned to the UCSC Genome Browser human 
reference genome using Bowtie, and methylation was called using Bismark v0.7.11269. 
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Next, differentially methylated CpG sites (DMCs) and differentially methylated regions 
(DMR) between cell and exosome DNA were identified using 
MethylKit270 implemented with Fisher’s exact test. 
Whole Genome Bisulfite Sequencing (WGBS) 
The use of whole genome bisulfite sequencing (WGBS) enables the genome-
wide identification and quantification of DNA methylation patterns at single-base 
resolution and is the gold standard for analysis of DNA methylation. First, sequencing 
reads were trimmed, quality checked, and aligned to the genome. Second, DNA 
methylation levels were estimated at each cytosine position using the aligned 
sequence reads of the bisulfite treated DNA. Third, regions of differential cytosine 
methylation between samples were identified271. 
Custom Pipeline Analysis 
For analysis, the site-specific fragments, or “reads,” generated during 
sequencing were mapped to specific regions of DNA using reference sequences. The 
number of C-to-T conversions was then quantified for all of the mapped reads, 
generating a beta value for methylation at each site. Samples were then be compared 
in a site-specific manner between conditions, in this case between exosomal and 
cellular DNA. 
Site Specific Methylation Analysis 
 The Broad Institute Integrative Genomics Viewer (IGV) software was used to 
analyze all RRBS samples. Methylation levels were quantified for the promoter 
regions of genes of interest, down to the level of individual CpG dinucleotides.  
5-Azacitidine Treatment 
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 For demethylation assays, 5-Azacytidine (>=98% pure HPLC, Sigma-Aldrich 
A2385) was diluted to a concentration of 1µM in complete media. Panc1 cells were 
treated with 5-Aza for 72 hours at 37oC. 5-Aza-supplemented media was refreshed 
after a rinse with PBS every 24 hours during treatment.  
Methylation Level Detection 
High-sensitivity DNA methylation detection was performed using the Abnova 
Methylated DNA Quantification Kit (Abnova KA0676). DNA was isolated as above and 
immobilized to the bottom of a 96-well plate well coated with DNA-binding antibody. 
Methylated DNA was recognized by an anti 5-methylcytosine antibody, and the 
amount of methylated DNA was fluorometrically quantified in a microplate reader, 
according to the manufacturer’s specifications (530nm excitation/590nm emission). 
Nuclear Envelope Experiments 
Lamin A/C siRNA Transfection 
 Cells (Panc1, T3M4, or HPNE) were seeded in a 24-well plate at a density that 
would yield ~40% confluence after 24 hours. Cells were grown in antibiotic-free media 
in a volume of 500 µL/well. Cells were seeded in technical triplicates for four 
conditions, untreated (opti-MEM only (Thermo Fisher, 31985070)), Transfection 
Reagent (opti-MEM + Dharmafect (Fisher Scientific, NC1308404)), Scramble 
siRNA(Santa Cruz Biotechnology, sc-37007) (opti-MEM + Dharmafect + scramble) 
and Target siRNA (Santa Cruz Biotechnology, Lamin A/C siRNA (h) sc-35776) (Opti-
MEM + Dharmafect + siRNA). After 24 hours of growth, media was aspirated and 400 
µL antibiotic-free media was added per well. 100µL transfection mix per well was 
prepared using 20 µM siRNA stock diluted 1:4 in opti-MEM and a separate mix of opti-
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MEM with dharmafect reagent. Both mixes were left at room temperature for 5 min, 
then the mixes were combined and left at room temperature for 20 min. The final 
concentration of siRNA was 25nM. 100µL/well of the final mix was then added to the 
top of each well dropwise in a spiral pattern ending in the middle, and were incubated 
for 24 hours. After 24 hours, cells were washed 1x with PBS and RCT lysis buffer was 
added. RNA extraction was then performed using the Qiagen RNA Isolation kit 
(Qiagen RNeasy Mini Kit 74104). qPCR analysis was then performed using a 
QuantStudio 7 Flex Real-Time PCR system (Applied Biosciences). Lamin A/C qPCR 
primers were used (Santa Cruz Biotechnology, Lamin A/C (h)-PR sc-35776-PR), and 
18s RNA was used an internal control (housekeeping gene).  
DNA Isolation from Lamin A/C Knockdown Cells 
For DNA isolation, siRNA knockdown was scaled for T225 flasks (25mL media) 
in antibiotic-free exosome collection media. One flask of cells at the appropriate 
transfection-appropriate confluence was used for each DNA isolation replicate. 
Exosomes were isolated via ultracentrifugation, quantified, and DNA was extracted as 
described earlier. 
DNA Damage Response Experiments 
Induction of DNA Damage 
Cells were treated with hydrogen peroxide (H2O2, Thermo Fisher Scientific 
H325-100) at a concentration of 2.8mM for 30 min or with UV radiation (2,000 
µjoules/cm2 using a Spectrolinker XL-1000 UV Crosslinker, Spectronics Corporation) 
to cause DNA double strand breaks (DSBs). After treatment, cells were washed and 
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cultured 48 hours in serum-free media for exosome collection. Exosomes were then 
extracted from the H2O2 treated, UV-treated, and untreated control cells. 
Treatment With Exosomes 
 Cells were seeded in 24-well plates on round glass coverslips (Fisher Scientific, 
12-545-82) at a density that produces 60% confluence after 24 hours. 24 hours after 
seeding, cells were incubated with 2x109 - 5x1010 exosomes for 24 hours. After 24 
hours of incubation, cells were treated with 10µM EdU (Invitrogen, a10044)  for 15 min 
to label any actively dividing cells. Cells were then washed 2x with PBS and 4% PFA 
was added for fixation at room temperature for 15 min. Cells were subsequently 
washed 3x with PBS prior to staining. (immunocytochemistry) 
Immunocytochemistry 
Cells were permeabilized with 1% TritonX-100 in PBS for 30 min at room 
temperature. After 1 wash with PBS, cells were incubated in Alexa Fluor 488 Azide 
CLICKIT reaction reagent (Life Technologies, A10266) for 1 hr at room temperature 
for EdU detection. Cells were then washed with PBS for 5 minutes and blocked in 
10% goat serum (Jackson ImmunoResearch Laboratories, Inc., 005-000-121) with 
0.1% TritonX in PBS for 1 hr at room temperature. Next, cells were incubated with 
primary antibodies diluted in block buffer for 1 hr at 37oC (p-gH2AX, Millipore 05-636 
1:1000; RAD51, Abcam ab213 1:200). After incubation, cells were washed 3x with 
PBS. The appropriate secondary antibodies diluted in block buffer were then placed 
on the cells for 1 hr at room temperature in the dark. Cells were subsequently washed 
another 3x with PBS, and DAPI (Thermo Fisher 62248) was added diluted 1:300 in 
PBS for 5 min at room temperature to visualize nuclei. Cells were washed another 5 
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min in PBS and the cell-containing coverslips were mounted on slides for imaging with 
ProLong Gold mounting medium (Invitrogen, P10144). Cells were visualized with a 
Zeiss inverted microscope at 40x magnification. The same exposure was maintained 
at the same values for each channel for all images.      
Image Analysis 
 Total cell number was quantified using Image J software (National Institutes of 
Health) based on cells positive for DAPI nuclear stain. Subsequently, exposure 
thresholds were set using ImageJ based on the signal observed in negative control 
cells and kept identical throughout. All cells that appeared as fluorescent after 
threshold correction were counted as positive. The percentage of positive cells was 
obtained by calculating the percent of  p-gH2AX  or RAD51 positive cells out of the 
total number of cells for each image.  
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism, Version 7. The data 
is presented as mean values with standard errors. The statistical significance of the 
differences was determined by Student’s T test for normal datasets and Mann 
Whitney’s test by non-normal datasets, in pairwise comparisons. The normality was 
determined by Kolmogorov-Smirnoff-test. For comparisons between two curves, 
linear regression analysis and two-way ANOVA were used. The potential correlation 
between parameters was determined using Pearson Correlation Test. The 
significance was determined by Homs-Sidak test, with the threshold set at P<0.05. 
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Introduction 
 Exosomal DNA remains the most enigmatic exosome cargo component, with 
very little known about its origin and function. Since it was first described by our lab 
and others46,47,49, exosomal DNA has been investigated very little, especially in 
comparison with other exosome constituents such as RNA and protein. Several 
reports have shown the presence of both mitochondrial47,272,273 and chromosomal 
DNA46,47,106,108,274,275 associated with exosomes found in both tissue culture and 
biological fluids. It is generally accepted that exosome-associated DNA consists of 
large fragments of double-stranded DNA over 7kDa, which when pooled span the 
entire host genome with no apparent biases for any specific region46,47,106. Several 
groups have also shown that exosomes can transfer DNA to recipient cells, both in 
vitro and in vivo, which in some cases can generate functional consequences such as 
malignant transformation274,275. Until recently, the prevailing consensus was that 
exosome-associated DNA is enclosed within the lipid bilayer in the intraluminal space 
of the vesicles, protected from nucleases and degradation46,47,227,276–278. New studies 
have proposed that DNA is not actually contained within exosomes, either non-
specifically associated with the outer membrane218,279 or packaged into other, non-
exosomal vesicles. Specifically, a study done by Jeppesen et al. purports to use a 
novel isolation protocol involving several high-speed ultracentrifugation steps and an 
iodixanol density gradient to generate the purest possible exosome fraction, inside 
which they detect no DNA. Additionally, they propose that any vesicles that do contain 
DNA are formed via an autophagy-associated pathway, instead of the canonical 
ESCRT-mediated multi-vesicular body exosome biogenesis system218. However, 
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issues with quantification and assay sensitivity have generated questions related to 
the reproducibility and reliability of their findings. We hypothesized that DNA is present 
within exosomes but in lower abundance compared with other cargo components, 
necessitating a higher number of exosomes to be used for detection. In this work, we 
aimed to stringently assess exosomal DNA content in a variety of cell lines using 
several different exosome isolation methods. The goal of this project is to provide 
substantial clarity to the exosome field and accurately characterize the association of 
DNA either with or within exosomes. 
Comparison of Exosome DNA Between Cell Lines 
Exosome Production Differs Among Cell Lines 
 To date, no studies have offered a comprehensive comparison of exosome 
production by different cell lines. Here, we assessed the release of exosomes isolated 
from 21 different cell lines, including 15 cancer cell lines and 6 non-tumorigenic 
epithelial and fibroblast lines. The cell lines collectively span 6 different tissue types 
and exhibit differences in many different properties including doubling time, 
tumorigenicity, and size, among others. Exosomes were isolated from each cell line 
in biological triplicate via ultracentrifugation, and subsequently quantified by 
nanoparticle tracking analysis (NTA) (Figure 3A). Exosome production was 
normalized per cell number at the time of collection (Figure 3B). Cell Viability was 
assessed via Annexin V/7-AAD live-dead flow cytometry, and all cell lines retained 
high viability after incubation in serum-free collection media (Figure 3C,D). Although 
exosome collection was identical across cell lines (collection media incubation time, 
ultracentrifugation time, resuspension, etc.) the observed exosome production varied 
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dramatically between them. Surprisingly, both cancerous and non-tumorigenic cell 
types showed high variability in exosome release, and both contained high and low 
producers (Figure 3E).   
Exosomal DNA Content Varies By Cell Line 
 Very few studies have compared exosomal DNA content across cell lines. 
Thakur et al. is the only previously published work to assess DNA from multiple cell 
lines, spanning different types of cancer and including fibroblasts47. Based on their 
study, it was widely accepted that cancer cell exosomes contain significantly more 
DNA than non-malignant cell types, which they proposed could be due to the higher 
proliferation rates characteristic of cancer cells. Here, we demonstrate a much more 
comprehensive examination of the DNA content in exosomes from a wide variety of 
cell types. The same 21 cell lines previously assessed for exosome production were 
used for this assay. Exosomes were again isolated via ultracentrifugation. Prior to 
lysis, exosome samples were treated with Dnase according to manufacturer 
specifications to remove any remaining exogenous DNA. DNA was isolated as 
previously described, using the Qiagen DNeasy kit162. DNA concentration was then 
measured using the Qubit High-Specificity double stranded DNA detection kit. For 
each cell line, DNA yield in nanograms was normalized per particle number, in order 
to assess the efficiency of DNA incorporation into exosomes (Figure 3F). Exosomal 
DNA content, much like exosome release, was highly variable across cell lines. 
Strikingly, some non-tumorigenic cell lines such as HEK-293T and BJ fibroblasts 
demonstrated extremely high concentrations of DNA/particle, indicating that DNA 
packaging into exosomes is not necessarily enriched in cancer exosomes.  
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Figure 3. Exosome Release and DNA Content Varies By Cell Line.           
(A) Representative NTA plot for exosome samples. All samples were diluted 1:100 for 
NTA. (B) Exosomes were isolated from 21 different cell lines, cultured to 
approximately 70% confluence. At the time of exosome collection media removal, cells 
were quantified with a Nexcelom Cellometer. Exosome number as determined by NTA 
(Nanosight) was then normalized to cell number. Error bars indicate SEM. (C) 
Percentage of viable cells after 48-hour incubation in serum-free, 1% BSA 
supplemented exosome collection media, assessed with an Annexin V/7-AAD 
live/dead flow cytometry assay. (D) Percentage of viable cells after 48-hour incubation 
in complete media, assessed with an Annexin V/7-AAD live/dead flow cytometry 
assay. (E) Tumorigenic (red) and non-tumorigenic (blue) cell lines were grown to 70% 
confluence and exosomes were collected after 48 hours of incubation in collection 
media. Particle concentration was detected by NTA (Nanosight) and EV production 
normalized per cell number at the time of collection (particle number per cell). Note 
differences in exosome production by distinct cell lines. Error bars indicate SEM. (F) 
nuclease-resistant exosome DNA was isolated and quantified by Qubit. The amount 
of nuclease-resistant DNA is normalized to particle number for each cell line. Error 
bars indicate SEM.  
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 Additionally, Pearson Correlation analyses were performed to determine 
whether exosomal DNA correlated with the particle numbers per cell or particle size. 
We determined that neither number of exosomes released, nor the size of the 
exosomes correlated with exosomal DNA yields (Figure 4A,B). The Qubit DNA assay 
detection limits were also evaluated, to determine the lowest amount of detectable 
DNA (Figure 4C). We then sought to ensure that Dnase treatment prior to DNA 
isolation did not affect the integrity of the exosomes themselves, as determined by 
NTA (Figure 4D). Finally, we demonstrated the efficacy of the Dnase treatment. 
Exosome-associated DNA was greatly reduced post-Dnase incubation, but we 
observed that if Dnase was inactivated prior to exosome lysis by adding EGTA or a 
commercial Dnase inhibitor, up to 49% of the total DNA was retained (Figure 4E, 
Table 5). We further demonstrated that the Dnase-resistant DNA fraction could be 
accessed and readily degraded if exosome membranes were permeabilized with 
detergent, such as 1-10% Triton-X100 (Figure 4E,F, Table 6). Exosome size was also 
assessed via NTA and did not appreciably differ between cell lines. (Figure 4G). 
Exosomal DNA Increases With Exosome Number 
 In order to definitively ascertain whether exosomal DNA was associated 
specifically with exosomes, we designed a dilution curve of increasing exosome 
concentrations. Three cell lines were chosen (MDA-MB-231, SW620, and DiFi) that 
corresponded with those used in the Jeppesen et al. paper to enable relevant 
comparisons between the two bodies of work218. Exosomes isolated via  
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Figure 4. Characterization of Exosomal DNA. 
(A) Pearson Correlation Analysis shows no significant correlation between exosome 
production and the amount of exosomal DNA. (B) Pearson Correlation Analysis shows 
no significant correlation between exosome size and the amount of exosomal DNA. 
(C) Qubit low and high detection limits for the high specificity double-stranded DNA 
detection assay were obtained by generating a dilution curve of purified salmon DNA. 
Error bars indicate SEM. (D) To assess potential damage from Dnase treatment, 
exosome preparations were quantified by NTA before and after Dnase treatment. 
Dnase was inactivated with 100 mM EGTA, where indicated. No significant changes 
in particle number was noted. (E, F) To determine whether nuclease-resistance of 
DNA is conferred by the lipid bilayer, exosomes were subjected to Dnase treatment 
before and after detergent (1% Triton X100). The remaining DNA was measured by 
Qubit. Exosomal DNA was readily accessible to nucleases after detergent lysis. (F) 
DNA quality was subsequently assessed by microcapillary electrophoresis 
(BioAnayzer). (G) Particle diameter for each cell line as measured by NTA. Error bars 
indicate SEM. All assays were performed at least in triplicate. Statistical significance 
was assessed by one-tailed Student’s t-test in pairwise comparisons. *, P<0.05; ns, 
not significant. Data in D, E, and F was collected in collaboration with Paul Kurywchak. 
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Table 5. DNA extraction from crude exosomes: effects of different detergent 
concentrations, buffers, and Dnase pre-treatment. 
 
With Jennifer Leveille 
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Table 6. DNA yields after Dnase addition following detergent lysis of exosomes. 
 
With Jennifer Leveille 
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ultracentrifugation were quantified by Nanosight NTA and samples were separated 
out that contained distinct quantities of exosomes, ranging from 5x108 to 10x1010. 
DNA was then isolated as previously described and quantified by Qubit. In all three  
cell lines tested, exosomal DNA increased proportionally with exosome quantity, 
further validating the hypothesis that DNA is affiliated specifically with exosomes 
(Figure 5).  
 
Figure 5. Exosome DNA Increases With Exosome Number.  
Exosomes were isolated from 3 different cell lines (MDA-MB-231, SW620, and DiFi), 
and cultured to approximately 70% confluence. Exosomes were isolated as described 
above. Exosome number was determined by NTA, and exosomes were separated 
into 6 fractions of determined exosome quantity. DNA was isolated from each fraction 
as described previously. Exosome DNA concentration correlates with the number of 
exosomes.   
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Evaluation of Exosome DNA Content With Different Isolation Methods 
Exosome DNA Isolated Via Ultracentrifugation 
 In order to further link nuclease-resistant DNA to exosomes, we analyzed DNA 
content in exosomes isolated by 3 different methods: ultracentrifugation alone, 
fractionation using discontinuous isopycnic iodixanol (optiPrep) density gradients, and 
size-exclusion chromatography (Izon qEV columns). The final two methods are 
designed to separate exosomes between 70-180nm in diameter from contaminants 
including larger vesicles and soluble proteins216,280,281. We utilized the same three cell 
lines indicated by the Jeppesen et al. paper, MDA-MB-231, SW620, and DiFi218, and 
performed DNA isolation on equal numbers of exosomes both with and without Dnase 
treatment pre-lysis. 
 The initial method utilized was ultracentrifugation. This method has long been 
considered the gold standard of exosome isolation, however one of the major 
drawbacks involved is the co-precipitation of non-exosomal vesicles and molecules 
during the spinning process. Additionally, since the exosomes are spun at 100,000g, 
they can be damaged by the high shear force exerted on them. This method lends 
itself well to high volume exosome isolations and generally produces a high yield of 
exosomes. Accordingly, we observed the largest amount of exosomal DNA when 
using this isolation method. However, pre-lysis Dnase treatment removed a larger 
amount of the total DNA than with any other method, likely a consequence of 
exogenous DNA precipitating out of the media with the exosome pellet during 
ultracentrifugation (Figure 6). 
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Figure 6. Exosome DNA Isolation Via Ultracentrifugation. 
Exosomes were isolated after ~70% confluent cells were incubated in exosome 
collection media for 48 hours. Exosomes were isolated with ultracentrifugation only 
and quantified by NTA. Shown is the yield of exosomal DNA for each increasing 
number of exosomes either pre-treated with Dnase (red) or without Dnase (blue). 
 
Exosome DNA Isolated Via Size Exclusion 
 Considered one of the best methods for maintaining exosome structural 
integrity during isolation, size exclusion chromatography has become increasingly 
user-friendly with the advent of automated collection machines that have significantly 
decreased collection time. Despite the shorter duration, current size exclusion 
methods continue to preserve vesicle integrity with gravity-based column technology, 
though they do require small input volumes. We observed DNA yields similar in 
magnitude to the ultracentrifugation samples, however in this case Dnase treatment 
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barely had an effect on the overall exosomal DNA isolation totals (Figure 7A). This 
indicates that size exclusion is a superior method in terms of both yield and vesicle 
fraction purity, as contaminants such as cell-free DNA are removed by the column. 
We also collected fractions beyond the exosome rich four (7-10). We assessed DNA 
content up to fraction 30, pooled in sets of four (11-14, 15-18, 19-22, and 27-30). As 
expected, the amount of DNA decreases precipitously outside of the exosome 
enriched fractions, with the most seen in fractions 11-14, which is likely due to some 
residual exosomes eluting out of the column (Figure 7B). In order to further confirm 
the presence of DNA within the SE fractions, we also isolated exosomal DNA from 
three additional cell lines, two cancer lines and one non-tumorigenic line (HPDE, 
T3M4, Panc1). Each of these cell lines also produced exosomal DNA (Figure 7C).       
 
 
 
Figure 7. Exosome DNA Isolation Via Size Exclusion. 
(A) Shown is the yield of exosomal DNA for each increasing number of exosomes 
either pre-treated with Dnase (red) or without Dnase (blue). Exosomes were quantified 
using NTA. (B) Analysis of DNA content in size exclusion collection fractions 7-30, in 
pooled sets of 4. The largest amount of DNA is present in the exosome-rich fractions 
7-10. (C) Exosomal DNA isolated from pancreas lines for SE combined fractions 7-10 
(400uL). Error bars indicate SEM. 
 75 
 
 
 
 
 
 
 
 76 
Exosome DNA Isolated Via OptiPrep Density Gradient 
 Recent studies have begun to utilize density fractionation gradients to isolate 
more purified populations of exosomes202,216. While purity of the resultant samples is 
high, the yield is extremely low, which is a function of both exosome loss during the 
process as well as the required small input volume. In a recent paper, Jeppesen et al. 
introduce a customized method aimed at maximizing exosome purity by combining 
ultracentrifugation and density gradient fractionation. While the specific steps of the 
process are described in the methods section, briefly, the protocol involves four 
ultracentrifuge spins of four hours at 120,000g plus a 15-hour density gradient 
fractionation at 120,000g between the second and third ultracentrifugation spin. In 
their study, they split the density gradient into 12 1mL fractions and pool the “light” or 
less dense fractions 1-6 together as well as the “heavy” or more dense fractions 7-12. 
They then proceeded to attempt to isolate DNA from each pool and reported that they 
could not detect any DNA in the light fractions. These less dense fractions also happen 
to be where the highest expression of exosome-specific markers such as tetraspanins 
were seen, including CD81, CD9, and CD63. These results led them to conclude that 
there is no DNA in exosomes, only in larger, more dense vesicles. However, there 
was no quantification of the number of exosomes the DNA was isolated from, which 
invites an inquiry into whether they used enough input exosomes to generate a 
detectable amount of DNA218. Indeed, in an even more recent paper published by 
Lötvall’s group using a similar method of density fractionation, albeit without several 
of the extra ultracentrifugation spins, they did in fact detect exosomal DNA in both low 
and high density particle fractions278. Therefore, we chose to fully replicate the 
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Jeppesen et al. isolation method with the same three cell lines mentioned previously, 
with the same concentration curve of input exosome number we used for the other 
methods, in an effort to definitively determine whether exosomes are present in the 
less dense fractions. While this method led to the lowest DNA yields of the three 
tested, we were in fact able to detect DNA in both the light and heavy gradient fractions 
in all 3 cell lines, even with Dnase treatment. Furthermore, several of the lower input 
number of exosome conditions, such as 5x108 and 1x109, generated little to no 
detectable DNA. These findings support the idea that a critical issue for Jeppesen et 
al. in their DNA detection assays was using too few exosomes for isolation (Figure 
8A). It is also worth noting that this isolation method caused extreme exosome loss 
over all of the centrifugation steps, so almost triple the number of cells had to be used 
to generate enough exosomes for analysis. In order to further confirm the presence of 
DNA within the light density fractions, we also isolated exosomal DNA from three 
additional cell lines, two cancer lines and one non-tumorigenic line (HPDE, T3M4, 
Panc1). Each of these cell lines also produced exosomal DNA in both the light and 
heavy gradient fractions. All samples in this case were pre-treated with Dnase prior to 
lysis (Figure 8B).  
Comparison of Exosome DNA Across Different Isolation Methods 
 DNA isolation and subsequent quality analysis was performed on exosomes 
from each of the three methods described above, with and without Dnase treatment. 
A comparison of the DNA yields across the methods reveals that ultracentrifugation 
allows the recovery of the most total DNA. However, after Dnase treatment a 
substantial fraction of the DNA is removed, demonstrating that a portion of the sample  
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Figure 8. Exosome DNA Isolation Via OptiPrep Density Gradient. 
(A) Exosomes were isolated with a combination of ultracentrifugation and OptiPrep 
Density Gradient methods. Shown is the yield of exosomal DNA for each increasing 
number of exosomes either pre-treated with Dnase (red) or without Dnase (blue). (B) 
Exosomes were isolated by the same methods using three pancreatic lines. All 
samples were treated with Dnase prior to lysis, and all showed DNA in both density 
fraction pools. 
 
is exogenous DNA external to the exosomes that has co-precipitated. The optiPrep 
fractionation method generated the lowest amount of exosomal DNA, which is likely 
due to both the small input volume and high number of centrifugation steps. Overall, 
size exclusion chromatography generated a substantial amount of highly pure 
exosome DNA, as evidenced by the loss of only very little total DNA after Dnase 
treatment (Figure 9A). After isolation, we subjected the DNA to quality assessment 
analysis via chip electrophoresis (bioanalyzer), which showed the presence of 
detectable amounts of high-molecular weight DNA in all of the conditions assessed 
(Figure 9B,C). Interestingly, the bioanalyzer results re-iterate that size exclusion 
exosomal DNA is the purest, as that approach is the only one to retain the high-
molecular weight fragments (>2Kb) of DNA after Dnase treatment (Figure 9C). 
Additionally, a 150bp band seen in several of the fractions is suggestive of 
nucleosome DNA organization (Figure 9C). NTA was performed on each sample prior 
to DNA isolation and showed consistent exosome size across each isolation method 
(Figure 9D). 
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Figure 9. Comparison of Exosome DNA Across Isolation Methods. 
(A) Exosomes were isolated by three distinct methods as previously described. DNA 
was obtained from the indicated particle numbers, either with or without Dnase pre-
treatment. The presence of nuclease resistant DNA is seen in all fractions tested. Size 
Exclusion exosomes demonstrate the least sensitivity to nuclease treatment, 
indicating the purity of the exosome fractions. Statistical significance was evaluated 
by multiple comparison t-test or two-way ANOVA. ****, P<0.0001; **, P<0.01; *, 
P<0.05; ns, not significant. (B) Exosome DNA from each method with and without 
Dnase pre-treatment was analyzed by capillary electrophoresis (BioAnalyzer). 
Genomic DNA isolated from matched cell sources were used as positive controls. (C) 
Visual representation of the data shown in B. Black arrow indicates the largest 
fragment size DNA, seen in cell samples; blue arrow indicates high molecular weight 
(>2Kb) fragments; red arrow indicates 150bp nucleosome band. (D) Representative 
NTA Nanosight plots for each isolation method, including ultracentrifugation, size 
exclusion, optiPrep fractions 1-6, and optiPrep fractions 7-12. Plots indicate consistent 
size distribution and provide particle concentrations for each sample. Samples were 
diluted 1:100 in sterile water for measurement.    
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Copy Number Analysis of Exosome DNA Across Different Isolation Methods 
 Whole genome sequencing was performed on the DNA isolated from 
exosomes from each method, with or without Dnase treatment. Prior to Dnase 
treatment, exosomal DNA fragments collected from each method, when pooled, cover 
the entire genome with copy number variations (CNVs) closely matching those found 
in matching cellular genomic DNA (Figure 10 A,B,C). However, after Dnase 
treatment, only the size exclusion-generated exosomal DNA produced CNVs that still 
matched the cellular DNA very closely. Yet, each sample still spanned the entire 
genome and generally reflected the CNV patterns of the cells of origin (Figure 10 
A,B,C). This data further suggests that size exclusion is the optimal exosome isolation 
method for exosomal DNA applications.     
Exosomal DNA is Degraded After Membrane Lysis 
 To ensure that the Dnase-resistant DNA was indeed able to be degraded after 
losing the protection of the exosome membrane, we treated isolated DNA with Dnase 
post-lysis. DNA was used from each exosome isolation method, as well as cellular 
genomic DNA, and all were analyzed by capillary electrophoresis (BioAnalyzer). As 
expected, the DNA was degraded when treated with Dnase post-lysis, but not pre-
lysis of the exosome membrane (Figure 11). This supports the notion that the DNA is 
intraluminal and is protected from degradation by being encapsulated within the 
exosomal membrane, instead of having degradation prevented by some other 
mechanism.  
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Figure 10. Exosomal DNA fragments Cumulatively Cover the Whole Genome. 
(A,B,C) Total exosomal DNA and Dnase-protected exosomal DNA were isolated from 
three different cell lines using the three methods described previously. DNA from each 
condition was subjected to whole genome sequencing and analyzed for copy number 
variations in comparison with genomic DNA isolated from the cells of origin. Exosome 
DNA isolated by size exclusion provides the best representation of copy number 
patterns compared with genomic DNA, regardless of DNase pre-treatment. The copy 
number patterns are shown for MDA-MB 231 (A), SW620 (B), and DiFi (C). Copy 
number gains are illustrated in red, losses in green, and neutral sites are blue. 
 
 
 
 
 
Figure 11. Exosomal DNA is degraded after membrane lysis. 
DNA was isolated from SW620 cells and exosomes. Exosomes were isolated by 
ultracentrifugation (UC), Size Exclusion (SE), and OptiPrep density gradient 
fractionation. For each method, samples were either untreated, treated with Dnase 
pre-lysis, or treated with Dnase post-lysis. In each case, treatment with Dnase post-
lysis degraded the large fragments of DNA while those fragments were preserved with 
treatment pre-lysis. 
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Western Blot Validation of Exosome Markers 
To demonstrate the presence of exosomes in the appropriate fractions for size 
exclusion and the optiPrep density gradients, western blots for canonical exosome 
markers were run for the samples from each cell line. As observed previously for the 
density gradients218, exosome markers CD63, CD81, and CD9 were predominantly 
seen in fractions 2-6 (Figure 12 B,D,F) with flotation density between 0.4-1.18. For 
size exclusion, the same markers co-localized as expected in the exosome-rich 
fractions 7-10, while soluble proteins eluted in the non-overlapping distal fractions 
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(Figure 12 C,E,G). Additionally, it is thought that extranuclear genomic DNA remains 
associated with histones and, at least in part, retains nucleosome organization282. 
Indeed, evidence of a band pattern consistent with approximately 150-bp nucleosome 
structures is clearly visible in Figure 9C. In agreement with this, optiPrep density 
gradient fractions showed an enrichment of histone 4, especially in the exosomes 
released by MDA-MB-231 and DiFi cells (Fig 12 B,D,F). All size exclusion fractions 
positive for CD63, CD81, and CD9 were also strongly positive for histone H4 (Figure 
12 C,E,G). Finally, to ensure that the optiPrep fractions had in fact separated into 
layers of increasing density from 1-12, absorbance was measured at 340nm 
wavelength with a plate reader for every gradient, as described elsewhere278. A 
representative plot of flotation density from one gradient is shown in Figure 12A.       
Flow Cytometry Validation of Exosome Markers 
 As a secondary method of exosome validation, we took exosomes from each 
isolation method, with and without DNase treatment, and assessed the samples for 
the presence of the canonical exosome markers CD9 and CD81 via flow cytometry. 
Exosomes were bound to aldehyde/sulfate beads (Invitrogen A37304) and incubated 
with the appropriate primary antibody (Table 4). Secondary antibody (Alexa Fluor 488 
donkey anti-mouse, Invitrogen A21202) was added and beads were subsequently run 
on the BD LSR Fortessa flow cytometer for analysis. Exosomes isolated by each 
method were highly positive for both markers, though the UC isolation samples were 
not as positive as SEC or density gradient, consistent with the idea that UC is the 
method with the lowest sample purity (Figure 13A,B). Additionally, this data serves to  
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Figure 12. Western Blots for Exosome Markers. 
(A) Flotation density plot for each optiPrep fraction as measured with a plate reader 
at 340nm wavelength. The “light” or less dense fractions are indicated by the pale 
background, while the heavy fractions have a red background. (B-G) Exosomes were 
isolated by ultracentrifugation from three cell lines, MDA-MB 231, SW 620 and DiFi 
and further purified by Iodixanol gradient ultracentrifugation (OptiPrep) and by size 
exclusion chromatography (Sephadex columns, qEV, Izon). Fractions were run on 
polyacrylamide gels and analyzed by western blots probed with antibodies for typical 
exosomal markers, CD9, CD63 and CD81. To assess the potential distribution of DNA 
among fractions, the membranes were also probed with antibodies for histone H4. 
Note the overlap of histone H4 with tetraspanin-positive fractions. 
 
Figure 13. Flow Cytometry Validation of Exosome Markers. 
(A) Assessment of CD9 tetraspanin expression by flow cytometry. Exosomes from 
each of the three isolation methods (UC, SE, Density Gradient) with or without DNase 
treatment prior to lysis were bound to beads and stained for CD9. Unstained cells and 
isotype controls were used for gating. The blue peak indicates CD9 expression in 
comparison to the red isotype negative control. All samples tested were positive for 
CD9, though the UC samples were the least positive (peak shifted left). (B) 
Assessment of CD81 tetraspanin expression by flow cytometry. Results same as for 
A, just with the CD81 marker, showing consistency in exosome marker expression 
across all samples. 
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confirm that even after DNase treatment, exosome surface markers remain intact, 
indicating that they retain membrane integrity. 
Argonaute-2 is also associated with exosomes across different isolation methods 
Previous studies in our lab and others showed cell-autonomous miRNA-
processing capacity of exosomes, due to the presence of intraluminal Argonaute-2 
(Ago-2) and other components of RISC complexes, such as Dicer30,283. These findings 
were also questioned in the recent Jeppesen study, which identified Ago-2 in the non-
EV fractions of isopycnic Iodixanol gradients218. Rigorous analysis of the exosomes 
released by the same cell lines used in the paper showed, that, like DNA uptake, the 
association of Ago-2 with the exosomes appeared to be at least partially cell-type 
dependent. After crude exosomes isolated from DiFi cells were separated by Iodixanol 
gradient, the exosomes were found in fractions 3-6, as was evidenced by WES of 
fraction aliquots for the exosome marker Flotillin-1 (Figure 14A). Ago-2 was clearly 
present in fractions 3-5 and formed a distinct secondary peak in fractions 7,8 (non-
exosome-containing fractions) (Figure 14A). In the case of MDA-MB 231, the 
exosomes were predominant in fractions 4-8. Ago-2 was significantly more abundant 
than in DiFi exosomes and segregated in fractions 6-8 and 9-10 (secondary peak, 
Figure 14B). Size exclusion eluates (fractions 7-10 and every 5th fraction thereafter) 
presented with Ago-2 in all exosome-containing fractions (Figure 14C, D), but only in 
the case of the DiFi cells were Ago-2 levels sufficiently high to detect a secondary 
peak in a soluble fraction (fraction 20, Figure 14C).  
To specifically determine the localization of Ago-2 relative to the exosome 
membrane, we performed limited proteinase K digestion of crude exosome 
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preparations as well as exosomes purified by size exclusion chromatography. As a 
positive control, we used antibodies raised against the large extracellular loop of CD81 
(aa 90-200), and antibodies against intraluminal protein Flotillin-1 served as a negative 
control. The conditions were adjusted so that CD81 was completely digested, while 
Flotillin remained intact (Figure 14E). Using the WES microcapillary immunoassay, 
we showed that after proteinase K digestion, Flotillin-1 and a significant portion of Ago-
2 remained intact, while the extramembrane portion of CD81 was no longer detectable 
(Figure 14F).  Interestingly, another protein thought to be associated with exosomes, 
an autophagy marker LC-3B, was clearly present in crude exosome preparations 
(Figure 14G). However, it was readily removed by proteinase K digestion and not 
detectable in the size exclusion-purified exosomes, suggesting that at least in this 
biological context, exosome formation was independent of autophagy.   
Conclusion 
 Here, we have definitively demonstrated the presence of DNA in exosomes 
using multiple isolation methods, both with and without Dnase treatment. The amount 
of DNA packaged within exosomes is highly variable depending on the cell line of 
origin, but cumulatively recapitulates the entire genome. Additionally, exosomes 
maintain surface marker integrity regardless of Dnase treatment, indicating their 
membranes are intact. Exosomes also contain proteins such as tetraspanins CD63, 
CD9, and CD81, as well as Histone H4 and Ago-2.  
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Figure 14. Argonaute-2 is present in size exclusion and density gradient isolated 
exosomes. 
(A,B) Exosome fractions were isolated by optiPrep density gradient from the cell lines 
DiFi (A) and MDA-MB 231 (B). Protein extracts were prepared and assessed for Ago-
2 content by WES microcapillary immunoassay. Similarly loaded extracts were probed 
with antibodies for Flotillin-1 as a control to assess protein loading. Differences are 
observed in Ago-2 incorporation between individual cell lines. (C, D) Crude Exosome 
isolates were fractionated by size exclusion chromatography for the indicated cell 
lines. Equal volume from each fraction was loaded onto a WES cassette and probed 
with antibodies against Flotillin-1 (C), or Ago-2 (D) to assess exosome protein content. 
Ago-2 was present in flotillin-positive fractions containing exosomes. (E) Proteinase k 
treatment was optimized to completely degrade exosome membrane marker CD81, 
representative of external exosome-associated proteins, but not flotillin-1, 
representative of intraluminal exosome proteins. (F) Proteinase k treated exosomes 
from the indicated cell lines and isolation methods demonstrated a decrease in Ago-
2 but still clearly showed some remaining, indicating that at least a portion of the Ago-
2 associated with exosomes is inside the intraluminal space. (G) The autophagy 
marker LC-3B is present in ultracentrifugation but not size exclusion-isolated 
exosomes, and is degraded by proteinase k treatment. This suggests that LC-3B is 
not contained within these exosomes, indicating they were generated in a process 
independent of autophagy. These experiments were performed in collaboration with 
Laura M. Snowden and Olga Volpert. 
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Introduction 
 Despite the relative paucity of characterization of exosomal DNA compared to 
other exosome cargo, several studies point to the great potential of exosomal DNA as 
a biomarker for diagnosis and monitoring of cancer and other diseases. Indeed, 
multiple groups have been able to isolate exosomal DNA from patient samples and 
identify specific polymorphisms and pathogenic mutations in those specimens 105–
107,162. There has been very little investigation, however, into determining whether or 
not epigenetic modifications can be detected on exosomal DNA and if so, whether 
they are representative of the state of the donor epigenome. Studies over the past 
several decades have made it increasingly obvious that mutations alone do not 
comprehensively define many complex disease states, such as cancer284. Epigenetic 
profiles, especially methylation patterns, have also been demonstrated to provide 
valuable clues for the diagnosis and treatment of disease, as methylation changes 
can be as effective as mutations in disease pathogenesis285,286. It has now been well 
established that differential methylation can produce clinically relevant changes in 
gene expression, with major roles in the development and outcome of several 
diseases287. Thus, developing new methods for the detection of aberrant methylation 
profiles or patterns, especially those linked to disease progression, would be 
invaluable.  
Perhaps because the field of exosomal DNA research is relatively nascent, 
there is a distinct lack of information with regards to exosomal DNA methylation. The 
existing epigenetics-related exosome studies have instead focused on the ability of 
exosomes to perpetrate epigenetic changes in recipient cells by delivering protein 
 100 
cargo capable of enhancing methylation or demethylation 288. To date, the number of 
published studies analyzing the potential of exosomal DNA for methylation detection 
remains minimal. In the first study, done by the Lyden group, a DNA dot blot probed 
for anti 5’-methyl cytosine and demonstrated comparable levels of methylation on 
cytosines in exosomal DNA and in cellular genomic DNA47. Another group interested 
in gastric cancer demonstrated similar methylation profiles of the BARHL2 locus, 
LINE1, and SOX17 genes in the exosomal DNA from the gastric juice and gastric 
cancer cells of patients by site-specific bisulfite PCR and bisulfite pyrosequencing289.  
Beyond these studies, no comprehensive analysis have been performed investigating 
the extent, patterning or potential function of exosomal DNA methylation. We 
hypothesized that exosomal DNA is methylated, and that the methylation patterns on 
exosomal DNA recapitulate those of the cell of origin. The aim of this section is to  
systematically address the correlation between methylation patterns in the exosomal 
DNA and cells of origin. These findings will provide solid foundation for potential use 
of exosomal DNA methylation analysis  as a diagnostic strategy. This is especially 
relevant for cancers notorious for late diagnosis, such as pancreatic ductal 
adenocarcinoma (PDAC). 
Characterization of PDAC Cell Line Exosome DNA Methylation 
Exosomal DNA is Methylated 
 Initial experiments aimed to determine whether exosomal DNA is methylated 
(Figure 15). For that purpose, genomic DNA was isolated from cells and matched 
exosomal DNA were collected by ultracentrifugation. Six tumorigenic PDAC lines 
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(Panc1, BXPC3, Capan-1, T3M4, MiaPaCa2, and PSN1) and two non-tumorigenic 
lines (HPNE and HPDE) were used. The DNA was then purified using the method  
 
Figure 15. Schematic of methylation detection experiment design 
Nuclear genomic and exosomal DNA were isolated from multiple cell lines, both 
tumorigenic and non-tumorigenic, and subsequently underwent bisulfite conversion, 
library formation, and reduced representation bisulfite sequencing (RRBS). 
 
described previously (DNeasy Mini Kit, Qiagen with minor modifications) and 
subjected to bisulfite conversion, a process that changes unmethylated cytosines into 
uracils, which are subsequently converted to thymidines during PCR amplification. 
This method allows for the identification of methylated and unmethylated cytosines 
when sequenced. Samples then underwent reduced representation bisulfite 
sequencing (RRBS). While genome-wide cytosine methylation analysis is possible, 
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methylated cytosines tend to cluster in CpG dinucleotide-rich areas called CpG 
islands, often in the promoter regions of genes, that collectively span a very small 
portion of the genome. RRBS targets CpG rich regions using a primer library, which 
then generates site-specific fragments. This method also only requires small amounts 
of DNA, which is useful for exosomal DNA applications290,291. During analysis, the 
amplified fragments, or reads, are mapped to specific regions of DNA using reference 
sequences. The number of C-to-T conversions is then quantified for all of the mapped 
reads, generating a beta value for methylation at each site. Samples can then be 
compared in a site-specific manner between conditions, in this case between 
exosomal and matched cellular DNA.  
 A custom bioinformatics analysis pipeline was generated for this application 
through a collaboration with Dr. Kunal Rai’s laboratory at MD Anderson Cancer 
Center. Analysis of the first cell line tested, Panc1, demonstrated site-specific 
methylation patterns for both the exosome and cellular nuclear DNA. A Pearson 
correlation coefficient was calculated and exosome DNA methylation was observed 
to be highly concordant with the nuclear DNA methylation (Figure 16). Interestingly, 
when differences were observed, exosomal DNA was more often hypermethylated 
(n=3510 genes) than hypomethylated (n=27 genes) compared to the nuclear DNA, 
suggesting that perhaps exosomal DNA is protected from demethylating enzymes 
when it is packaged inside exosomes. Subsequently, the analysis was expanded to 
include multiple cell lines, and the quality control of sequencing data showed sufficient 
quality, read depth, and alignment to produce reliable results (Figure 17 A-C). 
Therefore, we for the first time provide conclusive reliable and reproducible evidence  
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Figure 16. High correlation between cell and exosome methylation patterns. 
 Correlation of methylation patterns between cell gDNA end exosome DNA isolates 
was very high, with a Pearson Correlation coefficient of 0.94. These samples are 
representative of what was observed across multiple cell lines. Exosome samples 
were treated with Dnase prior to lysis. This analysis was performed by Dr. Tommy 
Tang in Dr. Kunal Rai’s laboratory. 
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Figure 17. Quality control of sequencing data 
(A) Alignment rates were high among all samples. (B) base call quality is high, 
indicating there are few sequencing errors and the reads can be accurately analyzed. 
(C) There is a high number of duplicates, which is expected as a result of the primer 
library used in RRBS to amplify specific sites of the genome. 
 
that exosomal DNA is methylated and harbors highly conserved methylation patterns 
from the cell of origin.     
Exosome DNA Methylation Patterns Reflect Methylation of the Cell of Origin 
We then aimed to determine whether the methylation patterns seen in the 
pooled exosome samples were sufficiently unique to provide a cell line-specific 
signature. To achieve this, broad Pearson Correlation analyses were performed to 
compare each cell and exosome sample from a given cell line to those from others 
(all done in biological triplicates, 6 samples total per line, 3 cell and 3 exosome). As 
illustrated in Figure 18, methylation patterns identified on cell gDNA and exosomal 
DNA are closely matched when compared within a single cell type. However, if 
samples are compared between cell lines, the correlation significantly decreases. 
These data suggest that exosomal DNA not only recapitulates the methylation 
patterns of the cell of origin but also carries a cell-specific methylation signature with 
high fidelity. 
Exosome DNA Methylation Patterns Can Specifically Identify the Cell of Origin 
 Since we discovered that methylation patterns found on exosomal DNA are 
distinct and correlated extremely well with the methylation patterns observed on the  
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Figure 18. There is high methylation pattern correlation among samples from 
the same cell line. Example of a comparison between genomic cell and exosome 
DNA for two lines, Panc1 and HPDE. As outlined in red, samples from the same cell 
type, regardless of origin, cluster together. Samples from different cell lines have 
markedly lower correlation. This analysis was performed by Dr. Tommy Tang in Dr. 
Kunal Rai’s laboratory. 
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Figure 19. Clustering Analysis for All Eight Cell Lines. 
All biological replicates of cellular and exosomal DNA from each individual cell line 
cluster together, based on methylation pattern comparison. The segregation of 
exosome and nuclear DNA according to the cell line of origin indicates that exosomal 
DNA carries a cell line-specific signature. This analysis was performed by Dr. Tommy 
Tang in Dr. Kunal Rai’s laboratory. 
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genomic DNA of the cell of origin, we then performed a clustering analysis across all 
cell and exosome samples. (Figure 19). This assay demonstrated that both the  
cellular gDNA and exosomal DNA from each individual cell line cluster together, and 
are unique and separate from any other line. This implies that exosome-derived 
methylation signatures could be used for the detection of cancer-specific markers in 
patients. 
Methylation Marks Detected on Exosome DNA Span All Chromosomes 
Since RRBS employs sequencing library generation using primers specific to 
known frequently methylated areas of the genome, it is possible to perform a post-
sequencing analysis of genome read coverage. We demonstrate here that exosomal 
DNA methylation patterns are representative of every chromosome in the genome in 
every sample. This finding provides conclusive evidence that pooled exosomal DNA 
preparations can yield genome-wide methylation data, with no overt biases for any 
specific loci or hotspots (Figure 20). 
Exosome DNA Can be Used to Investigate Site-Specific Methylation Changes 
We next tested the possibility of probing the exosomal RRBS sequencing 
datasets for the presence of cancer-specific methylation changes when comparing the 
PDAC and non-tumorigenic cell lines. An in-depth literature search identified over 75 
functionally diverse genes differentially methylated in PDAC (Table 7). The top six 
were chosen for site-specific analysis (Table 8). The Broad Institute Integrative 
Genomics Viewer (IGV) software was used to visualize methylation levels in the 
promoter regions of the genes of interest (Figure 21A). The percentage of methylated  
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Figure 20. Methylation marks from cells and exosomes span all chromosomes. 
Representative analysis of reads per chromosome for each sample (3 cellular 
genomic and 3 exosome DNA samples for each cell line, 8 cell lines total). Each plot 
represents a single sample, and each gray bar indicates a single chromosome. Every 
chromosome is represented in every sample. This analysis was performed by Dr. 
Tommy Tang in Dr. Kunal Rai’s laboratory. 
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Table 7. Genes Differentially Methylated in PDAC. 
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Table 7 Continued. 
Table References289,292–298 
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reads was determined on a single-base pair level, for all CpG dinucleotides within the 
promoter regions (Figure 21B). For the six genes of interest, the average overall 
promoter methylation was determined for both the genomic and exosomal DNA 
samples from all eight cell lines used in the study (Figure 22). Similar methylation 
patterns were maintained in exosomal/cellular gDNA in tumorigenic and non-
tumorigenic groups, with the non-tumorigenic lines generally demonstrating promoter 
hypomethylation and the tumorigenic lines presenting with promoter 
hypermethylation, consistent with published information for each of the gene 
methylation states (PDAC vs. healthy tissue). There is some variation within the 
groups on a cell-line specific basis, which is to be expected due to variability due to 
inherent cell culture heterogeneity.  These findings indicate that exosomal DNA can 
be utilized to identify site-specific methylation changes with good reliability, which 
could be utilized for discovery or precision medicine.   
Exosome DNA Can Detect Decreased Methylation in Cells Treated With 5AZA 
Since demethylating agents are being utilized in cancer therapy299, we chose 
to investigate whether exosomal DNA is suitable for the detection of large-scale 
methylation changes resulting from treatment with 5-Azacitidine (5AZA), a chemical  
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Figure 21. Use of Broad IGV Software to assess site-specific methylation. 
(A) Visualization of methylation (blue bars) in the promoter region (red box) of the 
gene ELOVL4 across cellular and exosomal DNA samples. This strategy allows for 
quantification of methylation in specific regions of genes of interest. (B) Methylation 
rates of individual CpG dinucleotide sites shown as percentage of methylated reads 
at each site in each sample. Allows for an assessment of the degree of methylation at 
each site in a given sample.  
 
 
 
 
Figure 22. Average Overall Promoter Methylation in Genes Frequently 
Hypermethylated in PDAC.  
(A-F) Six genes established as frequently hypermethylated in pancreatic cancer 
(ELOVL4 (A), BNIP3 (B), ZNF415 (C), TFPI2 (D), RASSF1A(E) and CLDN5 (F)) were 
assessed for percentage of promoter methylation levels in both cellular genomic and 
exosome DNA samples. Non-tumorigenic cell lines (HPNE, HPDE) are shown on the 
left and tumorigenic ones (Panc1, T3M4, BXPC3, MiaPaCa2, Capan1, PSN1) are on 
the right in each graph. Generally, the non-tumorigenic samples from both genomic 
and exosomal DNA exhibited hypomethylation while tumorigenic samples showed 
hypermethylation, consistent with PDAC methylation changes reported in the 
literature. 
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analogue of the nucleoside cytidine that, at low doses, inhibits DNA methyltransferase 
and causes DNA hypomethylation300. Panc1 cells were treated with increasing doses 
of 5AZA to generate a dose-response curve and determine the optimal non-lethal 
demethylating dose (Figure 23A). We then utilized this dose in a high- sensitivity 
fluorescence-based assay to detect methylated DNA using a 5-methylcytosine 
antibody in Panc1 nuclear gDNA and exosome DNA from cells with and without 
exposure to 5AZA. Preliminary experiments have shown that decreased methylation 
levels could be detected in exosomes isolated from 5AZA-treated cells (Figure 23B). 
This highlights a potential application for using patient-derived exosomes to monitor 
the in vivo efficacy of demethylating agents. 
 
 
 
 
Figure 23. Exosomes can be used to detect drug-induced methylation changes. 
(A) Dose-response curve to determine the optimal non-toxic dose of 5-AZA in Panc1 
cells (red box). (B) Methylation levels were assessed in nuclear genomic DNA and 
exosomal DNA from cells with or without 5AZA treatment using the Abnova 
Methylated DNA Quantification Kit. Formulas for methylation level calculations are 
shown. Methylation levels are decreased in both genomic and exosomal DNA 
samples after 5AZA treatment, indicating that exosomal DNA reflects rapid 
methylation changes due to drug treatment. 
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Analysis of Exosomal DNA Methylation in PDAC Patients 
PDAC Patient Information 
 In current work, we have begun to evaluate the utility of exosomes for clinical 
analysis of DNA methylation. We obtained three matched PDAC patient tumor - serum 
pairs in order to perform a comparison between methylation patterns. This is a 
significant challenge since only a fraction of exosomes in the patient’s circulation 
originates from the tumor, while other exosomes come from non-cancerous tissues 
and are likely to have distinct methylation patterns. Thus, it is unclear whether the 
sensitivity of this method will be sufficient to discern cancer-derived epigenetic 
signature(s). Patient information is shown in Table 9. All patients had a confirmed 
PDAC diagnosis and underwent a type of tumor resection surgery. We obtained snap-
frozen fragments of resected tumor and serum from each patient. 
 
Differences in Exosome Sequencing Preparation Using Serum Exosomes 
 DNA was isolated directly from tumor tissue for analysis. For the matched 
serum samples, a modified exosome isolation procedure via ultracentrifugation was 
employed  using an extended spin time to maximize exosome yield from small-volume 
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samples. Exosomal DNA yield varied widely between patients, necessitating 
additional ultracentrifugation of the retained supernatants. Additionally, the DNA 
isolation protocol was modified, by extending elution procedure from the purification 
columns for several hours to maximize DNA yields. We elected to perform whole 
genome bisulfite sequencing (WGBS) instead of RRBS for these samples, due to the 
lower quality and increased fragmentation of the serum exosome DNA. WGBS does 
not require site-specific library generation and thus is not hindered by increased 
fragmentation. A major limitation for methylation-based sequencing analyses is the 
requirement for sufficient amounts of template DNA for bisulfite conversion prior to 
sequencing, with large enough fragments for library preparation in case of RRBS. We 
found that a minimum of 200ng of exosome DNA is required for RRBS/WGBS to be 
successful, and given the heterogeneity of serum exosomal DNA additional sample is 
preferable in order to generate sufficient read depth. A schematic of the isolation 
workflow is presented in Figure 24. 
 
 
 
Figure 24. Schematic of patient sample isolation methods. 
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 Currently, we have completed bisulfite conversion, library generation, and 
sequencing for three matched sets of patient samples (tumor and serum exosome 
DNA). Obstacles for analysis have included high noise and low base read coverage, 
likely due to the presence of non-tumor exosomes in the patient serum, a confounding 
variable not present when isolating exosomes from purified cell line populations. 
Strategies for optimization may include utilizing a higher volume of input serum for 
exosome isolation or targeted sequence amplification for relevant site-specific 
oncogenic methylation changes. 
Conclusion 
 Exosomal DNA is methylated, and as shown above can faithfully recapitulate 
the methylation patterns of the cell of origin with high fidelity. Additionally, the 
exosomal DNA methylation marks collectively span the entire genome and can be 
sequenced and mapped for the analysis of genes of interest. Exosomal DNA 
methylation patterns can be used to detect site-specific changes in methylation, and 
can potentially identify oncogenic changes in cancer patients using biological fluid 
liquid biopsies.  
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Introduction 
 One of the major unanswered questions concerning exosomal DNA is the 
mechanism of DNA packaging into exosomes. Thus far, while several theories have 
been put forward, no studies have demonstrated how, or in what contexts, DNA is 
incorporated into exosomes. It is plausible that the mechanisms enabling the 
packaging of DNA into exosomes could be cell-type specific and dynamically 
regulated. While early studies suggested that exosomal DNA may be a characteristic 
of cancer cells and not of non-tumorigenic cells47, data presented earlier in this work 
clearly shows that both tumorigenic and non-tumorigenic lines are capable of 
producing large amounts of exosomal DNA. The levels of exosomal DNA are however 
widely variable between different cell lines regardless of tumorigenicity. It has been 
proposed that exosomal DNA could escape into the cytoplasm at times when the 
nuclear envelope is compromised or, in the case of mitosis, disassembled276. The 
biogenesis of exosomes involves the formation of multi-vesicular bodies of endosomal 
origin, which could potentially draw in cytoplasmic components during intraluminal 
membrane budding, to be encapsulated within exosomes40. If DNA, either free or 
organized in nucleosomes, was present in the cytoplasm, this could be one 
mechanism by which it could appear in exosomes. Indeed, a recent study by 
Takahashi et al. proposed that exosomes maintain cellular homeostasis by removing 
cytosolic DNA from cells, keeping DNA fragments from being sensed by STING and 
thereby preventing the activation of harmful innate immune responses and reactive 
oxygen species (ROS)-driven DNA damage responses108.  
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 The mechanism by which DNA could escape the nucleus, however, remains 
elusive. A family of proteins have been shown to be frequently disrupted in cancer 
cells with potential consequences for the integrity of the nuclear envelope. Altered or 
aberrant expression of the Lamin proteins, specifically Lamins A & C, have been 
commonly observed to be disrupted in cancer cells, leading to nuclear envelope 
disruption and other effects that can promote tumor progression301–303. Lamins have 
also been ascribed a role in chromosomal organization and movement during different 
phases of the cell cycle; this role indicates interactions with DNA304. We decided to 
investigate the hypothesis that exosomal DNA packaging is dependent on nuclear 
envelope integrity. Here, we sought to determine whether manipulating nuclear 
envelope integrity by altering Lamin A/C expression could influence exosomal DNA 
content by increasing the permeability of the nuclear membrane and increasing DNA 
mobility by reducing lamin-mediated anchorage. This could provide important 
mechanistic insight for exosomal DNA packaging by linking exosomal DNA content to 
the structural integrity and permeability of the nucleus.    
Linking Nuclear Envelope Integrity and Exosome DNA Content 
Demonstration of Lamin A/C Knockdown in Cells 
 Lamin A/C knockdown has been demonstrated to be non-lethal to cells, due in 
part to the functional redundancy of Lamin B305,306. We performed an siRNA 
knockdown of Lamin A/C in three cell lines, Panc1, T3M4, and HPNE. The lines were 
chosen based on their tumorigenicity and exosomal DNA packaging capabilities. 
Panc1 is tumorigenic, with low baseline DNA content, T3M4 is tumorigenic with high 
baseline DNA content, and HPNE is non-tumorigenic with very low amounts of 
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detectable exosomal DNA. Knockdown efficiency in each cell line was validated by 
qPCR expression analysis (Figure 25A).  
Exosome DNA Content Correlates With Lamin A/C Expression 
 After confirming the siRNA knockdown of Lamin A/C in the cells of interest, I 
proceeded to isolate exosomes from control (untreated, transfection agent alone, 
scrambled siRNA control), and Lamin A/C knockdown cells. The same number of cells 
were seeded for each condition and grown to 75-85% confluence prior to exosome 
collection. DNA was then isolated from  exosomes as described previously. For each 
cell line, Lamin A/C knockdown caused a dramatic increase in exosomal DNA content, 
which was statistically significant (Figure 25B). This work implies a link between 
exosomal DNA packaging and the integrity of the nuclear envelope.  
Conclusion 
 Here, we demonstrate that by decreasing the expression of the nuclear 
envelope structural proteins Lamin A & C a corresponding increase in exosomal DNA 
was observed. This implies that nuclear envelope breakdown or compromise could be 
an integral part of the process of packaging DNA into exosomes. While further work 
is necessary to characterize the mechanism by which this occurs, this implicates both 
normal (cell cycle mediated nuclear envelope breakdown) and pathological (Lamin 
expression dysregulation) processes in exosomal DNA packaging.  
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Figure 25. Lamin A/C Knockdown significantly increases exosomal DNA 
content. 
(A) Lamin A/C siRNA knockdown validation by qPCR expression assay. (B) Exosomal 
DNA content is significantly upregulated after Lamin A/C knockdown in all three cell 
lines tested (Panc1, T3M4, and HPNE) when compared with untreated, transfection 
reagent, and siRNA scramble control conditions. Only one T225 flask of subconfluent 
cells per condition was used, as compared with the initial exosomal DNA 
characterization experiments where 3 flasks per line were used.  
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Introduction 
 Increasing evidence suggests that exosomes are critical for cell-cell and cross-
tissue communication under both normal physiological conditions and in cancer by 
shuttling variegated cargo, including DNA, RNA, and proteins, between cells16,84,202. 
Exosome-mediated signaling has been implicated in a variety of functions such as 
angiogenesis, immunity, proliferation, and tumorigenesis40,65,152,307. Since exosomes 
are released from virtually all cell types, and because their cargo has been shown to 
vary based on microenvironmental context such as cytotoxic stress, it is likely that 
their roles are context dependent and are influenced by environmental factors308.  
Chemotherapy and radiation eliminate cancer cells by causing acute genotoxic 
stress due to massive, genome-wide DNA damage. An unintended consequence of 
these treatments is the transfer of DNA damage response (DDR) from cancer cells to 
non-cancerous cells nearby309. Termed the bystander effect, this induction of DDR 
signals has been characterized in cells that have not been directly subjected to DNA 
damage but exist in proximity to irradiated cells 310,311. The bystander effect can have 
deleterious functional consequences, including DNA damage, chromosomal 
instability, mutations, and apoptosis309,312. While some molecular mediators of the 
bystander effect have been established, including reactive oxygen species 
(ROS)313,314, other mechanisms remain unclear. Additionally, almost all studies of the 
bystander effect focus on radiation-mediated damage, while little is known regarding 
the bystander effect of soluble damaging agents like chemotherapy. Some studies 
have suggested soluble factors such as cytokines could play a role312,315.  
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Given the well-established roles of exosomes in intercellular signaling, several 
groups have proposed exosomes as mediators of the bystander DDR effect. Some 
studies have shown that exosomes derived from irradiated cells show characteristic 
changes in cargo, including protein and RNA species, that could lead to downstream 
effects in naïve cells316–318. Additionally, it has been demonstrated that exosomes can 
induce bystander responses in naïve cells, potentially related to the transport of ROS 
or RNA molecules319–321. Overall, however, the mechanisms by which exosomes can 
generate bystander responses in cells remain vague and undefined. We hypothesize 
that exosomes mediate paracrine bystander DNA damage responses via the 
transportation of signaling molecules from cancer cells to naïve recipient cells. Here, 
we propose a role and a potential mechanism for exosomes in mediating paracrine 
DNA damage response activation in treatment-naïve, undamaged cells (Figure 26).  
 
Figure 26. Proposed model of exosome-mediated paracrine DDR activation. 
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Effects of DNA Damage on Exosomes 
DNA Damage Increases Exosome Release 
    Initially, we decided to characterize some of the properties of exosomes in 
the context DNA damage using different agents, hydrogen peroxide (H2O2) and 
ultraviolet (UV) radiation. H2O2 is a soluble factor that is converted into ROS and 
generates genome-wide double strand breaks, while UV radiation is a non-soluble 
DNA-damaging agent that causes the formation of T-T and T-C dimers, subsequently 
resulting in single and double-strand breaks 322. We first assessed exosome release 
in the context of DNA damage in three different PDAC cell lines (Panc1, T3M4, HPNE) 
and normalized the particle concentration to cell number. We found that while these 
two DNA-damaging agents did elicit a moderate increase in exosome release across 
all cell lines, the increase was not significant in comparison with control untreated cells 
(Figure 27A). One caveat to this approach is that the doses of response agents used 
were optimized specifically to be non-lethal, to enable cell survival for exosome 
collection, so a dose-response curve may be able to discern whether more toxic, and 
therefore more stressful, doses of each agent generate more exosomes.    
DNA Damage Does Not Impact Exosome Size 
 We also assessed the average size of the exosomes released by the same 
three cell lines, under the same conditions. Using Nanoparticle Tracking Analysis 
(Nanosight) we were able to determine that the size of exosomes is not impacted by 
DNA damaging agents. In fact, exosomes from each cell line in each condition had 
remarkably uniform size profiles (Figure 27B). 
DNA Damage Rarely Impacts Exosome DNA Content 
 130 
 Initially, we hypothesized that DNA damaging agents might generate an 
increased number of cytoplasmic DNA fragments that would be packaged into 
exosomes, leading to higher levels of DNA in exosomes released by the cells 
subjected to DNA damage. In this case, large amounts of fragmented exosomal DNA 
delivered to recipient cells could be the cause of bystander DDR by activating ectopic 
DNA sensing molecules in the cytosol, such as STING and Toll-Like Receptors 
(TLRs)108,323,324. However, when we measured DNA in the exosomes released from 
cells treated with DNA damaging agents, we found very modest upregulation of 
exosome DNA levels (Figure 27C). There was one notable exception; when T3M4 
cells were subjected to UV radiation (but not H2O2) their exosomal DNA content was 
increased more than 10-fold compared to all other conditions. This finding again 
indicates that packaging and sorting of exosomal contents is cell line and context 
dependent. 
 
 
Figure 27. Effects of DNA damage on exosome properties. 
(A) Treatment with either soluble (H2O2) or non-soluble (UV) DNA damaging agents 
modestly increased exosome release in three different cell lines (Panc1, T3M4, 
HPNE), however none of the differences were statistically significant. (B) DNA 
damage induction did not change the size of exosomes released by cells, as 
measured by Nanosight NTA. (C) DNA damaging agents did not significantly increase 
exosomal DNA levels, with the exception of UV-damaged T3M4 cells, which showed 
a dramatic increase in exosomal DNA content after treatment, 
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Exosomes from cells treated with DNA damaging agents Elicit Paracrine DNA 
Damage Responses in Naïve Cells 
Exosomes from PDAC Cells with Induced Damage Activate DDR In Naïve Cells. 
 After establishing that treatment of cells with DNA damaging agents did not 
appreciably alter exosomal DNA content, with the exception of UV-treated T3M4 cells, 
we tested exosomes exosomes from identically treated cells for the ability to elicit a 
DNA damage response in naïve (untreated) cells. We chose to incubate naïve cells 
with exosomes from the two cancer cell lines, Panc1 and T3M4, that had been 
exposed either to a soluble (H2O2) or non-soluble (UV) DNA damaging agent. We 
tested four conditions, untreated negative control, exosomes from naïve (untreated) 
cells, treatment with exosomes from cells following DNA damage, and cells treated 
directly with the DNA damaging agent of choice (positive control). At the end of 
treatment, the cells were stained with EdU to visualize actively replicating cells in S-
Phase, when homologous repair of DNA double-strand breaks occurs,  and p-gH2AX 
as an indicator of DNA damage response. Nuclei were visualized with the DNA 
intercalating dye DAPI. We utilized non-malignant pancreatic epithelial cells HPDE as 
recipient cells, in order to partially recapitulate the balance between cancer cells as 
donors and normal stroma as recipients of exosomes in the tumor microenvironment. 
A schematic of the experimental design is shown in Figure 28. 
 Interestingly, when we incubated the treatment-naïve cells with exosomes from 
the cancer cells exposed to DNA damage, we saw a significant upregulation in p-
gH2AX signal, suggestive of DNA damage response. We did not observe a significant  
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Figure 28. Schematic of DNA damage response experimental design. 
 
 
 
 
 
 
Figure 29. Exosomes from damaged cancer cells generate activated DDR in 
treatment-naïve recipient cells. 
(A) Staining images of HPDE cells. conditions are untreated negative control, 
incubated with exosomes from undamaged Panc1 cells, exosomes from H2O2-
damaged Panc1 cells, and positive control H2O2 treatment. DNA damage is indicated 
by the red p-gH2AX-positive cells, while replicating cells are the green EdU-positive 
cells. (B) Same as A but with T3M4 exosomes. (C) Same as A but with UV as the 
damaging agent. (D) Same as B but with UV as the damaging agent. Scale bar 20µm. 
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increase in the cells incubated with exosomes from undamaged cancer cells (Figure 
29A-D). To further analyze this phenomenon, we generated a dose-response by  
testing increasing concentrations of exosomes for the treatment of naïve cells (2 
billion, 10 billion, or 50 billion per condition).We observed a dose-dependent increase 
in cells positive for p-gH2AX with increasing exosome concentration, demonstrating 
that the induction of DDR in the recipient cells was exosome mediated (Figure 30A-
D). The increase in DDR activation signal was observed with exosomes from both 
Panc1 and T3M4 cells of origin, treated with either H2O2 or UV. 
Exosomes from Non-Malignant Cell Lines subjected to DNA Damage Do Not Activate 
DDR in Naïve Cells 
 Next, we wanted to investigate whether the induction of paracrine DDR 
activation was specific to exosomes from cancer cells. We induced DNA damage 
using the UV and H2O2 in two non-malignant cell lines, BJ fibroblasts and HPNE 
pancreatic epithelial cells. Exosomes were isolated and experiments performed 
following the same experimental design as above, and we assessed DNA damage 
activation in the same recipient HPDE cells by percentage of p-gH2AX positive cells. 
Strikingly, we saw that the exosomes from non-malignant cells failed to induce 
paracrine DDR in the naïve recipient cells, despite the exposure of the exosome donor 
cells to DNA damaging agents that were shown to induce DDR (p-gH2AX positivity) in 
positive control cells (Figure 31). This effect was even more apparent when dose 
response was evaluated and no induction of paracrine DDR was observed with up to 
5x1010 exosomes (Figure 32 A-D).  
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Figure 30. Exosomes from damaged cancer cells increases activation of DDR in 
recipient cells. 
(A) Dose response of HPDE cells to exosomes from Panc1 treated with H2O2. 
Between 2 and 50 billion exosomes were used. Data are expressed as % p-gH2AX 
positive cells (a marker of DDR activation). There was no significant increase in DDR 
activation when HPDE cells were incubated with 10 billion exosomes from untreated 
cells. HPDE cells treated directly with H2O2 were used as a positive control. (B) 
Identical experiment was performed using exosomes from Panc-1 cells treated with 
UV. Positive control – UV-irradiated HPDE cells. (C,D) Identical experiments were 
performed using T3M4 cells for exosome collection. 
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Exosomes from Treatment-Naïve Cells Do Not Induce DDR 
 We then sought to determine whether exosomes isolated from naïve cancer 
and non-malignant cells would induce a DDR if applied at higher concentrations. 
Exosomes were isolated from the same cell lines (Panc1, T3M4, BJ, HPNE), and used 
to treat HPDE recipient cells at increasing concentrations to assess potential dose 
response (Figure 33; 34A-D). However, we were unable to detect DDR induction 
upon treatment with exosomes from naïve cells, regardless of exosome  
number used. These findings suggest that the induction of the paracrine DDR was 
specific only to exosomes released by cancer cells undergoing genotoxic stress. 
 
 
 
 
 
 
Figure 31. Exosomes from non-tumorigenic cells do not induce paracrine DDR 
activation in recipient cells. 
Staining images of HPDE cells. conditions are untreated negative control, incubated 
with exosomes from undamaged non-tumorigenic HPNE cells, exosomes from H2O2-
damaged HPNE cells, and positive control H2O2 treatment. DNA damage is indicated 
by the red p-gH2AX-positive cells, while replicating cells are the green EdU-positive 
cells. No significant increase in DDR was observed in either of the exosome 
conditions. Scale bar 20µm. 
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Figure 32. Exosomes from damaged non-tumorigenic cells do not increase 
activation of DDR in recipient cells. 
(A) Dose response of HPDE recipient cells to exosomes from H2O2-treated HPNE 
cells, shown as % p-gH2AX positive cells. Note the lack of increase in DDR upon 
treatment and apparent increase in the positive control (H2O2). (B) Same as A, with 
UV as the DNA damaging agent. Positive control, UV-treated HPDE cells. (C, D) 
Experimental design as in A, B using BJ fibroblasts as the exosome donor cells. Scale 
bar 20µm 
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Exosome-induced DDR is independent of Recipient Cell Type 
 To this point, we had consistently utilized HPDE as the recipient cell line for 
exosome-induced DDR assessment. To determine if the effect was restricted to HPDE 
cells, we performed similar experiments using Panc1 cells as exosome recipients, to 
ascertain whether exosome-induced activated DDR could be elicited in cancer cells 
as well as non-tumorigenic epithelial cells. Additionally, we wanted to determine 
whether exosomes could induce a positive feedback loop by propagating DDR in  
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Figure 33. Exosomes from undamaged cells do not induce DDR. 
HPDE cells were incubated with increasing concentrations of untreated HPNE cell 
exosomes. No induction of DNA damage response was observed in the recipient cells 
regardless of exosome concentration (red signal, p-gH2AX positive cells). Similar 
results were seen regardless of exosome donor cell line. Scale bar 20µm. 
 
unaffected cells. We repeated the experimental strategies outlined above using naïve 
untreated Panc1 cells as exosome recipients with nearly identical results, wherein 
exosomes from cancer cells undergoing DNA damage had the capacity to propagate 
DDR in the naïve cells, while exosomes from naïve cancer cells and all non-
tumorigenic cells post-DNA damage did not induce a significant DDR response 
(Figure 35 A-C, 36A-L). 
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Figure 34. Exosomes from undamaged cells do not increase activation of DDR 
in recipient cells. 
(A) Dose response of HPDE recipient cells treated with Panc1 naïve cell exosomes, 
shown as % p-gH2AX positive cells. There was no significant increase in DDR 
activation by exosomes from naïve cells, even with high exosome numbers. H2O2-
treated HPDE cells were used as a positive control. (B-D) Identical experimental 
design was used to test exosomes from T3M4 (B), HPNE (C) and BJ cells (D), 
respectively. 
 
 143 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 144 
 
Figure 35 DDR activation experiments done with Panc1 recipient cells.  
(A) The same experimental strategies for HPDE recipient cells were employed. 
Consistent with the previous data, exosomes from damaged cancer cells are able to 
induce DDR in recipient cells. This panel shows the effect of exosomes isolated from 
Panc1 cells treated with H2O2. Interestingly, this also demonstrates that exosomes 
can induce DDR in cells that are the same type as their cell of origin. (B) Same 
approach as in A, but with T3M4 exosomes and UV as the damaging agent. (C) As 
demonstrated previously, exosomes from undamaged cells still could not generate 
DDR in recipient cells. Shown are Panc1 cells incubated with exosomes from 
untreated BJ fibroblasts in increasing concentrations. No significant induction of DDR 
was observed. Scale bar 20µm. 
 145 
 
 
 
 
 146 
 
 
Figure 36. Panc1 recipient cells behave similarly to HPDE recipient cells. 
(A) Panc1 recipient cells treated with H2O2-treated Panc1 exosomes (B) Panc1 
recipient cells treated with H2O2-T3M4 exosomes. (C) Panc-1 recipient cells treated 
with H2O2-treated HPNE exosomes (D) Panc1 recipient cells treated with H2O2-treated 
BJ exosomes. (E) Panc1 recipient cells treated with UV-treated Panc1 exosomes. (F) 
Panc1 recipient cells treated with UV-treated T3M4 exosomes. (G) Panc1 recipient 
cells treated with UV-treated HPNE exosomes. (H) Panc1 recipient cells treated with 
UV-treated BJ exosomes.  (I) Panc1 recipient cells treated with naive Panc1 
exosomes. (J) Panc1 recipient cells treated with naive T3M4 exosomes. (K) Panc1 
recipient cells treated with naive HPNE exosomes. (L) Panc1 recipient cells treated 
with naive BJ exosomes.  
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Exosome Treatment Does Not Damage the DNA of Recipient Cells 
 Next, we wanted to determine whether exosomes were somehow causing DNA 
breaks in the recipient cells, in an effort to determine whether the activated DDR was 
a result of physical DNA damage in the recipient cells or whether the activation 
occurred by some other mechanism. To indirectly assess double stranded DNA 
breaks (DSBs) we performed staining for the DNA repair protein RAD51, which 
localizes to the physical sites of DNA damage325. Thus, in the case of increased DNA 
damage by exosomes, we expected increased levels of RAD51 in the nuclei of 
exosome-treated recipient cells. However, we did not observe nuclear RAD51 
upregulation in any of the exosome-treated conditions (Figure 37). This result implies 
that recipient cell DNA is not being damaged by exosome treatment, however a major 
caveat is that RAD51 is involved in homologous repair, and is thus only detectable in 
S-phase cells. In order to clearly assess the integrity of the recipient cell DNA, 
additional experiments must be performed, such as Comet assays to assess 
fragmentation and identify single vs double strand DNA species.  
  Exosomes From Damaged Cancer Cells Contain Activated DDR Pathway Proteins 
 To  further investigate the potential mechanism by which exosomes from cells 
undergoing DNA damage propagate DDR, we proceeded to analyze exosome cargo. 
Since we observed that the exosome DNA content in most cases did not significantly 
change, it is unlikely that exosome DNA mediates the DDR transmission by 
exosomes, as was initially hypothesized. We therefore chose to examine exosome 
protein content, specifically proteins involved in the activation and propagation of 
DDR.   
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Figure 37. Exosomes do not cause DNA damage in recipient cells. 
HPDE recipient cells were incubated with Panc1 exosomes isolated from either naive, 
H2O2, or UV-treated cells. None of these generated an increase in RAD51 expression 
in recipient cells, suggesting no induction of DNA damage. 
 
There are several proteins involved in the sensing of DNA damage, as well as 
subsequent downstream activation of DDR mediators and effectors that dictate cell 
fate outcomes. We posited that, potentially, exosomes might be transferring activated 
DDR pathway proteins to recipient cells, allowing for horizontal activation in the 
recipient cells. We focused specifically on the proteins CHK1 and CHK2 downstream 
of the apical kinases ATR and ATM, respectively, in the DNA damage response 
pathway325. 
  CHK1 and CHK2 are 56 and 62 kDa proteins that could be easily packaged 
into exosomes. In the canonical DDR pathway, CHK1 and CHK2 are phosphorylated 
by ATR/ATM and recruit downstream effectors such as p53 and CDC25325. We 
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generated protein lysates from three cell lines (Panc1, T3M4, HPNE) under 3 different 
conditions (naïve, H2O2-treated, UV-treated), and performed Western blots for 
phosphorylated CHK2. Phospho-CHK2 was indeed present and upregulated in cells 
when DNA damage was induced (Figure 38A). Next, we probed for p-CHK2 in protein 
extracts from exosomes from the same cells, identically treated.  We observed that, 
highly consistent with the results of p-gH2AX staining, p-CHK2 was increased in the 
exosomes isolated from cells that underwent DNA damage, and was much higher in 
the exosomes from cancer cells compared to exosomes from non-malignant cells 
exposed to the DNA damaging agents (Figure 38B). Finally, we probed for p-CHK1, 
with similar results. Interestingly, however, p-CHK1 levels were relatively high in 
exosomes from naïve cancer cells (Figure 38C).  
Conclusion 
 This exciting data is the first reported evidence that exosomes carry activated 
DNA damage response proteins that could possibly have functional outcomes in 
recipient cells. While further analysis is required to better establish and characterize 
the shuttling of these proteins to recipient cells via exosomes, this is promising 
evidence of a potential mechanism of exosome-mediated paracrine DDR activation. 
A schematic of the proposed mechanism is shown in Figure 39. Interestingly, only 
exosomes from damaged malignant cells were able to induce DDR in recipient cells, 
which could be due to survival adaptations that are tumor specific. While further 
investigation is required to elucidate the exact mechanisms of exosome-mediated 
DDR activation, this data provides evidence that exosomes are important signaling 
vehicles in the tumor microenvironment.  
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Figure 38. Western Blots for p-CHK1 and p-CHK2 show the presence of 
activated DDR proteins in cancer cell exosomes with induced DNA damage. 
(A) Protein lysates from Panc1, T3M4, and HPNE cell lines untreated, H2O2 treated, 
or UV treated were indicated were run on polyacrylamide gels, transferred to PVDF 
membranes and proved with antibodies for phospho-CHK2. Phosphorylated CHK2 is 
present in cells and is upregulated upon DNA damage induction, as expected. (B) Blot 
for p-CHK2 using protein lysates isolated from the same cells treated with indicated 
agents, as in A. Phosphorylated CHK2 is present in exosomes and increased in those 
isolated from cancer cells undergoing DNA damage. (C) Blot for p-CHK1 using the 
same exosome lysates as in B. Phosphorylated CHK1 is also present in exosomes 
and increased in those isolated from damaged cancer cells. Interestingly, p-CHK1 was 
also highly expressed in undamaged cancer cell exosomes. 
 
 Figure 39. Working Model of Exosome DDR Activation. 
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Discussion 
Characterization of Exosomal DNA 
 Exosomes have been repeatedly demonstrated to have heterogeneous 
functions and cargo, implying potential roles for them in a variety of biological 
contexts202. While many of the molecules found in exosomes, such as proteins and 
RNA, have been extensively investigated, exosomal DNA has remained largely 
unexplored. Here, we sought to provide better characterization of exosomal DNA and 
establish groundwork for further study. 
 The canonical definition of exosomes is that they are heterogeneous vesicles 
surrounded by lipid bilayer, between 50-150nm in size, released from multi-vesicular 
bodies into the extracellular milieu, and eventually make their way into body fluids 
including blood, urine, saliva, etc40. True to the definition of heterogeneity, exosomes 
are broadly varied in terms of their DNA content, depending on their cell line of origin. 
Through the isolation of exosomal DNA from a large number of cell lines spanning a 
wide variety of malignant and non-malignant cell types, we were able to show that the 
amount of DNA packaged into exosomes changes on a cell-by-cell basis. This is an 
important consideration for the potential development of diagnostic tools based on 
exosomal DNA, as their potential utility would depend on how much DNA the cells 
/tissues of interest, such as tumors, package into their exosomes.  
Evaluation of Exosome Isolation Methods for DNA Collection 
Among the most controversial topics in the exosome field is identifying the best 
method of exosome isolation. As exosomes have grown in popularity in the research 
community, numerous isolation technologies, from affinity columns to precipitation 
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reagents, have been developed. Each method has distinct advantages and 
drawbacks, and ultimately the best technique likely depends on the desired 
downstream application. In the context of exosomal DNA, a recent study by Jeppesen 
et al218 utilized the method of ultracentrifugation in a buoyancy flotation iodixanol 
gradient (IG), yielding high purity exosome populations based on particle size and 
surface markers. However, these particles were devoid of DNA. We chose to 
investigate this method, as well as the two other most commonly used isolation 
techniques, size exclusion chromatography (SEC) and ultracentrifugation (UC), to 
provide a comprehensive evaluation of exosomal DNA and the effects of different 
isolation methods on the DNA yields and quality. We were able to definitively prove 
the presence of double-stranded DNA content  associated with exosomes isolated by 
each method, including IG. Additionally, we utilized DNase I treatment prior to 
exosome lysis to demonstrate that intravesicular DNA content is protected from 
DNase digestion by the lipid bilayer. Therefore, the DNase resistant DNA associated 
with exosomes is localized inside the exosome lumen. We employed multiple forms 
of characterization, including flow cytometry, western blotting for established exosome 
markers, and nanoparticle tracking analysis (NTA) to demonstrate the purity, integrity 
and identity of the exosomes.  
 Overall, while we showed that exosomal DNA is present in exosomes isolated 
by each method, not every method is was equally efficient in terms of the quality and 
quantity of exosomal DNA extracted. UC generated the largest amount of total DNA, 
however it was most susceptible to DNase treatment, showing that much of the DNA 
in UC exosome preparations is extravesicular. There were also other contaminants 
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present, such as cell-free DNA and protein. This is to be expected, as UC isolation is 
based on sedimentation by centrifugation forces and precipitates all material in a given 
sample. The optiPrep density gradient is designed to separate subfractions of 
exosomes by size, and indeed with the high number of ultracentrifugation washes 
involved this method yielded relatively pure populations. However, due to the multiple 
wash steps, the yields were surprisingly low, despite high input (number of flasks/cells 
used for exosome harvest). The quality of the DNA, as ascertained by chip 
electrophoresis, was generally much lower as well. It has been shown that high-speed 
ultracentrifugation can be damaging to exosome membranes235, and while the 
optiPrep itself may be a gentle mode of isolation, the four wash steps could serve to 
rupture and degrade exosomes and their contents, making this method less than ideal 
in terms of the yields of exosomes and luminal cargo for further applications. The best 
method for the isolation of exosomal DNA, at least among those tested by us, was 
size exclusion chromatography. Known to be a kinder method of obtaining exosomes, 
as it uses the force of gravity to pass samples through a gel-filtration resin, we saw 
the highest yields with the least susceptibility to DNase treatment. This coupled with 
the ease of isolation and minimal exosome loss pointed to SEC as the superior 
technique for collecting exosomal DNA.    
Exosomal DNA is Methylated 
Only two groups have previously shown the presence of methylation marks on 
exosomal DNA47,289. Additionally, neither went into much depth in terms of 
characterizing the scale of exosomal DNA methylation or testing whether exosome 
methylation patterns could readily and reproducibly provide insight into the epigenome 
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of the cells of origin, such as pro-tumorigenic methylation states. Here, we 
demonstrated conclusively that exosomal DNA is, in fact, methylated. We were able 
to successfully perform reduced representation bisulfite sequencing and characterize 
the methylome of both tumorigenic and non-tumorigenic human pancreatic cells. 
Furthermore, with only ~200ng of input DNA, we were able to evaluate each sample 
on an individual base-pair level. This allowed an investigation into site-specific 
promoter methylation patterns, which led us to identify matched differentially 
methylated sites in the exosomal and nuclear DNA from tumorigenic vs. non-
tumorigenic cells. This opens up the potential opportunity to utilize exosomal DNA 
methylation patterns as a complement to conventional mutation analysis for cancer 
diagnostics and monitoring. Since exosomes are readily isolated in the bodily fluids of 
patients, exosomal DNA mutations and methylation patterns could be utilized as a 
viable non-invasive method for liquid biopsy.     
Exosomal DNA Methylation Patterns Are Cell Line Specific 
 Using correlation analyses, we compared the methylation patterns obtained 
from exosomes isolated from different cell lines. Remarkably, the exosomal DNA not 
only almost fully recapitulated the methylation patterns of the cells of origin, but it could 
also be used to directly identify the cells of origin. Therefore, we indicate for the first 
time that exosomal DNA carries a distinct, cell-specific signature that can be readily 
detected for analysis and evaluation. This characteristic could prove invaluable for the 
early detection of diseases like cancer, which are often asymptomatic and difficult to 
detect in early stages. In preliminary work, we isolated DNA from matched tumor 
tissue and serum exosomes from PDAC patients for initial evaluation of the clinical 
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utility of exosomal DNA methylation for tumor detection. Thus far, we have been able 
to successfully perform whole genome methylation sequencing of the serum exosome 
DNA, and sequence analysis is ongoing.  
Exosome DNA Packaging 
 To date, there is no established mechanism for the packaging of DNA into 
exosomes. While several studies have suggested that factors such as increased DNA 
damage and fragmentation, as well as the genomic instability inherent to diseases 
such as cancer, could lead to more DNA becoming available to be sorted into 
exosomes276, no work has been done to specifically identify how DNA could escape 
the nucleus into the cytosol for subsequent incorporation into exosomes for 
extracellular release. Here, our initial findings indicate the potential importance of 
nuclear membrane integrity for the loading of exosomes into DNA. Upon successful 
knockdown of Lamins A and C, two major structural components of nuclear envelope, 
we observed a significant increase in exosomal DNA in three cell lines with different 
phenotypes.  
Thus, while further investigation is still needed, we propose that the disruption 
of nuclear envelope is a critical part of the mechanism of DNA transfer from the 
nucleus to multi-vesicular bodies. One of the major unanswered questions regarding 
DNA packaging into exosomes is how exosome DNA, cumulatively, can span the 
whole genome with no apparent biases. If nuclear envelope integrity is in fact critical 
for exosomal DNA packaging, then the nuclear breakdown during cell cycle 
progression may be the next critical area of investigation regarding the mechanism of 
DNA packaging into exosomes. An interesting potential experiment would involve cell 
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cycle arrest to synchronize cells, releasing them into S phase, and then damaging the 
DNA in a site-specific manner, using an agent such as cisplatin, to observe whether 
a parallel increase in site-specific DNA fragments are found in exosomes isolated from 
those cells. This would provide crucial information regarding the mechanism of 
exosomal DNA packaging and its potential relationship to nuclear envelope integrity, 
cell cycle progression, and DNA damage.  Understanding the mechanism of exosomal 
DNA packaging would provide critical insight that could be used to identify the best 
contexts in which exosomal DNA would have the highest diagnostic or prognostic 
utility, perhaps in some pathological or stress-induced states that would produce more 
DNA for isolation and analysis. Here, we provide a first step towards elucidating the 
mechanism of exosomal DNA packaging. 
Exosomes as DNA Damage Response Mediators 
 For many years, studies have shown that radiation treatment can induce 
bystander DNA damage responses (DDR) in treatment naïve cells309. While some 
molecular mediators, such as ROS326, have been implicated in these effects, the 
molecular mechanisms of bystander responses remain unclear. Here, we 
demonstrate that exosomes from cancer cells with induced DNA damage can activate 
DDR in treatment-naïve cells, thus serving to propagate cellular stress signals. It has 
been shown that several tumor types can influence the microenvironment with pro-
tumorigenic secretory signaling in times of cytotoxic stress327. We identify exosomes 
as a vehicle of intercellular communication, to transfer DNA damage stress responses 
between cancer cells and both malignant and non-malignant cells in the tumor 
microenvironment. Potentially, exosome-transmitted DDR can also be communicated 
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to peripheral organs, including myeloid cells of immune system, causing the formation 
of pre-metastatic niches or inducing pro-tumorigenic pathways. Indeed, it has been 
shown that genotoxic cancer treatments can activate DDR programs in naïve cells, 
leading to the generation of a pro-angiogenic, pro-inflammatory environments that are 
tumor permissive328. Thus, exosome-assisted transmission of DDR could cause 
enhanced treatment resistance, tumor growth, and metastasis. Identifying the 
mechanisms by which exosomes mediate DDR activation could provide opportunities 
for interventions to increase treatment efficacy, such as inhibiting exosome release 
during chemotherapy or radiation.  
Interestingly, non-malignant cells and undamaged cancer cells (not exposed to 
DNA damaging agents) were incapable of DDR initiation in naïve cells, suggesting 
that exosomes only acquire DDR-inducing cargo in cancer and DDR-specific contexts. 
One potential mechanism that we have begun to investigate is the presence of 
replication fork-protection defects in cancer cells that could lead to tumor-specific 
responses to DNA damage. This work was initiated in collaboration with 
Venkateswarlu Popuri, when we observed that only exosomes I generated from 
tumorigenic cell lines, not non-tumorigenic lines, could elicit DDR signaling in naïve 
cells. Additionally, non-tumorigenic cells may be more resistant to exosome uptake, 
which could also explain the lack of increased DDR activation in those cells, 
necessitating experiments with labeled exosomes to visualize whether exosomes 
preferentially localize within malignant cells. This evidence supports the hypothesis 
that cancer cells can utilize exosomes as a survival mechanism to enable treatment 
resistance by evading DNA damage related death or senescence.  
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Exosomes Carry Activated DNA Damage Response Pathway Proteins 
 While our group and others generated data that implicate exosomes in 
bystander DDR activation320,329, the mechanisms by which exosomes mediate these 
effects remain unknown. Here, we show for the first time that exosomes from cancer 
cells with induced DNA damage contain activated (phosphorylated) DDR pathway 
proteins, specifically CHK1 and CHK2. Up to this point, no other groups had observed 
the paracrine transfer of activated DDR proteins, which could potentially induce 
horizontal activation of the DDR cascade upon delivery to recipient cells. While this 
initial data is promising, additional experimental validation of these results is required, 
such as an assessment of total protein in comparison to phosphorylated protein alone, 
as well as densitometry measurements for more accurate quantification. Additionally, 
the levels of both total and phosphorylated protein need to be assessed in the recipient 
cells, to demonstrate the functional transfer of these proteins. Further clarification of 
the role of exosomes, specifically their cargo, in mediating DDR-inducing cancer cell 
signaling could help clarify their roles in tumor-promoting programs such as treatment 
resistance, enhanced growth, and survival. Manipulating exosome release or cargo 
sorting could negatively impact tumor-promoting responses in the microenvironment 
after genotoxic treatment, thus mitigating their protective effects and enhancing 
treatment efficacy.  
Future Directions 
The future indications for this work involve further investigation into molecular 
mechanisms of exosomal DNA packaging, exosome-transmitted DNA damage 
response, and clinical applications of exosomal DNA as a biomarker source. My 
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preliminary results suggest that exosomes could be used to assess the epigenetic 
status of patient tumors and thus identify additional therapeutic targets and predict 
treatment responsiveness. The primary short-term goal will be to continue to optimize 
exosome isolation and DNA extraction from patient samples, including serum and 
potentially other biofluids such as urine, to maximize DNA yield and quality for 
downstream analyses, like sequencing or methylation sequencing, for both genomic 
and epigenomic alterations. Subsequently, the development of a predictive biomarker 
assay for tumor types that are difficult to detect early, such as PDAC, could allow for 
patient-derived exosomal DNA sequencing data to inform early diagnostic capabilities. 
Further work is also required for elucidating the detailed molecular and 
biological mechanisms of exosome-mediated DDR activation. We would like to 
investigate the cancer-specific nature of exosome-mediated DDR induction by utilizing 
isogenic cell lines transformed with different oncogenes, such as Kras, to better 
characterize the DDR induction capabilities of exosomes from transformed vs non-
transformed cells. By performing a more detailed analysis of DDR pathway-related 
exosome cargo and identifying how cancer cells can co-opt exosomes for stress 
response signaling, potential targets for therapeutic intervention could be discovered. 
Work could include an assessment of the effects of inhibiting exosome release on 
DDR activation in naïve cells, or investigating whether cells with exosome-induced 
DDR become more resistant to therapy or death signaling. Much remains to be 
discovered regarding the roles of exosomes in patient treatment responses. 
Exosome biogenesis and function is still a nascent field of study, where 
relatively little is known regarding their physiological and pathological roles. Based on 
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recent work demonstrating the transfer of functional molecules, including DNA, to 
target cells via exosomes, there is considerable reason to believe that exosomes 
could mediate an even broader range of paracrine effects. Exosomes travel easily 
throughout the body and are released and taken up by all cell types, enabling their 
potential involvement in a variety of functions, including DNA damage response 
activation. Therefore, the future goals of this research will be to explore a potential 
role for exosomes in improving diagnostic capacities, as well as investigating their 
involvement in drug induced chemoresistance and tumor progression, all major 
barriers for current cancer treatment efficacy. This research provides the foundation 
for the advancement of therapeutic modalities using exosomes, as they can be easily 
detected, targeted, and manipulated.  
Conclusion 
 The main goal of this body of work was to gain more information about the 
origin, function, and utility of exosomal DNA. As I hope I have conveyed, exosomal 
DNA is packaged into exosomes in a cell type-specific manner and released into the 
extracellular environment, where it can subsequently be transferred to recipient cells 
or isolated for analysis. Exosome DNA has tremendous potential for therapy, both in 
cancer and other diseases, as a diagnostic and monitoring tool. As more information 
about exosomes is discovered, I believe that it is likely they will become important 
factors in many therapies and detection assays. It is a privilege to contribute my work 
to such an exciting and translationally relevant field of biology. 
   
 
 163 
Bibliography 
 
1.  Anderson HC. Vesicles associated with calcification in the matrix of epiphyseal 
cartilage. J Cell Biol. 1969;41(1):59-72. doi:10.1083/jcb.41.1.59 
2.  Bonucci E. Fine structure of early cartilage calcification. J Ultrasructure Res. 
1967;20(1-2):33-50. doi:10.1016/S0022-5320(67)80034-0 
3.  Wolf P. The nature and significance of platelet products in human plasma. Br J 
Haematol. 1967;13(3):269-288. doi:10.1111/j.1365-2141.1967.tb08741.x 
4.  Trams EG, Lauter CJ, Norman Salem J, Heine U. Exfoliation of membrane 
ecto-enzymes in the form of micro-vesicles. BBA - Biomembr. 1981;645(1):63-
70. doi:10.1016/0005-2736(81)90512-5 
5.  Harding Stahl, P. C. Transferrin Recycling in Reticulocytes: pH and Iron are 
Important Determinants of Ligand Binding and Processing. Biochem Biophys 
Res Commun. 1983;113(2):650-658. 
6.  Pan BT, Johnstone RM. Fate of the transferrin receptor during maturation of 
sheep reticulocytes in vitro: Selective externalization of the receptor. Cell. 
1983;33(3):967-978. doi:10.1016/0092-8674(83)90040-5 
7.  Théry, Clotilde, Regnault, Armelle Garin, Jérôme, Wolfers, Joseph, Zitvogel, 
Laurence, Ricciardi-Castagnoli, Paola, Raposo, Graça, Amigorena S. 
Molecular characterization of dendritic cell-derived exosomes: Selective 
accumulation of the heat shock protein hsc73. J Cell Biol. 1999;147(3):599-
610. doi:10.1083/jcb.147.3.599 
8.  G. Raposo, H. Nijman, W. Stoorvogel, R. Leijendekker, C. Harding, C. Melief 
 164 
HG. B Lymphocytes Secrete Antigen-presentingVesicles. J Exp Med. 
1996;183(March). 
9.  Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation 
during reticulocyte maturation. Association of plasma membrane activities with 
released vesicles (exosomes). J Biol Chem. 1987;262(19):9412-9420. 
10.  Faure J, Lachenal G, Court M, Hirrlinger J, Chatellard-Causse C, Blot B, 
Grange J, Schoehn G, Goldberg Y, Boyer V, Kirchhoff F, Raposo G, Garin J 
SR. Exosomes are released by cultured cortical neurones. Mol Cell Neurosci. 
2006;31(4):642-648. doi:10.1016/j.mcn.2005.12.003 
11.  Guescini M, Genedani S, Stocchi V, Agnati LF. Astrocytes and Glioblastoma 
cells release exosomes carrying mtDNA. J Neural Transm. 2010;117(1):1-4. 
doi:10.1007/s00702-009-0288-8 
12.  Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P RM. Embryonic 
stem cell-derived microvesicles reprogram hematopoietic progenitors: 
Evidence for horizontal transfer of mRNA and protein delivery. Leukemia. 
2006;20(5):847-856. doi:10.1038/sj.leu.2404132 
13.  Lai RC, Chen TS, Lim SK. Mesenchymal stem cell exosome: A novel stem 
cell-based therapy for cardiovascular disease. Regen Med. 2011;6(4):481-
492. doi:10.2217/rme.11.35 
14.  Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Curry WT, Carter BS, 
Krichevsky AM BX. Glioblastoma microvesicles transport RNA and proteins 
that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 
2008;10(12):1470-1476. doi:10.1038/ncb1800 
 165 
15.  Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak A. Endothelial expression 
of autocrine VEGF upon the uptake of tumor-derived microvesicles containing 
oncogenic EGFR. Proc Natl Acad Sci U S A. 2009;106(10):3794-3799. 
doi:10.1073/pnas.0804543106 
16.  Kalluri R. The biology and function of exosomes in cancer. J Clin Invest. 
2016;126:1208-1215. doi:10.1038/nrc.2016.73 
17.  Ellis TN, Kuehn MJ. Virulence and Immunomodulatory Roles of Bacterial 
Outer Membrane Vesicles. Microbiol Mol Biol Rev. 2010;74(1):81-94. 
doi:10.1128/mmbr.00031-09 
18.  Beveridge TJ. Structures of gram-negative cell walls and their derived 
membrane vesicles. J Bacteriol. 1999;181(16):4725-4733. 
19.  Caradec J, Kharmate G, Hosseini-Beheshti E, Adomat H, Gleave M, Guns E. 
Reproducibility and efficiency of serum-derived exosome extraction methods. 
Clin Biochem. 2014;47(13-14):1286-1292. 
doi:10.1016/j.clinbiochem.2014.06.011 
20.  Ashcroft BA, De Sonneville J, Yuana Y, Osanto S, Bertina R, Kuil ME OT. 
Determination of the size distribution of blood microparticles directly in plasma 
using atomic force microscopy and microfluidics. Biomed Microdevices. 
2012;14(4):641-649. doi:10.1007/s10544-012-9642-y 
21.  Dear JW, Street JM, Bailey MA. Urinary exosomes: A reservoir for biomarker 
discovery and potential mediators of intrarenal signalling. Proteomics. 
2013;13(10-11):1572-1580. doi:10.1002/pmic.201200285 
22.  Admyre C, Johansson SM, Qazi KR, Filén JJ, Lahesmaa R, Norman M, Neve 
 166 
EPA, Scheynius A GS. Exosomes with Immune Modulatory Features Are 
Present in Human Breast Milk. J Immunol. 2007;179(3):1969-1978. 
doi:10.4049/jimmunol.179.3.1969 
23.  Keller S, Ridinger J, Rupp AK, Janssen JWG, Altevogt P. Body fluid derived 
exosomes as a novel template for clinical diagnostics. J Transl Med. 2011;9:1-
9. doi:10.1186/1479-5876-9-86 
24.  C, Lässer, Seyed Alikhani V, Ekström K, Eldh M, Torregrosa Paredes P, 
Bossios A, Sjöstrand M, Gabrielsson S, Lötvall J VH. Human saliva, plasma 
and breast milk exosomes contain RNA: Uptake by macrophages. J Transl 
Med. 2011;9:1-8. doi:10.1186/1479-5876-9-9 
25.  Madison MN, Roller RJ, Okeoma CM. Human semen contains exosomes with 
potent anti-HIV-1 activity. Retrovirology. 2014;11(1). doi:10.1186/s12977-014-
0102-z 
26.  JM, Street, Barran PE, Mackay CL, Weidt S, Balmforth C, Walsh TS, 
Chalmers RTA, Webb DJ DJ. Identification and proteomic profiling of 
exosomes in human cerebrospinal fluid. J Transl Med. 2012;10(1):1-7. 
doi:10.1186/1479-5876-10-5 
27.  S, Gatti, Bruno S, Deregibus MC, Sordi, Cantaluppi V, Tetta C CG. 
Microvesicles derived from human adult mesenchymal stem cells protect 
against ischaemia-reperfusion-induced acute and chronic kidney injury. 
Nephrol Dial Transplant. 2011;26(5):1474-1483. doi:10.1093/ndt/gfr015 
28.  Lachenal G, Pernet-Gallay K, Chivet M, Hemming FJ, Belly A, Bodon G, Blot 
B, Haase G, Goldberg Y SR. Release of exosomes from differentiated 
 167 
neurons and its regulation by synaptic glutamatergic activity. Mol Cell 
Neurosci. 2011;46(2):409-418. doi:10.1016/j.mcn.2010.11.004 
29.  Kalluri R. The biology and function of Exosomes in cancer. J Clin Invest. 
2016;16(9):582-598. doi:10.1038/nrc.2016.73 
30.  Melo SA, Sugimoto H, O’Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, 
Vitkin E, Perelman LT, Melo CA, Lucci A, Ivan C, Calin GA KR. Cancer 
Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote 
Tumorigenesis. Cancer Cell. 2014;26(5):707-721. 
doi:10.1016/j.ccell.2014.09.005 
31.  Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, 
Hoshino A, Mark MT, Molina H, Xiang, J, Zhang T, Theilen TM, García-Santos 
G, Williams C, Ararso Y, Huang Y, Rodrigues G, Shen TL, Labori KJ, Lothe 
IMB, Kure EH, Hernandez J, Douss LD. Pancreatic cancer exosomes initiate 
pre-metastatic niche formation in the liver. Nat Cell Biol. 2015;17(6):816-826. 
doi:10.1038/ncb3169 
32.  Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno 
G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar CM, Nitadori-
Hoshino A, Hoffman C, Badal K, Garcia BA, Callahan MK, Yuan J, Martins 
VR, Skog J, Kaplan RN, Brady MS, Wolc LD. Melanoma exosomes educate 
bone marrow progenitor cells toward a pro-metastatic phenotype through 
MET. Nat Med. 2012;18(6):883-891. doi:10.1038/nm.2753 
33.  Mack M, Kleinschmidt A, Brühl H, Klier C, Nelson PJ, Cihak J, Plachý J, 
Stangassinger M, Erfle V SD. Transfer of the chemokine receptor CCR5 
 168 
between cells by membrane- derived microparticles: A mechanism for cellular 
human immunodeficiency virus 1 infection. Nat Med. 2000;6(7):769-775. 
doi:10.1038/77498 
34.  Bellingham SA, Guo BB, Coleman BM, Hill AF. Exosomes: Vehicles for the 
transfer of toxic proteins associated with neurodegenerative diseases? Front 
Physiol. 2012;3 MAY(May):1-12. doi:10.3389/fphys.2012.00124 
35.  Russo I, Bubacco L, Greggio E. Exosomes-associated neurodegeneration and 
progression of Parkinson’s disease. Am J Neurodegener Dis. 2012;1(3):217-
225. 
36.  Andreu Z, Yáñez-Mó M. Tetraspanins in extracellular vesicle formation and 
function. Front Immunol. 2014;5(SEP):1-12. doi:10.3389/fimmu.2014.00442 
37.  Pols MS, Klumperman J. Trafficking and function of the tetraspanin CD63. Exp 
Cell Res. 2009;315(9):1584-1592. doi:10.1016/j.yexcr.2008.09.020 
38.  Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, Geuze HJ. 
Selective enrichment of tetraspan proteins on the internal vesicles of 
multivesicular endosomes and on exosomes secreted by human B-
lymphocytes. J Biol Chem. 1998;273(32):20121-20127. 
doi:10.1074/jbc.273.32.20121 
39.  Bobrie A, Colombo M, Krumeich S, Raposo G, Théry C. Diverse 
subpopulations of vesicles secreted by different intracellular mechanisms are 
present in exosome preparations obtained by differential ultracentrifugation. J 
Extracell Vesicles. 2012;1(1). doi:10.3402/jev.v1i0.18397 
40.  Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and 
 169 
function. Nat Rev Immunol. 2002;2(8):569-579. doi:10.1038/nri855 
41.  El Andaloussi S, Mäger I, Breakefield XO, Wood MJA. Extracellular vesicles: 
Biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 
2013;12(5):347-357. doi:10.1038/nrd3978 
42.  Lötvall J, Hill AF, Hochberg F, Buzás EI, Vizio DD, Gardiner C, Gho YS, 
Kurochkin IV, Mathivanan S, Quesenberry P, Sahoo S, Tahara H, Wauben 
MH, Witwer KW TC. Minimal experimental requirements for definition of 
extracellular vesicles and their functions: A position statement from the 
International Society for Extracellular Vesicles. J Extracell Vesicles. 2014;3(1). 
doi:10.3402/jev.v3.26913 
43.  Raposo G, Stoorvogel W. Extracellular vesicles: Exosomes, microvesicles, 
and friends. J Cell Biol. 2013;200(4):373-383. doi:10.1083/jcb.201211138 
44.  Zaborowski MP, Balaj L, Breakefield XO, Lai CP. Extracellular Vesicles: 
Composition, Biological Relevance, and Methods of Study. Bioscience. 
2015;65(8):783-797. doi:10.1093/biosci/biv084 
45.  Shurtleff MJ, Yao J, Qin Y, Nottingham RM, Temoche-Diaz MM, Schekman R 
LA. Broad role for YBX1 in defining the small noncoding RNA composition of 
exosomes. Proc Natl Acad Sci U S A. 2017;114(43):E8987-E8995. 
doi:10.1073/pnas.1712108114 
46.  Kahlert C, Melo SA, Protopopov A, Tang J, Seth S, Koch O, Zhang J, Weitz J, 
Chin L, Futreal A KR. Identification of doublestranded genomic dna spanning 
all chromosomes with mutated KRAS and P53 DNA in the serum exosomes of 
patients with pancreatic cancer. J Biol Chem. 2014;289(7):3869-3875. 
 170 
doi:10.1074/jbc.C113.532267 
47.  Thakur BK, Zhang H, Becker A, Matei I, Huang Y, Costa-Silva B, Zheng Y, 
Hoshino A, Brazier H, Xiang J, Williams C, Rodriguez-Barrueco R, Silva JM, 
Zhang W, Hearn S, Elemento O, Paknejad N, Manova-Todorova K, Welte K, 
Bromberg J, Peinado H LD. Double-stranded DNA in exosomes: a novel 
biomarker in cancer detection. Cell Res. 2014;24(6):766-769. 
doi:10.1038/cr.2014.44 
48.  Lee TH, Chennakrishnaiah S, Audemard E, Montermini L, Meehan B, Rak J. 
Oncogenic ras-driven cancer cell vesiculation leads to emission of double-
stranded DNA capable of interacting with target cells. Biochem Biophys Res 
Commun. 2014;451(2):295-301. doi:10.1016/j.bbrc.2014.07.109 
49.  Balaj L, Lessard R, Dai L, Cho YJ, Pomeroy SL, Breakefield XO SJ. Tumour 
microvesicles contain retrotransposon elements and amplified oncogene 
sequences. Nat Commun. 2011. doi:10.1038/ncomms1180.Tumour 
50.  Colombo M, Raposo G, Théry C. Biogenesis, Secretion, and Intercellular 
Interactions of Exosomes and Other Extracellular Vesicles. Annu Rev Cell Dev 
Biol. 2014;30(1):255-289. doi:10.1146/annurev-cellbio-101512-122326 
51.  Kamerkar S, Lebleu VS, Sugimoto H, Yang S, Ruivo CF, Melo SA, Lee JJ KR. 
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic 
cancer. Nature. 2017;546(7659):498-503. doi:10.1038/nature22341 
52.  Kowal J, Tkach M, Théry C. Biogenesis and secretion of exosomes. Curr Opin 
Cell Biol. 2014;29(1):116-125. doi:10.1016/j.ceb.2014.05.004 
53.  Huotari J, Helenius A. Endosome maturation. EMBO J. 2011;30(17):3481-
 171 
3500. doi:10.1038/emboj.2011.286 
54.  Hanson PI, Cashikar A. Multivesicular Body Morphogenesis. Annu Rev Cell 
Dev Biol. 2012;28(1):337-362. doi:10.1146/annurev-cellbio-092910-154152 
55.  Colombo M, Moita C, van Niel G, Kowal J, Vigneron J, Benaroch P, Manel N, 
Moita LF, Théry C RG. Analysis of ESCRT functions in exosome biogenesis, 
composition and secretion highlights the heterogeneity of extracellular 
vesicles. J Cell Sci. 2013;126(Pt 24):5553-5565. doi:10.1242/jcs.128868 
56.  Stuffers S, Sem Wegner C, Stenmark H, Brech A. Multivesicular endosome 
biogenesis in the absence of ESCRTs. Traffic. 2009;10(7):925-937. 
doi:10.1111/j.1600-0854.2009.00920.x 
57.  Chairoungdua A, Smith DL, Pochard P, Hull M, Caplan MJ. Exosome release 
of β-catenin: A novel mechanism that antagonizes Wnt signaling. J Cell Biol. 
2010;190(6):1079-1091. doi:10.1083/jcb.201002049 
58.  Nazarenko I, Rana S, Baumann A, McAlear J, Hellwig A, Trendelenburg M, 
Lochnit G, Preissner KT ZM. Cell surface tetraspanin Tspan8 contributes to 
molecular pathways of exosome-induced endothelial cell activation. Cancer 
Res. 2010;70(4):1668-1678. doi:10.1158/0008-5472.CAN-09-2470 
59.  Hurwitz SN, Conlon MM, Rider MA, Brownstein NC, Meckes DG. Nanoparticle 
analysis sheds budding insights into genetic drivers of extracellular vesicle 
biogenesis. J Extracell Vesicles. 2016;5(1). doi:10.3402/jev.v5.31295 
60.  Zhu H, Guariglia S, Yu RYL, Li W, Brancho D, Peinado H, Lyden D, Salzer J, 
Bennett C CC. Mutation of SIMPLE in Charcot-Marie-Tooth 1C alters 
production of exosomes. Mol Biol Cell. 2013;24(11):1619-1637. 
 172 
doi:10.1091/mbc.E12-07-0544 
61.  McMahon HT, Boucrot E. Membrane curvature at a glance. J Cell Sci. 
2015;128(6):1065-1070. doi:10.1242/jcs.114454 
62.  Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, Schwille 
P, Brügger B SM. Ceramide triggers budding of exosome vesicles into 
multivesicular endosomes. Science. 2008;319(April):1244-1247. 
doi:10.1126/science.1153124 
63.  Ghossoub R, Lembo F, Rubio A, Gaillard CB, Bouchet J, Vitale N, Slavík J, 
Machala M ZP. Syntenin-ALIX exosome biogenesis and budding into 
multivesicular bodies are controlled by ARF6 and PLD2. Nat Commun. 
2014;5. doi:10.1038/ncomms4477 
64.  Alonso R, Mazzeo C, Rodriguez MC, Marsh M, Fraile-Ramos A, Calvo V, 
Avila-Flores A, Merida I IM. Diacylglycerol kinase α regulates the formation 
and polarisation of mature multivesicular bodies involved in the secretion of 
Fas ligand-containing exosomes in T lymphocytes. Cell Death Differ. 
2011;18(7):1161-1173. doi:10.1038/cdd.2010.184 
65.  Maas SLN, Breakefield XO, Weaver AM. Extracellular Vesicles: Unique 
Intercellular Delivery Vehicles. Trends Cell Biol. 2017;27(3):172-188. 
doi:10.1016/j.tcb.2016.11.003 
66.  Villarroya-Beltri C, Baixauli F, Mittelbrunn M, Fernández-Delgado I, Torralba 
D, Moreno-Gonzalo O, Baldanta S, Enrich C, Guerra S S-MF. ISGylation 
controls exosome secretion by promoting lysosomal degradation of MVB 
proteins. Nat Commun. 2016;7. doi:10.1038/ncomms13588 
 173 
67.  Hoshino D, Kirkbride KC, Costello K, Clark ES, Sinha S, Grega-Larson N, 
Tyska MJ WA. Exosome secretion is enhanced by invadopodia and drives 
invasive behavior. Cell Rep. 2013;5(5):1159-1168. 
doi:10.1016/j.celrep.2013.10.050 
68.  Sinha S, Hoshino D, Hong NH, Kirkbride KC, Grega-Larson NE, Seiki M, 
Tyska MJ WA. Cortactin promotes exosome secretion by controlling branched 
actin dynamics. J Cell Biol. 2016;214(2):197-213. doi:10.1083/jcb.201601025 
69.  Ostrowski M, Carmo NB, Krumeich S, Fanget I, Raposo G, Savina A, Moita 
CF, Schauer K, Hume AN, Freitas RP, Goud B, Benaroch P, Hacohen N, 
Fukuda M, Desnos C, Seabra MC, Darchen F, Amigorena S, Moita LF TC. 
Rab27a and Rab27b control different steps of the exosome secretion pathway. 
Nat Cell Biol. 2010;12(1):19-30. doi:10.1038/ncb2000 
70.  Bobrie A, Krumeich S, Reyal F, Recchi C, Moita LF, Seabra MC, Ostrowski M 
TC. Rab27a supports exosome-dependent and -independent mechanisms that 
modify the tumor microenvironment and can promote tumor progression. 
Cancer Res. 2012;72(19):4920-4930. doi:10.1158/0008-5472.CAN-12-0925 
71.  Loomis RJ, Holmes DA, Elms A, Solski PA, Der CJ, Su L. Citron kinase, a 
RhoA effector, enhances HIV-1 virion production by modulating exocytosis. 
Traffic. 2006;7(12):1643-1653. doi:10.1111/j.1600-0854.2006.00503.x 
72.  Koles K, Nunnari J, Korkut C, Barria R, Brewer C, Li Y, Leszyk J, Zhang B B 
V. Mechanism of evenness interrupted (Evi)-exosome release at synaptic 
boutons. J Biol Chem. 2012;287(20):16820-16834. 
doi:10.1074/jbc.M112.342667 
 174 
73.  Abrami L, Brandi L, Moayeri M, Brown MJ, Krantz BA, Leppla SH VF. 
Hijacking Multivesicular Bodies Enables Long-Term and Exosome-Mediated 
Long-Distance Action of Anthrax Toxin. Cell Rep. 2013;5(4):986-996. 
doi:10.1016/j.celrep.2013.10.019 
74.  Ostrowski M, Carmo NB, Krumeich S, Fanget I, Raposo G, Savina A, Moita 
CF, Schauer K, Hume AN, Freitas RP, Goud B, Benaroch P, Hacohen N, 
Fukuda M, Desnos C, Seabra MC, Darchen F, Amigorena S, Moita LF TC. 
Rab27a and Rab27b control different steps of the exosome secretion pathway. 
Nat Cell Biol. 2010;12(1):19-30. doi:10.1038/ncb2000 
75.  Pfeffer SR. Unsolved Mysteries in Membrane Traffic. Annu Rev Biochem. 
2007;76(1):629-645. doi:10.1146/annurev.biochem.76.061705.130002 
76.  Bonifacino JS, Glick BS. The Mechanisms of Vesicle Budding and Fusion. 
Cell. 2004;116(2):153-166. doi:10.1016/S0092-8674(03)01079-1 
77.  Grosshans BL, Ortiz D, Novick P. Rabs and their effectors: Achieving 
specificity in membrane traffic. Proc Natl Acad Sci U S A. 
2006;103(32):11821-11827. doi:10.1073/pnas.0601617103 
78.  Lehmann BD, Paine MS, Brooks AM, McCubrey JA, Renegar RH, Wang R 
TD. Senescence-associated exosome release from human prostate cancer 
cells. Cancer Res. 2008;68(19):7864-7871. doi:10.1158/0008-5472.CAN-07-
6538 
79.  Beer L, Zimmermann M, Mitterbauer A, Ellinger A, Gruber F, Narzt MS, Zellner 
M, Gyöngyösi M, Madlener S, Simader E, Gabriel C, Mildner M AH. Analysis 
of the secretome of apoptotic peripheral blood mononuclear cells: Impact of 
 175 
released proteins and exosomes for tissue regeneration. Sci Rep. 
2015;5(October):1-18. doi:10.1038/srep16662 
80.  Xiao X, Yu S, Li S, Wu J, Ma R, Cao H, Zhu Y FJ. Exosomes: Decreased 
sensitivity of lung cancer A549 cells to cisplatin. PLoS One. 2014;9(2):1-6. 
doi:10.1371/journal.pone.0089534 
81.  HW K, MZ M, JM G. Hypoxic enhancement of exosome release by breast 
cancer cells. BMC Cancer. 2012;12:421. http://dx.doi.org/10.1186/1471-2407-
12-421. 
82.  Hessvik NP, Llorente A. Current knowledge on exosome biogenesis and 
release. Cell Mol Life Sci. 2018;75(2):193-208. doi:10.1007/s00018-017-2595-
9 
83.  Fang Y, Wu N, Gan X, Yan W, Morrell JC, Gould SJ. Higher-order 
oligomerization targets plasma membrane proteins and HIV Gag to exosomes. 
PLoS Biol. 2007;5(6):1267-1283. doi:10.1371/journal.pbio.0050158 
84.  Pegtel DM, Gould SJ. Exosomes. Annu Rev Biochem. 2019:487-514. 
85.  Laulagnier K, Motta C, Hamdi S, Roy S, Fauvelle F, Pageaux JF, Kobayashi 
T, Salles JP, Perret B, Bonnerot C RM. Mast cell- and dendritic cell-derived 
display a specific lipid composition and an unusual membrane organization. 
Biochem J. 2004;380(1):161-171. doi:10.1042/BJ20031594 
86.  Llorente A, Skotland T, Sylvänne T, Kauhanen D, Róg T, Orłowski A, 
Vattulainen I, Ekroos K SK. Molecular lipidomics of exosomes released by PC-
3 prostate cancer cells. Biochim Biophys Acta - Mol Cell Biol Lipids. 
2013;1831(7):1302-1309. doi:10.1016/j.bbalip.2013.04.011 
 176 
87.  Fitzner D, Schnaars M, Van Rossum D, Krishnamoorthy G, Dibaj P, Bakhti M, 
Regen T, Hanisch UK SM. Selective transfer of exosomes from 
oligodendrocytes to microglia by macropinocytosis. J Cell Sci. 
2011;124(3):447-458. doi:10.1242/jcs.074088 
88.  Ridder K, Keller S, Dams M, Rupp AK, Schlaudraff J, Del Turco D, Starmann 
J, Macas J, Karpova D, Devraj K, Depboylu C, Landfried B, Arnold B, Plate 
KH, Höglinger G, Sültmann H, Altevogt P MS. Extracellular Vesicle-Mediated 
Transfer of Genetic Information between the Hematopoietic System and the 
Brain in Response to Inflammation. PLoS Biol. 2014;12(6). 
doi:10.1371/journal.pbio.1001874 
89.  Subra C, Grand D, Laulagnier K, Stella A, Lambeau G, Paillasse M, De 
Medina P, Monsarrat, B, Perret B, Silvente-Poirot S, Poirot M RM. Exosomes 
account for vesicle-mediated transcellular transport of activatable 
phospholipases and prostaglandins. J Lipid Res. 2010;51(8):2105-2120. 
doi:10.1194/jlr.M003657 
90.  Sano S, Izumi Y, Yamaguchi T, Yamazaki T, Tanaka M, Shiota M, Osada-Oka 
M, Nakamura Y, Wei M, Wanibuchi H, Iwao H YM. Lipid synthesis is promoted 
by hypoxic adipocyte-derived exosomes in 3T3-L1 cells. Biochem Biophys 
Res Commun. 2014;445(2):327-333. doi:10.1016/j.bbrc.2014.01.183 
91.  Zhao H, Yang L, Baddour J, Achreja A, Bernard V, Moss T, Marini JC, Tudawe 
T, Seviour EG, San Lucas FA, Alvarez H, Gupta S, Maiti SN, Cooper L, Peehl 
D, Ram PT, Maitra A ND. Tumor microenvironment derived exosomes 
pleiotropically modulate cancer cell metabolism. Elife. 
 177 
2016;5(FEBRUARY2016):1-27. doi:10.7554/eLife.10250 
92.  Cristina Escrevente, Sascha Keller, Peter Altevogt JC. Interaction and uptake 
of exosomes by ovarian cancer cells. BMC Cancer. 2011;11(108). 
doi:10.1016/j.bbrc.2014.12.015 
93.  Sinha A, Ignatchenko V, Ignatchenko A, Mejia-Guerrero S, Kislinger T. In-
depth proteomic analyses of ovarian cancer cell line exosomes reveals 
differential enrichment of functional categories compared to the NCI 60 
proteome. Biochem Biophys Res Commun. 2014;445(4):694-701. 
doi:10.1016/j.bbrc.2013.12.070 
94.  Théry C, Boussac M, Véron P, Ricciardi-Castagnoli P, Raposo G, Garin J AS. 
Proteomic Analysis of Dendritic Cell-Derived Exosomes: A Secreted 
Subcellular Compartment Distinct from Apoptotic Vesicles. J Immunol. 
2001;166(12):7309-7318. doi:10.4049/jimmunol.166.12.7309 
95.  Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A RJ. Intercellular 
transfer of the oncogenic receptor EGFRvIII by microvesicles derived from 
tumour cells. Nat Cell Biol. 2008;10(5):619-624. doi:10.1038/ncb1725 
96.  Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-
mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic 
exchange between cells. Nat Cell Biol. 2007;9(6):654-659. 
doi:10.1038/ncb1596 
97.  Bellingham SA, Coleman BM, Hill AF. Small RNA deep sequencing reveals a 
distinct miRNA signature released in exosomes from prion-infected neuronal 
cells. Nucleic Acids Res. 2012;40(21):10937-10949. doi:10.1093/nar/gks832 
 178 
98.  Huang X, Yuan T, Tschannen M, Sun Z, Jacob H, Du M, Liang M, Dittmar RL, 
Liu Y, Liang M, Kohli M, Thibodeau SN, Boardman L WL. Characterization of 
human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics. 
2013;14(1):1-14. doi:10.1186/1471-2164-14-319 
99.  Bolukbasi MF, Mizrak A, Ozdener GB, Madlener S, Ströbel T, Erkan EP, Fan 
JB, Breakefield XO SO. MiR-1289 and “zipcode”-like sequence enrich mRNAs 
in microvesicles. Mol Ther - Nucleic Acids. 2012;1(2):e10. 
doi:10.1038/mtna.2011.2 
100.  Villarroya-Beltri C, Gutiérrez-Vázquez C, Sánchez-Cabo F, Pérez-Hernández 
D, Vázquez J, Martin-Cofreces N, Martinez-Herrera DJ, Pascual-Montano A, 
Mittelbrunn M S-MF. Sumoylated hnRNPA2B1 controls the sorting of miRNAs 
into exosomes through binding to specific motifs. Nat Commun. 2013;4:1-10. 
doi:10.1038/ncomms3980 
101.  Koppers-Lalic D, Hackenberg M, Bijnsdorp IV, van Eijndhoven MAJ, Sadek P, 
Sie D, Zini N, Middeldorp JM, Ylstra B, de Menezes RX, Würdinger T, Meijer 
GA PD. Nontemplated nucleotide additions distinguish the small RNA 
composition in cells from exosomes. Cell Rep. 2014;8(6):1649-1658. 
doi:10.1016/j.celrep.2014.08.027 
102.  Lai CP, Kim EY, Badr CE, Weissleder R, Mempel TR, Tannous BA BX. 
Visualization and tracking of tumour extracellular vesicle delivery and RNA 
translation using multiplexed reporters. Nat Commun. 2015;6(May). 
doi:10.1038/ncomms8029 
103.  Mittelbrunn M, Gutiérrez-Vázquez C, Villarroya-Beltri C, González S, Sánchez-
 179 
Cabo F, González MA, Bernad A S-MF. Unidirectional transfer of microRNA-
loaded exosomes from T cells to antigen-presenting cells. Nat Commun. 
2011;2(1). doi:10.1038/ncomms1285 
104.  Redzic JS, Balaj L, van der Vos KE, Breakefield XO. Extracellular RNA 
mediates and marks cancer progression. Semin Cancer Biol. 2014;28:14-23. 
doi:10.1016/j.semcancer.2014.04.010 
105.  Lázaro-Ibáñez E, Sanz-Garcia A, Visakorpi T, Escobedo-Lucea C, Siljander P, 
Ayuso-Sacido A YM. Different gDNA content in the subpopulations of prostate 
cancer extracellular vesicles: Apoptotic bodies, microvesicles, and exosomes. 
Prostate. 2014;74(14):1379-1390. doi:10.1002/pros.22853 
106.  San Lucas FA, Allenson K, Bernard V, Castillo J, Kim DU, Ellis K, Ehli EA, 
Davies GE, Petersen JL, Li D, Wolff R, Katz M, Varadhachary G, Wistuba I, 
Maitra A AH. Minimally invasive genomic and transcriptomic profiling of 
visceral cancers by next-generation sequencing of circulating exosomes. Ann 
Oncol. 2016;27(4):635-641. doi:10.1093/annonc/mdv604 
107.  Svennerholm K, Rodsand P, Hellman U, Waldenström A, Lundholm M, Ahrén 
D, Biber B, Ronquist G HM. DNA content in extracellular vesicles isolated from 
porcine coronary venous blood directly after myocardial ischemic 
preconditioning. PLoS One. 2016;11(7):1-12. 
doi:10.1371/journal.pone.0159105 
108.  Takahashi A, Okada R, Nagao K, Kawamata Y, Hanyu A. Exosomes maintain 
cellular homeostasis by excreting harmful DNA from cells. Nat Commun. 
2017;8(May):1-14. doi:10.1038/ncomms15287 
 180 
109.  Kitai Y, Kawasaki T, Sueyoshi T, Kobiyama K, Ishii KJ, Zou J, Akira S, 
Matsuda T KT. DNA-Containing Exosomes Derived from Cancer Cells Treated 
with Topotecan Activate a STING-Dependent Pathway and Reinforce 
Antitumor Immunity. J Immunol. 2017:1601694. 
doi:10.4049/jimmunol.1601694 
110.  Cai J, Wu G, Jose PA, Zeng C. Functional transferred DNA within extracellular 
vesicles. Exp Cell Res. 2016;349(1):179-183. doi:10.1016/j.yexcr.2016.10.012 
111.  Cai J, Han Y, Ren H, Chen C, He D, Zhou L, Eisner GM, Asico LD, Jose PA 
ZC. Extracellular vesicle-mediated transfer of donor genomic DNA to recipient 
cells is a novel mechanism for genetic influence between cells. J Mol Cell Biol. 
2013;5(4):227-238. doi:10.1093/jmcb/mjt011 
112.  Fischer S, Cornils K, Speiseder T, Badbaran A, Reimer R, Indenbirken D, 
Grundhoff A, Brunswig-Spickenheier B, Alawi M LC. Indication of Horizontal 
DNA Gene Transfer by Extracellular Vesicles. PLoS One. 
2016;11(9):e0163665. doi:10.1371/journal.pone.0163665 
113.  Lian Q, Xu J, Yan S, Huang M, Ding H, Sun X, Bi A, Ding J, Sun B GM. 
Chemotherapy-induced intestinal inflammatory responses are mediated by 
exosome secretion of double-strand DNA via AIM2 inflammasome activation. 
Cell Res. 2017;27(6):784-800. doi:10.1038/cr.2017.54 
114.  Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-
Castagnoli P, Raposo G AS. Eradication of established murine tumors using a 
novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med. 
1998;4(5):594-600. 
 181 
http://www.ncbi.nlm.nih.gov/pubmed/9585234%0Ahttp://www.nature.com/natu
remedicine. 
115.  Ramachandra L, Qu Y, Wang Y, Lewis CJ, Cobb BA, Takatsu K, Boom WH, 
Dubyak GR HC. Mycobacterium tuberculosis synergizes with ATP to induce 
release of microvesicles and exosomes containing major histocompatibility 
complex class II molecules capable of antigen presentation. Infect Immun. 
2010;78(12):5116-5125. doi:10.1128/IAI.01089-09 
116.  Robbins PD, Morelli AE. Regulation of immune responses by extracellular 
vesicles. Nat Rev Immunol. 2014;14(3):195-208. doi:10.1038/nri3622 
117.  Okoye IS, Coomes SM, Pelly VS, Czieso S, Papayannopoulos V, Tolmachova 
T, Seabra MC WM. MicroRNA-Containing T-Regulatory-Cell-Derived 
Exosomes Suppress Pathogenic T Helper 1 Cells. Immunity. 2014;41(1):89-
103. doi:10.1016/j.immuni.2014.05.019 
118.  SL, Tung, Boardman DA, Sen M, Letizia M, Peng Q, Cianci N, Dioni L, Carlin 
LM, Lechler R, Bollati V, Lombardi G SL. Regulatory T cell-derived 
extracellular vesicles modify dendritic cell function. Sci Rep. 2018;8(1):1-12. 
doi:10.1038/s41598-018-24531-8 
119.  Phinney DG, Di Giuseppe M, Njah J, Sala E, Shiva S, St Croix CM, Stolz DB, 
Watkins SC, Di YP, Leikauf GD, Kolls J, Riches DWH, Deiuliis G, Kaminski N, 
Boregowda SV, McKenna DH OL. Mesenchymal stem cells use extracellular 
vesicles to outsource mitophagy and shuttle microRNAs. Nat Commun. 
2015;6. doi:10.1038/ncomms9472 
120.  Zhang Q, Fu L, Liang Y, Guo Z, Wang L, Ma C WH. Exosomes originating 
 182 
from MSCs stimulated with TGF-β and IFN-γ promote Treg differentiation. J 
Cell Physiol. 2018;233(9):6832-6840. doi:10.1002/jcp.26436 
121.  Choudhuri K, Llodrá J, Roth EW, Tsai J, Gordo S, Wucherpfennig KW, Kam 
LC, Stokes DL DM. Polarized release of T-cell-receptor-enriched 
microvesicles at the immunological synapse. Nature. 2014;507(7490):118-
123. doi:10.1038/nature12951 
122.  Chow A, Zhou W, Liu L, Fong MY, Champer J, Van Haute D, Chin AR, Ren X, 
Gugiu BG, Meng Z, Huang W, Ngo V, Kortylewski M WS. Macrophage 
immunomodulation by breast cancer-derived exosomes requires Toll-like 
receptor 2-mediated activation of NF-κ B. Sci Rep. 2014;4. 
doi:10.1038/srep05750 
123.  Wu L, Zhang X, Zhang B, Shi H, Yuan X, Sun Y, Pan Z, Qian H XW. 
Exosomes derived from gastric cancer cells activate NF-κB pathway in 
macrophages to promote cancer progression. Tumor Biol. 2016;37(9):12169-
12180. doi:10.1007/s13277-016-5071-5 
124.  Mitsuhashi S, Feldbrügge L, Csizmadia E, Mitsuhashi M, Robson SC, Moss 
AC. Luminal Extracellular Vesicles (EVs) in Inflammatory Bowel Disease (IBD) 
Exhibit Proinflammatory Effects on Epithelial Cells and Macrophages. Inflamm 
Bowel Dis. 2016;22(7):1587-1595. doi:10.1097/MIB.0000000000000840 
125.  Deng ZB, Poliakov A, Hardy RW, Clements R, Liu C, Liu Y, Wang J, Xiang X, 
Zhang S, Zhuang X, Shah SV, Sun D, Michalek S, Grizzle WE, Garvey T, 
Mobley J ZH. Adipose tissue exosome-like vesicles mediate activation of 
macrophage-induced insulin resistance. Diabetes. 2009;58(11):2498-2505. 
 183 
doi:10.2337/db09-0216 
126.  Ferrante SC, Nadler EP, Pillai DK, Hubal MJ, Wang Z, Wang JM, Gordish-
Dressman H, Koeck E, Sevilla S, Wiles A FR. Adipocyte-derived exosomal 
miRNAs: A novel mechanism for obesity-related disease. Pediatr Res. 
2015;77(3):447-454. doi:10.1038/pr.2014.202 
127.  Kato T, Miyaki S, Ishitobi H, Nakamura Y, Nakasa T, Lotz MK OM. Exosomes 
from IL-1β stimulated synovial fibroblasts induce osteoarthritic changes in 
articular chondrocytes. Arthritis Res Ther. 2014;16(4):1-11. 
doi:10.1186/ar4679 
128.  Gupta A, Pulliam L. Exosomes as mediators of neuroinflammation. J 
Neuroinflammation. 2014;11:1-10. doi:10.1186/1742-2094-11-68 
129.  Console L, Scalise M, Indiveri C. Exosomes in inflammation and role as 
biomarkers. Clin Chim Acta. 2019;488(July 2018):165-171. 
doi:10.1016/j.cca.2018.11.009 
130.  Atkin-Smith GK, Poon IKH. Disassembly of the Dying: Mechanisms and 
Functions. Trends Cell Biol. 2017;27(2):151-162. 
doi:10.1016/j.tcb.2016.08.011 
131.  Vallabhaneni KC, Hassler MY, Abraham A, Whitt J, Mo YY, Atfi A PR. 
Mesenchymal stem/stromal cells under stress increase osteosarcoma 
migration and apoptosis resistance via extracellular vesicle mediated 
communication. PLoS One. 2016;11(11):1-14. 
doi:10.1371/journal.pone.0166027 
132.  Chen L, Wang Y, Pan Y, Zhang L, Shen C, Qin G, Ashraf M, Weintraub N, Ma 
 184 
G TY. Cardiac progenitor-derived exosomes protect ischemic myocardium 
from acute ischemia/reperfusion injury. Biochem Biophys Res Commun. 
2013;431(3):566-571. doi:10.1016/j.bbrc.2013.01.015 
133.  Sabapatha A, Gercel-taylor C, Taylor DD. Specific isolation of placenta-
derived exosomes from the circulation of pregnant women and their 
immunoregulatory consequences. Am J Reprod Immunol. 2006;56(5-6):345-
355. doi:10.1111/j.1600-0897.2006.00435.x 
134.  Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P, Squarcina P, 
Accornero P, Lozupone F, Lugini L, Stringaro A, Molinari A, Arancia G, Gentile 
M, Parmiani G FS. Induction of lymphocyte apoptosis by tumor cell secretion 
of FasL-bearing microvesicles. J Exp Med. 2002;195(10):1303-1316. 
doi:10.1084/jem.20011624 
135.  Herrera MB, Fonsato V, Gatti S, Deregibus MC, Sordi A, Cantarella D, 
Calogero R, Bussolati B, Tetta C CG. Human liver stem cell-derived 
microvesicles accelerate hepatic regeneration in hepatectomized rats. J Cell 
Mol Med. 2010;14(6 B):1605-1618. doi:10.1111/j.1582-4934.2009.00860.x 
136.  S, Keller, König AK, Marmé F, Runz S, Wolterink S, Koensgen D, Mustea A, 
Sehouli J AP. Systemic presence and tumor-growth promoting effect of 
ovarian carcinoma released exosomes. Cancer Lett. 2009;278(1):73-81. 
doi:10.1016/j.canlet.2008.12.028 
137.  Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, 
Curry WT, Carter BS, Krichevsky AM BX. Glioblastoma microvesicles 
transport RNA and proteins that promote tumour growth and provide 
 185 
diagnostic biomarkers. Nat Cell Biol. 2008;10(12):1470-1476. 
doi:10.1038/ncb1800 
138.  Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, Wei J NG. A doxorubicin 
delivery platform using engineered natural membrane vesicle exosomes for 
targeted tumor therapy. Biomaterials. 2014;35(7):2383-2390. 
doi:10.1016/j.biomaterials.2013.11.083 
139.  Baj-Krzyworzeka M, Majka M, Pratico D, Ratajczak J, Vilaire G, Kijowski J, 
Reca R, Janowska-Wieczorek A RM. Platelet-derived microparticles stimulate 
proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp 
Hematol. 2002;30(5):450-459. doi:10.1016/S0301-472X(02)00791-9 
140.  Tan CY, Lai RC, Wong W, Dan YY, Lim SK, Ho HK. Mesenchymal stem cell-
derived exosomes promote hepatic regeneration in drug-induced liver injury 
models. Stem Cell Res Ther. 2014;5(3):1-14. doi:10.1186/scrt465 
141.  Adams RH, Alitalo K. Molecular regulation of angiogenesis and 
lymphangiogenesis. Nat Rev Mol Cell Biol. 2007;8(6):464-478. 
doi:10.1038/nrm2183 
142.  Kaur S, Chang T, Singh SP, Lim L, Mannan P, Garfield SH, Pendrak ML, 
Soto-Pantoja DR, Rosenberg AZ, Jin S RD. CD47 Signaling Regulates the 
Immunosuppressive Activity of VEGF in T Cells. J Immunol. 
2014;193(8):3914-3924. doi:10.4049/jimmunol.1303116 
143.  Atay S, Gercel-Taylor C, Suttles J, Mor G, Taylor DD. Trophoblast-derived 
exosomes mediate monocyte recruitment and differentiation. Am J Reprod 
Immunol. 2011;65(1):65-77. doi:10.1111/j.1600-0897.2010.00880.x 
 186 
144.  Sidhu SS, Mengistab AT, Tauscher AN, LaVail J, Basbaum C. The 
microvesicle as a vehicle for EMMPRin in tumor-stromal interactions. 
Oncogene. 2004;23(4):956-963. doi:10.1038/sj.onc.1207070 
145.  Zhang B, Wang M, Gong A, Zhang X, Wu X, Zhu Y, Shi H, Wu L, Zhu W, Qian 
H XW. HucMSc-exosome mediated-Wnt4 signaling is required for cutaneous 
wound healing. Stem Cells. 2015;33(7):2158-2168. doi:10.1002/stem.1771 
146.  Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 
2011. doi:10.1016/j.cell.2011.02.013 
147.  Hood JL, Pan H, Lanza GM, Wickline SA. Paracrine induction of endothelium 
by tumor exosomes. Lab Investig. 2009;89(11):1317-1328. 
doi:10.1038/labinvest.2009.94 
148.  P, Kucharzewska, Christianson HC, Welch JE, Svensson KJ, Fredlund E, 
Ringnér M, Mörgelin M, Bourseau-Guilmain E, Bengzon J BM. Exosomes 
reflect the hypoxic status of glioma cells and mediate hypoxia-dependent 
activation of vascular cells during tumor development. Proc Natl Acad Sci U S 
A. 2013;110(18):7312-7317. doi:10.1073/pnas.1220998110 
149.  Hood JL, San Roman S, Wickline SA. Exosomes released by melanoma cells 
prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 
2011;71(11):3792-3801. doi:10.1158/0008-5472.CAN-10-4455 
150.  Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, 
O’Connor STF, Chin AR, Yen Y, Wang Y, Marcusson EG, Chu P, Wu J, Wu X, 
Li AX, Li Z, Gao H, Ren X, Boldin MP, Lin PC WS. Cancer-Secreted miR-105 
destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 
 187 
2014;25(4):501-515. doi:10.1016/j.ccr.2014.03.007 
151.  Fidler IJ. The pathogenesis of cancer metastasis: the “seed and soil” 
hypothesis revisited. Nat Rev Cancer. 2003;3(6):453-458. 
doi:10.1038/nrc1098 
152.  Kucharzewska P, Belting M. Emerging roles of extracellular vesicles in the 
adaptative response of tumor cells to microenvironmental stress. J Extracell 
Vesicles. 2013;1:1-10. doi:10.3402/jev.v210.20304 
153.  Tomasetti M, Lee W, Santarelli L, Neuzil J. Exosome-derived microRNAs in 
cancer metabolism: Possible implications in cancer diagnostics and therapy. 
Exp Mol Med. 2017;49(1). doi:10.1038/emm.2016.153 
154.  Ortiz A, Gui J, Zahedi F, Yu P, Cho C, Bhattacharya S, Carbone CJ, Yu Q, 
Katlinski KV, Katlinskaya YV, Handa S, Haas V, Volk SW, Brice AK, Wals K, 
Matheson NJ, Antrobus R, Ludwig S, Whiteside TL, Sander C, Tarhini AA, 
Kirkwood JM, Lehner PJ, Guo W, Rui H, FS. An Interferon-Driven Oxysterol-
Based Defense against Tumor-Derived Extracellular Vesicles. Cancer Cell. 
2019;35(1):33-45.e6. doi:10.1016/j.ccell.2018.12.001 
155.  Zomer A, Maynard C, Verweij FJ, Kamermans A, Schäfer R, Beerling E, 
Schiffelers RM, De Wit E, Berenguer J, Ellenbroek SIJ, Wurdinger T, Pegtel 
DM VRJ. In vivo imaging reveals extracellular vesicle-mediated phenocopying 
of metastatic behavior. Cell. 2015;161(5):1046-1057. 
doi:10.1016/j.cell.2015.04.042 
156.  Lässer C. Identification and Analysis of Circulating Exosomal MicroRNA in 
Human Body Fluids. Vol 1024.; 2013. doi:10.1007/978-1-62703-453-1_9 
 188 
157.  Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes 
as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110(1):13-
21. doi:10.1016/j.ygyno.2008.04.033 
158.  Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu 
VS, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C, Pilarsky C, Fraga MF, 
Piwnica-Worms D KR. Glypican-1 identifies cancer exosomes and detects 
early pancreatic cancer. Nature. 2015;523(7559):177-182. 
doi:10.1038/nature14581 
159.  Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, 
Hoshino A, Mark MT, Molina H, Xiang, J, Zhang T, Theilen TM, García-Santos 
G, Williams C, Ararso Y, Huang Y, Rodrigues G, Shen TL, Labori KJ, Lothe 
IMB, Kure EH, Hernandez J, Douss LD. Pancreatic cancer exosomes initiate 
pre-metastatic niche formation in the liver. Nat Cell Biol. 2015;17(6):816-826. 
doi:10.1038/ncb3169 
160.  Tanaka Y, Kamohara H, Kinoshita K, Kurashige J, Ishimoto T, Iwatsuki M, 
Watanabe M BH. Clinical impact of serum exosomal microRNA-21 as a clinical 
biomarker in human esophageal squamous cell carcinoma. Cancer. 
2013;119(6):1159-1167. doi:10.1002/cncr.27895 
161.  Li Z, Ma YY, Wang J, Zeng XF, Li R, Kang W HX. Exosomal microRNA-141 is 
upregulated in the serum of prostate cancer patients. Onco Targets Ther. 
2015;9:139-148. doi:10.2147/OTT.S95565 
162.  Yang S, Che SPY, Kurywchak P, Tavormina JL, Gansmo LB, Correa de 
Sampaio P, Tachezy M, Bockhorn M, Gebauer F, Haltom AR, Melo SA, 
 189 
LeBleu VS KR. Detection of Mutant KRAS and TP53 DNA in Circulating 
Exosomes from Healthy Individuals and Patients with Pancreatic Cancer. 
Cancer Biol Ther. 2017;0(0):0-0. doi:10.1080/15384047.2017.1281499 
163.  André F, Schartz NEC, Chaput N, Flament C, Raposo G, Amigorena S, 
Angevin E ZL. Tumor-derived exosomes: A new source of tumor rejection 
antigens. Vaccine. 2002;20(SUPPL. 4):28-31. doi:10.1016/S0264-
410X(02)00384-5 
164.  Wolfers J, Lozier A, Raposo G, Regnault A, Théry C, Masurier C, Flament C, 
Pouzieux S, Faure F, Tursz T, Angevin E, Amigorena S ZL. Tumor-derived 
exosomes are a source of shared tumor rejection antigens for CTL cross-
priming. Nat Med. 2001;7(3):297-303. doi:10.1038/85438 
165.  Andre F, Schartz NEC, Movassagh M, Flament C, Pautier P, Morice P, Pomel 
C, Lhomme C, Escudier B, Le Chevalier T, Tursz T, Amigorena S, Raposo G, 
Angevin E ZL. Malignant effusions and immunogenic tumour-derived 
exosomes. Lancet. 2002;360(9329):295-305. doi:10.1016/S0140-
6736(02)09552-1 
166.  Lancaster GI, Febbraio MA. Exosome-dependent trafficking of HSP70: A novel 
secretory pathway for cellular stress proteins. J Biol Chem. 
2005;280(24):23349-23355. doi:10.1074/jbc.M502017200 
167.  Pucci F, Garris C, Lai CP, Newton A, Pfirschke C, Engblom C, Alvarez D, 
Sprachman M, Evavold C, Magnuson A, Von Andrian UH, Glatz K, Breakefield 
XO, Mempel TR, Weissleder R PM. SCS macrophages suppress melanoma 
by restricting tumor-derived vesicle-B cell interactions. Science (80- ). 
 190 
2016;352(6282):242-246. doi:10.1126/science.aaf1328 
168.  Yu S, Liu C, Su K, Wang J, Liu Y, Zhang L, Li C, Cong Y, Kimberly R, Grizzle 
WE FC, HG. Z. Tumor Exosomes Inhibit Differentiation of Bone Marrow 
Dendritic Cells. J Immunol. 2007;178(11):6867-6875. 
doi:10.4049/jimmunol.178.11.6867 
169.  Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z. Human Tumor-
Derived Exosomes Down-Modulate NKG2D Expression. J Immunol. 
2008;180(11):7249-7258. doi:10.4049/jimmunol.180.11.7249 
170.  Söderberg A, Barral AM, Söderström M, Sander B, Rosén A. Redox-signaling 
transmitted in trans to neighboring cells by melanoma-derived TNF-containing 
exosomes. Free Radic Biol Med. 2007;43(1):90-99. 
doi:10.1016/j.freeradbiomed.2007.03.026 
171.  Taylor DD, Gerçel-Taylor C. Tumour-derived exosomes and their role in 
cancer-associated T-cell signalling defects. Br J Cancer. 2005;92(2):305-311. 
doi:10.1038/sj.bjc.6602316 
172.  Clayton A, Mitchell JP, Court J, Mason MD, Tabi Z. Human tumor-derived 
exosomes selectively impair lymphocyte responses to interleukin-2. Cancer 
Res. 2007;67(15):7458-7466. doi:10.1158/0008-5472.CAN-06-3456 
173.  De Vrij J, Niek Maas SL, Kwappenberg KMC, Schnoor R, Kleijn A, Dekker L, 
Luider TM, De Witte LD, Litjens M, Van Strien ME, Hol EM, Kroonen J, Robe 
PA, Lamfers ML, Schilham MW BM. Glioblastoma-derived extracellular 
vesicles modify the phenotype of monocytic cells. Int J Cancer. 
2015;137(7):1630-1642. doi:10.1002/ijc.29521 
 191 
174.  Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, 
Shreeniwas R, Sutton MA, Delcayre A, Hsu DH, Le Pecq JB LH. A phase I 
study of dexosome immunotherapy in patients with advanced non-small cell 
lung cancer. J Transl Med. 2005;3:1-8. doi:10.1186/1479-5876-3-9 
175.  Umezu T, Ohyashiki K, Kuroda M, Ohyashiki JH. Leukemia cell to endothelial 
cell communication via exosomal miRNAs. Oncogene. 2013;32(22):2747-
2755. doi:10.1038/onc.2012.295 
176.  Park JE, Tan HS, Datta A, Lai RC, Zhang H, Meng W, Lim SK SS. Hypoxic 
tumor cell modulates its microenvironment to enhance angiogenic and 
metastatic potential by secretion of proteins and exosomes. Mol Cell 
Proteomics. 2010;9(6):1085-1099. doi:10.1074/mcp.M900381-MCP200 
177.  Hong BS, Cho JH, Kim H, Choi EJ, Rho S, Kim J, Kim JH, Choi DS, Kim YK 
HD, YS. G. Colorectal cancer cell-derived microvesicles are enriched in cell 
cycle-related mRNAs that promote proliferation of endothelial cells. BMC 
Genomics. 2009;10:1-13. doi:10.1186/1471-2164-10-556 
178.  Webber JP, Spary LK, Sanders AJ, Chowdhury R, Jiang WG, Steadman R, 
Wymant J, Jones AT, Kynaston H, Mason MD, Tabi Z CA. Differentiation of 
tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene. 
2015;34(3):319-333. doi:10.1038/onc.2013.560 
179.  Cho JA, Park H, Lim EH, Lee KW. Exosomes from breast cancer cells can 
convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like 
cells. Int J Oncol. 2012;40(1):130-138. doi:10.3892/ijo.2011.1193 
180.  Webber J, Steadman R, Mason MD, Tabi Z, Clayton A. Cancer exosomes 
 192 
trigger fibroblast to myofibroblast differentiation. Cancer Res. 
2010;70(23):9621-9630. doi:10.1158/0008-5472.CAN-10-1722 
181.  Hu Y, Yan C, Mu L, Huang K, Li X, Tao D, Wu Y QJ. Fibroblast-derived 
exosomes contribute to chemoresistance through priming cancer stem cells in 
colorectal cancer. PLoS One. 2015;10(5):1-17. 
doi:10.1371/journal.pone.0125625 
182.  Boelens MC, Wu TJ, Nabet BY, Xu B, Qiu Y, Yoon T, Azzam DJ, Twyman-
Saint Victor C, Wiemann BZ, Ishwaran H, Ter Brugge PJ, Jonkers J, 
Slingerland J MA. Exosome transfer from stromal to breast cancer cells 
regulates therapy resistance pathways. Cell. 2014;159(3):499-513. 
doi:10.1016/j.cell.2014.09.051 
183.  Mu W, Rana S, Zöller M. Host matrix modulation by tumor exosomes 
promotes motility and invasiveness. Neoplasia (United States). 
2013;15(8):875-887. doi:10.1593/neo.13786 
184.  Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark 
M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, 
Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang 
T, Zhang H, Hernandez J, Weiss JM, Dum LD. Tumour exosome integrins 
determine organotropic metastasis. Nature. 2015;527(7578):329-335. 
doi:10.1038/nature15756 
185.  Le MTN, Hamar P, Guo C, Basar E, Perdigão-Henriques R, Balaj L LJ. MiR-
200-containing extracellular vesicles promote breast cancer cell metastasis. J 
Clin Invest. 2014;124(12):5109-5128. doi:10.1172/JCI75695 LK - 
 193 
http://sfx.library.uu.nl/utrecht?sid=EMBASE&issn=15588238&id=doi:10.1172%
2FJCI75695&atitle=MiR-200-
containing+extracellular+vesicles+promote+breast+cancer+cell+metastasis&st
itle=J.+Clin.+Invest.&title=Journal+of+Clinical+Investigation&volume=124&iss
ue=12&spage=5109&epage=5128&aulast=Le&aufirst=Minh+T.+N.&auinit=M.
T.N.&aufull=Le+M.T.N.&coden=JCINA&isbn=&pages=5109-
5128&date=2014&auinit1=M&auinitm=T.N. 
186.  Luga V, Zhang L, Viloria-Petit AM, Ogunjimi AA, Inanlou MR, Chiu E, 
Buchanan M, Hosein AN, Basik M WJ. Exosomes mediate stromal 
mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. 
Cell. 2012;151(7):1542-1556. doi:10.1016/j.cell.2012.11.024 
187.  Sung BH, Ketova T, Hoshino D, Zijlstra A, Weaver AM. Directional cell 
movement through tissues is controlled by exosome secretion. Nat Commun. 
2015;6(May). doi:10.1038/ncomms8164 
188.  Aga M, Bentz GL, Raffa S, Torrisi MR, Kondo S, Wakisaka N, Yoshizaki T, 
Pagano JS SJ. Exosomal HIF1α supports invasive potential of 
nasopharyngeal carcinoma-associated LMP1-positive exosomes. Oncogene. 
2014;33(37):4613-4622. doi:10.1038/onc.2014.66 
189.  Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang WC, Li P, Li M, Wang 
X, Zhang C, Wang H, Ellis K, Cheerathodi M, McCarty JH, Palmieri D, Saunus 
J, Lakhani S, Huang S, Sahin AA, Aldape KD, Steeg PS YD. 
Microenvironment-induced PTEN loss by exosomal microRNA primes brain 
metastasis outgrowth. Nature. 2015;527(7576):100-104. 
 194 
doi:10.1038/nature15376 
190.  Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield 
XO WA. Prostate cancer-derived urine exosomes: A novel approach to 
biomarkers for prostate cancer. Br J Cancer. 2009;100(10):1603-1607. 
doi:10.1038/sj.bjc.6605058 
191.  Corcoran C, Friel AM, Duffy MJ, Crown J, O’Driscoll L. Intracellular and 
extracellular microRNAs in breast cancer. Clin Chem. 2011;57(1):18-32. 
doi:10.1373/clinchem.2010.150730 
192.  Li J, Sherman-Baust CA, Tsai-Turton M, Bristow RE, Roden RB, Morin PJ. 
Claudin-containing exosomes in the peripheral circulation of women with 
ovarian cancer. BMC Cancer. 2009;9:244. doi:10.1186/1471-2407-9-244 
193.  Logozzi M, De Milito A, Lugini L, Borghi M, Calabrò L, Spada M, Perdicchio M, 
Marino ML, Federici C, Iessi E, Brambilla D, Venturi G, Lozupone F, Santinami 
M, Huber V, Maio M, Rivoltini L FS. High levels of exosomes expressing CD63 
and caveolin-1 in plasma of melanoma patients. PLoS One. 2009;4(4). 
doi:10.1371/journal.pone.0005219 
194.  Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P SK. 
Alzheimer’s disease β-amyloid peptides are released in association with 
exosomes. Proc Natl Acad Sci U S A. 2006;103(30):11172-11177. 
doi:10.1073/pnas.0603838103 
195.  T, Tapiola, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H 
PT. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of 
Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66(3):382-
 195 
389. doi:10.1001/archneurol.2008.596 
196.  Sonoda H, Yokota-Ikeda N, Oshikawa S, Kanno Y, Yoshinaga K, Uchida K, 
Ueda Y, Kimiya K, Uezono S, Ueda A, Ito K IM. Decreased abundance of 
urinary exosomal aquaporin-1 in renal ischemia-reperfusion injury. Am J 
Physiol - Ren Physiol. 2009;297(4):1006-1016. 
doi:10.1152/ajprenal.00200.2009 
197.  Rood IM, Deegens, JKJ, Merchant ML, Tamboer WPM, Wilkey DW, Wetzels 
JFM KJ. Comparison of three methods for isolation of urinary microvesicles to 
identify biomarkers of nephrotic syndrome. Kidney Int. 2010;78(8):810-816. 
doi:10.1038/ki.2010.262 
198.  Zhou H, Pisitkun T, Aponte A, Yuen PST, Hoffert JD, Yasuda H, Hu X, Chawla 
L, Shen RF, Knepper MA SR. Exosomal Fetuin-A identified by proteomics: A 
novel urinary biomarker for detecting acute kidney injury. Kidney Int. 
2006;70(10):1847-1857. doi:10.1038/sj.ki.5001874 
199.  Toth B, Lok CAR, Böing A, Diamant M, Van Der Post JAM, Friese K NR. 
Microparticles and exosomes: Impact on normal and complicated pregnancy. 
Am J Reprod Immunol. 2007;58(5):389-402. doi:10.1111/j.1600-
0897.2007.00532.x 
200.  Kruh-Garcia NA, Wolfe LM, Chaisson LH, Worodria WO, Nahid P, Schorey JS, 
Davis JL DK. Detection of Mycobacterium tuberculosis peptides in the 
exosomes of patients with active and latent M. tuberculosis infection using 
MRM-MS. PLoS One. 2014;9(7):1-11. doi:10.1371/journal.pone.0103811 
201.  Vlassov A V., Magdaleno S, Setterquist R, Conrad R. Exosomes: Current 
 196 
knowledge of their composition, biological functions, and diagnostic and 
therapeutic potentials. Biochim Biophys Acta - Gen Subj. 2012;1820(7):940-
948. doi:10.1016/j.bbagen.2012.03.017 
202.  Gurunathan S, Kang M-H, Jeyaraj M, Qasim M, Kim J-H. Review of the 
Isolation, Characterization, Biological Function, and Multifarious Therapeutic 
Approaches of Exosomes. Cells. 2019;8(4):307. doi:10.3390/cells8040307 
203.  Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, 
Boireau W, Rouleau A, Simon B, Lanneau D, De Thonel A, Multhoff G, 
Hamman A, Martin F, Chauffert B, Solary E, Zitvogel L, Garrido C, Ryffel B, 
Borg C, Apetoh L, Rébé C GF. Membrane-associated Hsp72 from tumor-
derived exosomes mediates STAT3-dependent immunosuppressive function 
of mouse and human myeloid-derived suppressor cells. J Clin Invest. 
2010;120(2):457-471. doi:10.1172/JCI40483 
204.  Lima LG, Chammas R, Monteiro RQ, Moreira MEC, Barcinski MA. Tumor-
derived microvesicles modulate the establishment of metastatic melanoma in 
a phosphatidylserine-dependent manner. Cancer Lett. 2009;283(2):168-175. 
doi:10.1016/j.canlet.2009.03.041 
205.  Cai Z, Yang F YL, Yu, Zhou, Jiang L, Wang Q, Yang Y, Wang L, Cao X WJ. 
Activated T Cell Exosomes Promote Tumor Invasion via Fas Signaling 
Pathway. J Immunol. 2012;188(12):5954-5961. doi:10.4049/jimmunol.1103466 
206.  Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, 
Sun H, Xia H, Man Q, Zhong W, Antelo LF, Wu B, Xiong X, Liu X, Guan L, Li 
T, Liu S, Yang R, Lu Y, Dong L, McGettigan S, Somasundaram R, 
 197 
Radhakrishnan R, Mills G, Lu Y, Kim J, Chen YH, D GW. Exosomal PD-L1 
contributes to immunosuppression and is associated with anti-PD-1 response. 
Nature. 2018;560(7718):382-386. doi:10.1038/s41586-018-0392-8 
207.  Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, Montabana E, Lang UE, 
Fu Q, Fong L BR. Suppression of Exosomal PD-L1 Induces Systemic Anti-
tumor Immunity and Memory. Cell. 2019;177(2):414-427.e13. 
doi:10.1016/j.cell.2019.02.016 
208.  Biancone L, Bruno S, Deregibus MC, Tetta C, Camussi G. Therapeutic 
potential of mesenchymal stem cell-derived microvesicles. Nephrol Dial 
Transplant. 2012;27(8):3037-3042. doi:10.1093/ndt/gfs168 
209.  Bruno S, Grange C, Deregibus MC, Calogero RA, Saviozzi S, Collino F, 
Morando L, Busca A, Falda M, Bussolati B, Tetta C CG. Mesenchymal stem 
cell-derived microvesicles protect against acute tubular injury. J Am Soc 
Nephrol. 2009;20(5):1053-1067. doi:10.1681/ASN.2008070798 
210.  Lydia Alvarez-Erviti, Yiqi Seow, HaiFang Yin, Corinne Betts, Samira Lakhal 
MW. Delivery of sirNA to the mouse brain by systemic injection of targeted 
exosomes. Nat Biotechnol. 2011;29(4):341-347. doi:10.1038/nbt.1807 
211.  Thierry, Théry C, Amigorena S, Raposo G, Clayton A. Isolation and 
Characterization of Exosomes from Cell Culture Supernatants. Curr Protoc 
Cell Biol. 2006;Chapter 3:1-29. doi:10.1002/0471143030.cb0322s30 
212.  Peterson MF, Otoc N, Sethi JK, Gupta A, Antes TJ. Integrated systems for 
exosome investigation. Methods. 2015;87:31-45. 
doi:10.1016/j.ymeth.2015.04.015 
 198 
213.  Zeringer E, Barta T, Li M, Vlassov A V. Strategies for isolation of exosomes. 
Cold Spring Harb Protoc. 2015;2015(4):319-323. doi:10.1101/pdb.top074476 
214.  Li P, Kaslan M, Lee SH, Yao J, Gao Z. Progress in exosome isolation 
techniques. Theranostics. 2017;7(3):789-804. doi:10.7150/thno.18133 
215.  Witwer KW, Buzás EI, Bemis LT, Bora A, Lässer C, Lötvall J, Nolte-’t Hoen 
EN, Piper MG, Sivaraman S, Skog J, Théry C, Wauben MH HF. 
Standardization of sample collection, isolation and analysis methods in 
extracellular vesicle research. J Extracell Vesicles. 2013;2(1). 
doi:10.3402/jev.v2i0.20360 
216.  Van Deun J, Mestdagh P, Sormunen R, Cocquyt V, Vermaelen K, 
Vandesompele J, Bracke M, De Wever O HA. The impact of disparate 
isolation methods for extracellular vesicles on downstream RNA profiling. J 
Extracell Vesicles. 2014;3(1). doi:10.3402/jev.v3.24858 
217.  Sangiliyandi Gurunathan, Michel Marash, Adina Weinberger JEG. t-SNARE 
Phosphorylation Regulates Endocytosis in Yeast. Mol Biol Cell. 2002;13:1594-
1607. doi:10.1091/mbc.01 
218.  Jeppesen DK, Fenix AM, Franklin JL, Higginbotham JN, Zhang Q, Zimmerman 
LJ, Liebler DC, Ping J, Liu Q, Evans R, Fissell WH, Patton JG, Rome LH, 
Burnette DT CR. Reassessment of Exosome Composition. Cell. 
2019;177(2):428-445.e18. doi:10.1016/j.cell.2019.02.029 
219.  Alvarez ML, Khosroheidari M, Kanchi Ravi R, Distefano JK. Comparison of 
protein, microRNA, and mRNA yields using different methods of urinary 
exosome isolation for the discovery of kidney disease biomarkers. Kidney Int. 
 199 
2012;82(9):1024-1032. doi:10.1038/ki.2012.256 
220.  Quintana JF, Makepeace BL, Babayan SA, Ivens A, Pfarr KM, Blaxter M, 
Debrah A, Wanji S, Ngangyung HF, Bah GS, Tanya VN, Taylor DW, Hoerauf 
A BA. Extracellular Onchocerca-derived small RNAs in host nodules and 
blood. Parasites and Vectors. 2015;8(1):1-11. doi:10.1186/s13071-015-0656-1 
221.  Cheruvanky A, Zhou, Hua, Pisitkun T, Kopp JB, Knepper MA, Yuen PST SR. 
Rapid isolation of urinary exosomal biomarkers using a nanomembrane 
ultrafiltration concentrator. Am J Physiol - Ren Physiol. 2007;292(5):1657-
1661. doi:10.1152/ajprenal.00434.2006 
222.  Batrakova E V., Kim MS. Using exosomes, naturally-equipped nanocarriers, 
for drug delivery. J Control Release. 2015;219:396-405. 
doi:10.1016/j.jconrel.2015.07.030 
223.  Liga A, Vliegenthart ADB, Oosthuyzen W, Dear JW, Kersaudy-Kerhoas M. 
Exosome isolation: A microfluidic road-map. Lab Chip. 2015;15(11):2388-
2394. doi:10.1039/c5lc00240k 
224.  Xin H, Li Y, Buller B, Katakowski M, Zhang Y, Wang X, Shang X, Zhang ZG 
CM. Exosome-mediated transfer of miR-133b from multipotent mesenchymal 
stromal cells to neural cells contributes to neurite outgrowth. Stem Cells. 
2012;30(7):1556-1564. doi:10.1002/stem.1129 
225.  Kang D, Oh S, Ahn SM, Lee BH, Moon MH. Proteomic analysis of exosomes 
from human neural stem cells by flow field-flow fractionation and nanoflow 
liquid chromatography-tandem mass spectrometry. J Proteome Res. 
2008;7(8):3475-3480. doi:10.1021/pr800225z 
 200 
226.  Petersen KE, Manangon E, Hood JL, Wickline SA, Fernandez DP, Johnson 
WP GB. A review of exosome separation techniques and characterization of 
B16-F10 mouse melanoma exosomes with AF4-UV-MALS-DLS-TEM. Anal 
Bioanal Chem. 2014;406(30):7855-7866. doi:10.1007/s00216-014-8040-0 
227.  Zhang H, Freitas D, Kim HS, Fabijanic K, Li Z, Chen H, Mark MT, Molina H, 
Martin AB, Bojmar L, Fang J, Rampersaud S, Hoshino A, Matei I, Kenific CM, 
Nakajima M, Mutvei AP, Sansone P, Buehring W, Wang H, Jimenez JP, 
Cohen-gould L, Paknejad N, Brendel M, Ma CA. Identification of distinct 
nanoparticles and subsets of extracellular vesicles by asymmetric flow field-
flow fractionation. Nat Cell Biol. 2018;20(March). doi:10.1038/s41556-018-
0040-4 
228.  Zarovni N, Corrado A, Guazzi P, Zocco D, Lari E, Radano G, Muhhina J, 
Fondelli C, Gavrilova J CA. Integrated isolation and quantitative analysis of 
exosome shuttled proteins and nucleic acids using immunocapture 
approaches. Methods. 2015;87:46-58. doi:10.1016/j.ymeth.2015.05.028 
229.  Ueda K, Ishikawa N, Tatsuguchi A, Saichi N, Fujii R, Nakagawa H. Antibody-
coupled monolithic silica microtips for highthroughput molecular profiling of 
circulating exosomes. Sci Rep. 2014;4:1-9. doi:10.1038/srep06232 
230.  Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of 
extracellular circulating microRNA. Nucleic Acids Res. 2011;39(16):7223-
7233. doi:10.1093/nar/gkr254 
231.  Lee K, Shao H, Weissleder R, Lee H. Acoustic purification of extracellular 
microvesicles. ACS Nano. 2015;9(3):2321-2327. doi:10.1021/nn506538f 
 201 
232.  Yang F, Liao X, Tian Y, Li G. Exosome separation using microfluidic systems: 
size-based, immunoaffinity-based and dynamic methodologies. Biotechnol J. 
2017;12(4):1-9. doi:10.1002/biot.201600699 
233.  Chihchen Chen, Johan Skog, Chia-Hsien Hsu, Ryan T. Lessard, Leonora 
Balaj, Thomas Wurdinger, Bob S. Carter, Xandra O. Breakefield, Mehmet 
Toner DI. Microfluidic isolation and transcriptome analysis of serum 
microvesicles. Lab Chip. 2010;10(4):505-511. doi:10.1039/b916199f 
234.  Shailender Singh Kanwar, Christopher James Dunlay, Diane M. Simeone SN. 
Microfluidic device (ExoChip) for on-chip isolation, quantification and 
characterization of circulating exosomes. Lab Chip. 2013;15(207890):4491-
4498. doi:10.1039/c2lc41193h 
235.  Moralès O. Mini Review: Exosomes from Discovery to Isolation. Biomed J Sci 
Tech Res. 2019;15(2):11286-11293. doi:10.26717/bjstr.2019.15.002683 
236.  Dragovic RA, Gardiner C, Brooks AS, Tannetta DS, Ferguson DJP, Hole P, 
Carr B, Redman CWG, Harris AL, Dobson PJ, Harrison P SI. Sizing and 
phenotyping of cellular vesicles using Nanoparticle Tracking Analysis. 
Nanomedicine Nanotechnology, Biol Med. 2011;7(6):780-788. 
doi:10.1016/j.nano.2011.04.003 
237.  De Necochea-Campion R, Gonda A, Kabagwira J, Mirshahidi S, Cao H, 
Reeves ME WN. A practical approach to extracellular vesicle characterization 
among similar biological samples. Biomed Phys Eng Express. 2018;4(6). 
doi:10.1088/2057-1976/aad6d8 
238.  Szatanek R, Baj-Krzyworzeka M, Zimoch J, Lekka M, Siedlar M, Baran J. The 
 202 
methods of choice for extracellular vesicles (EVs) characterization. Int J Mol 
Sci. 2017;18(6). doi:10.3390/ijms18061153 
239.  Bryant G, Thomas JC. Improved Particle Size Distribution Measurements 
Using Multiangle Dynamic Light Scattering. Langmuir. 1995;11(7):2480-2485. 
doi:10.1021/la00007a028 
240.  Hoo CM, Starostin N, West P, Mecartney ML. A comparison of atomic force 
microscopy (AFM) and dynamic light scattering (DLS) methods to characterize 
nanoparticle size distributions. J Nanoparticle Res. 2008;10(SUPPL. 1):89-96. 
doi:10.1007/s11051-008-9435-7 
241.  Pospichalova V, Svoboda J, Dave Z, Kotrbova A, Kaiser K, Klemova D, 
Ilkovics L, Hampl A, Crha I, Jandakova E, Minar L, Weinberger V B V. 
Simplified protocol for flow cytometry analysis of fluorescently labeled 
exosomes and microvesicles using dedicated flow cytometer. J Extracell 
Vesicles. 2015;4(2015):1-15. doi:10.3402/jev.v4.25530 
242.  Suárez H, Gámez-Valero A, Reyes R, López-Martín S, Rodríguez MJ, 
Carrascosa JL, Cabañas C, Borràs FE Y-MM. A bead-assisted flow cytometry 
method for the semi-quantitative analysis of Extracellular Vesicles. Sci Rep. 
2017;7(1):1-11. doi:10.1038/s41598-017-11249-2 
243.  van der Vlist EJ, Nolte-’t Hoen ENM, Stoorvogel W, Arkesteijn GJA, Wauben 
MHM. Fluorescent labeling of nano-sized vesicles released by cells and 
subsequent quantitative and qualitative analysis by high-resolution flow 
cytometry. Nat Protoc. 2012;7(7):1311-1326. doi:10.1038/nprot.2012.065 
244.  Erdbrügger U, Rudy CK, E. Etter M, Dryden KA, Yeager M, Klibanov AL LJ. 
 203 
Imaging flow cytometry elucidates limitations of microparticle analysis by 
conventional flow cytometry. Cytom Part A. 2014;85(9):756-770. 
doi:10.1002/cyto.a.22494 
245.  Morales CP, Holt SE, Ouellette M, Kaur KJ, Yan Y, Wilson KS, White MA, 
Wright WE SJ. Absence of cancer-associated changes in human fibroblasts 
immortalized with telomerase. Nat Genet. 1999;21(1):115-118. 
doi:10.1038/5063 
246.  Tan MH, Nowak NJ, Loor R, Ochi H, Sandberg AA, Lopez C, Pickren JW, 
Berjian R, Douglass HO CT. Characterization of a new primary human 
pancreatic tumor line. Cancer Invest. 1986;4(1):15-23. 
doi:10.3109/07357908609039823 
247.  Brooks S, Locke E, Soule H. Estrogen receptor in a human cell line (MCF-7) 
from breast carcinoma. J Biol Chem. 1973;248(10):6251-6253. 
248.  Soule HD, Maloney TM, Wolman SR, Brenz R, McGrath CM, Russo J, Pauley 
R, Jones RF BS. Isolation and Characterization of a Spontaneously 
Immortalized Human Breast Epithelial Cell Line, MCF-10. Cancer Res. 
1990;50(18):6075-6086. 
249.  Young RK, Cailleau RM, Mackay B, Reeves WJ. Establishment of epithelial 
cell line MDA-MB-157 from metastatic pleural effusion of human breast 
carcinoma. In Vitro. 1974;9(4):239-245. doi:10.1007/BF02616069 
250.  Yunis AA, Arimura GK, Russin DJ. Human pancreatic carcinoma (mia paca-2) 
in continuous culture: Sensitivity to asparaginase. Int J Cancer. 
1977;19(1):128-135. doi:10.1002/ijc.2910190118 
 204 
251.  Hamilton TC, Young RC, McKoy WM., Grotzinger KR, Green JA, Chu EW, 
Whang-Peng J, Rogan AM, Green WR OR. Characterization of a Human 
Ovarian Carcinoma Cell Line (NIH:OVCAR-3) with Androgen and Estrogen 
Receptors. Cancer Res. 1983;43:5379-5389. doi:10.1002/1097-
0142(19890115)63:2<280::AID-CNCR2820630213>3.0.CO;2-N 
252.  Hamilton TC, Young RC, Louie KG, Behrens BC, McKoy WM, Grotzinger KR 
OR. Characterization of a xenograft model of human ovarian carcinoma which 
produces intraperitoneal carcinomatosis and metastases in mice. Int J Cancer. 
1984;44:5288-5290. doi:10.1002/(SICI)1097-0215(19961127)68:5<588::AID-
IJC6>3.0.CO;2-V 
253.  Lieber M, Mazzetta J, Nelson-rees W, Kaplan M, Todaro G. Establishment of a 
Continuous Tumor-Cell Line (Panc-1) from a Human Carcinoma of the 
Exocrine Pancreas. Int J Cancer. 1975;747:741-747. 
254.  Yamada H, Yoshida T, Sakamoto H, Terada M, Sugimura T. Establishment of 
a human pancreatic adenocarcinoma cell line (PSN-1) with amplifications of 
both c-myc and activated c-Ki-ras by a point mutation. Biochem Biophys Res 
Commun. 1986;140(1):167-173. doi:10.1016/0006-291X(86)91072-7 
255.  Leibovitz A, Stinson JC, McCombs WB, McCoy CE, Mazur KC, Mabry ND. 
Classification of Human Colorectal Adenocarcinoma Cell Lines. Cancer Res. 
1976;36(12):4562-4569. 
256.  Okabe T, Yamaguchi N, Ohsawa N. Establishment and characterization of a 
carcinoembryonic antigen (CEA)-producing cell line from a human carcinoma 
of the exocrine pancreas. Cancer. 1983;51(4):662-668. doi:10.1002/1097-
 205 
0142(19830215)51:4<662::AID-CNCR2820510419>3.0.CO;2-X 
257.  Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, 
Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N TT. Secondary 
mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. 
Nature. 2008;451(7182):1116-1120. doi:10.1038/nature06633 
258.  Tait L, Soule H, Russo J. Ultrastructural and Immunocytochemical 
Characterization of an Immortalized Human Breast Epithelial Cell Line, MCF-
10. Cancer Res. 1990:6087-6094. doi:10.1111/j.1365-2591.2006.01089.x 
259.  Fogh J, Fogh JM, Orfeo T. One hundred and twenty seven cultured human 
tumor cell lines producing tumors in nude mice. J Natl Cancer Inst. 
1977;59(1):221-226. doi:10.1093/jnci/59.1.221 
260.  Olive M, Untawale S, Coffey RJ, Siciliano MJ, Wildrick DM, Fritsche H, Pathak 
SEN, Cherry LM, Blick M LP, LD, Roubein, Levin B, Bruce A BM. 
Characterization of the DiFi Rectal carcinoma cell line derived from a familial 
adenomatous polyposis patient. Vitr Cell Dev Biol. 1993;(March):239-248. 
261.  Ramakrishnan S, Xu FJ, Brandt SJ, Niedel JE, Bast RC, Brown EL. 
Constitutive production of macrophage colony-stimulating factor by human 
ovarian and breast cancer cell lines. J Clin Invest. 1989;83(3):921-926. 
doi:10.1172/JCI113977 
262.  DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP. Analysis of 
mutation in human cells by using an Epstein-Barr virus shuttle system. Mol 
Cell Biol. 1987;7(1):379-387. doi:10.1128/mcb.7.1.379 
263.  Ryan MJ, Johnson G, Kirk J, Fuerstenberg SM, Zager RA, Torok-Storb B. HK-
 206 
2: An immortalized proximal tubule epithelial cell line from normal adult human 
kidney. Kidney Int. 1994;45(1):48-57. doi:10.1038/ki.1994.6 
264.  Ouyang H, Mou L, Luk C, Liu N, Karaskova J, Squire J. Immortal Human 
Pancreatic Duct Epithelial Cell Lines with Near Normal Genotype and 
Phenotype. Am J Pathol. 2000;157(5):1623-1631. doi:10.1016/S0002-
9440(10)64800-6 
265.  Lee KM, Nguyen C, Ulrich AB, Pour PM, Ouellette MM. Immortalization with 
telomerase of the Nestin-positive cells of the human pancreas. 
2003;301:1038-1044. doi:10.1016/S0006-291X(03)00086-X 
266.  Lee TH, Chennakrishnaiah S, Meehan B, Montermini L, Garnier D, D’Asti E, 
Hou W, Magnus N, Gayden T, Jabado N, Eppert K, Majewska L RJ. Barriers 
to horizontal cell transformation by extracellular vesicles containing oncogenic 
H-ras. Oncotarget. 2016;7(32):51991-52002. doi:10.18632/oncotarget.10627 
267.  Meissner A MT, Gu H, Wernig M, Hanna J, Sivachenko A, Zhang X, Bernstein 
BE, Nusbaum C, Jaffe DB, Gnirke A, Jaenisch R LE. Genome-scale DNA 
methylation maps of pluripotent and differentiated cells. Nature. 
2008;454(7205):766-770. doi:10.1038/nature07107 
268.  Gu H, Smith ZD, Bock C, Boyle P, Gnirke A, Meissner A. Preparation of 
reduced representation bisulfite sequencing libraries for genome-scale DNA 
methylation profiling. Nat Protoc. 2011;6(4):468-481. 
doi:10.1038/nprot.2010.190 
269.  Krueger F, Andrews SR. Bismark: A flexible aligner and methylation caller for 
Bisulfite-Seq applications. Bioinformatics. 2011;27(11):1571-1572. 
 207 
doi:10.1093/bioinformatics/btr167 
270.  Akalin A, Kormaksson M, Li S, Garrett-Bakelman FE, Figueroa ME, Melnick A 
MC. MethylKit: a comprehensive R package for the analysis of genome-wide 
DNA methylation profiles. Genome Biol. 2012;13(10). doi:10.1186/gb-2012-13-
10-R87 
271.  Jeltsch A, Rots M. Epigenome Editing.; 2018. 
272.  Guescini M, Guidolin D, Vallorani L, Casadei L, Gioacchini AM, Tibollo P, 
Battistelli M, Falcieri E, Battistin L, Agnati LF S V. C2C12 myoblasts release 
micro-vesicles containing mtDNA and proteins involved in signal transduction. 
Exp Cell Res. 2010;316(12):1977-1984. doi:10.1016/j.yexcr.2010.04.006 
273.  Sansone P, Savini C, Kurelac I, Chang Q, Amato LB, Strillacci A, Stepanova 
A, Iommarini L, Mastroleo C, Daly L, Galkin A, Thakur BK, Soplop N, Uryu K, 
Hoshinob A, Norton L, Bonafé M, Cricca M, Gasparre G, Lyden D BJ. 
Packaging and transfer of mitochondrial DNA via exosomes regulate escape 
from dormancy in hormonal therapy-resistant breast cancer. Proc Natl Acad 
Sci U S A. 2017;114(43):E9066-E9075. doi:10.1073/pnas.1704862114 
274.  Cai J, Han Y, Ren H, Chen C, He D, Zhou L, Eisner GM, Asico LD, Jose PA 
ZC. Extracellular vesicle-mediated transfer of donor genomic DNA to recipient 
cells is a novel mechanism for genetic influence between cells. J Mol Cell Biol. 
2013;(October):227-238. 
275.  Cai J, Wu G, Tan X, Han Y, Chen C, Li C, Wang N, Zou X, Chen X, Zhou F, 
He D, Zhou L, Jose PA ZC. Transferred BCR/ABL DNA from K562 
extracellular vesicles causes chronic myeloid leukemia in immunodeficient 
 208 
mice. PLoS One. 2014;9(8):1-11. doi:10.1371/journal.pone.0105200 
276.  Kalluri R, LeBleu VS. Discovery of Double-Stranded Genomic DNA in 
Circulating Exosomes. Cold Spring Harb Symp Quant Biol. 
2017;LXXXI:030932. doi:10.1101/sqb.2016.81.030932 
277.  Montermini L, Meehan B, Garnier D, Lee WJ, Lee TH, Guha A, Al-Nedawi K 
RJ. Inhibition of oncogenic epidermal growth factor receptor kinase triggers 
release of exosome-like extracellular vesicles and impacts their 
phosphoprotein and DNA content. J Biol Chem. 2015;290(40):24534-24546. 
doi:10.1074/jbc.M115.679217 
278.  Lázaro-Ibáñez E, Lässer C, Shelke GV, Crescitelli R, Jang SC, Cvjetkovic A, 
García-Rodríguez A LJ. DNA analysis of low- and high-density fractions 
defines heterogeneous subpopulations of small extracellular vesicles based on 
their DNA cargo and topology. J Extracell Vesicles. 2019;8(1):1656993. 
doi:10.1080/20013078.2019.1656993 
279.  Miranda KC, Bond DT, McKee M, Skog J, Punescu TG, Da Silva N, Brown D 
RL. Nucleic acids within urinary exosomes/microvesicles are potential 
biomarkers for renal disease. Kidney Int. 2010;78(2):191-199. 
doi:10.1038/ki.2010.106 
280.  Lobb R, Moller A. Size Exclusion Chromatography: A Simple and Reliable 
Method for Exosome Purification.; 2017. doi:10.1016/j.semcdb.2017.05.016 
281.  Tauro BJ, Greening DW, Mathias RA, Ji H, Mathivanan S, Scott AM SR. 
Comparison of ultracentrifugation, density gradient separation, and 
immunoaffinity capture methods for isolating human colon cancer cell line 
 209 
LIM1863-derived exosomes. Methods. 2012;56(2):293-304. 
doi:10.1016/j.ymeth.2012.01.002 
282.  Marsman G, Zeerleder S, Luken BM. Extracellular histones, cell-free DNA, or 
nucleosomes: Differences in immunostimulation. Cell Death Dis. 2016;7(12). 
doi:10.1038/cddis.2016.410 
283.  McKenzie AJ,, Hoshino D, Hong NH, Cha DJ, Franklin JL, Coffey RJ, Patton 
JG WA. KRAS-MEK Signaling Controls Ago2 Sorting into Exosomes. Cell 
Rep. 2016;15(5):978-987. doi:10.1016/j.celrep.2016.03.085 
284.  Tsai H-C, Baylin SB. Cancer epigenetics: linking basic biology to clinical 
medicine. Nat Publ Gr. 2011;2124(21):502-517. doi:10.1038/cr.2011.24 
285.  Berdasco M, Esteller M. Clinical epigenetics: seizing opportunities for 
translation. Nat Rev Genet. 2018. doi:10.1038/s41576-018-0074-2 
286.  Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock 
theory of ageing. Nat Rev Genet. 2018. doi:10.1038/s41576-018-0004-3 
287.  Feinberg AP, Koldobskiy MA, Göndör A. Epigenetic modulators, modifiers and 
mediators in cancer aetiology and progression. Nat Rev Genet. 
2016;17(5):284-299. doi:10.1038/nrg.2016.13 
288.  Bakhshandeh B, Kamaleddin MA, Aalishah K. A Comprehensive Review on 
Exosomes and Microvesicles as Epigenetic Factors. Curr Stem Cell Res Ther. 
2017;12(1):31-36. doi:10.2174/1574888X11666160709211 
289.  Yamamoto H, Watanabe Y, Oikawa R, Morita R. BARHL2 Methylation Using 
Gastric Wash DNA or Gastric Juice Exosomal DNA is a Useful Marker For 
Early Detection of Gastric Cancer in an H . pylori -Independent Manner. 
 210 
2016;7(7):e184-11. doi:10.1038/ctg.2016.40 
290.  Chen Y, Pal B, Visvader JE, Smyth GK, Hickey PF. Differential methylation 
analysis of reduced representation bisulfite sequencing experiments using 
edgeR [ version 1 ; referees : 2 approved , 1 approved with reservations ] 
Referee Status : 2017;(0). doi:10.12688/f1000research.13196.1 
291.  Gu H, Smith ZD, Bock C, Boyle P, Gnirke A, Meissner A. Preparation of 
reduced representation bisulfite sequencing libraries for genome-scale DNA 
methylation profiling. Nat Protoc. 2011;6(4):468-481. 
doi:10.1038/nprot.2010.190 
292.  Sato N, Goggins M. The role of epigenetic alterations in pancreatic cancer. J 
Hepatobiliary Pancreat Surg. 2006;13(4):286-295. doi:10.1007/s00534-005-
1057-1 
293.  Fukushima N, Walter KM, Uek T, Sato N, Matsubayashi H, Cameron JL, 
Hruban RH, Canto M, Yeo CJ GM. Diagnosing pancreatic cancer using 
methylation specific PCR analysis of pancreatic juice. Cancer Biol Ther. 
2003;2(1):78-83. doi:10.4161/cbt.183 
294.  Singh R, Lillard Jr J, Singh S. Epigenetic Changes and Potential Targets in 
Pancreatic Cancer.; 2016. doi:10.1007/978-3-319-24951-3 
295.  Matsubayashi H, Canto M, Sato N, Klein A, Abe T, Yamashita K, Yeo CJ, 
Kalloo A, Hruban R GM. DNA methylation alterations in the pancreatic juice of 
patients with suspected pancreatic disease. Cancer Res. 2006;66(2):1208-
1217. doi:10.1158/0008-5472.CAN-05-2664 
296.  Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, 
 211 
Moskaluk CA, Hahn SA, Schwarte-waldhoff I, Schmiegel W, Baylin SB, Kern 
SE HJ. Advances in Brief Abrogation of the Rb / p16 Tumor-suppressive 
Pathway in Virtually All Pancreatic Carcinomas ’. Cancer Res. 1997:3126-
3131. 
297.  Liggett T, Melnikov A, Yi Q, Replogle C, Brand R. Differential Methylation of 
Cell-Free Circulating DNA Among Patients With Pancreatic Cancer Versus 
Chronic Pancreatitis. 2010:1674-1680. doi:10.1002/cncr.24893 
298.  Roberts NJ, Norris AL, Petersen GM, Bondy ML, Brand R, Gallinger S, Kurtz 
RC, Olson SH, Rustgi AK, Schwartz AG, Stoffel E, Syngal S, Zogopoulos G, 
Ali SZ, Axilbund J, Chaffee KG, Chen YC, Cote ML, Childs EJ, Douville C, 
Goes FS, Herman JM, Iacobuzio-Donah PN, KW, Kinzler, Vogelstein B, 
Hruban RH KA. Whole Genome Sequencing Defines the Genetic 
Heterogeneity of Familial Pancreatic Cancer. Vol 6.; 2016. doi:10.1158/2159-
8290.CD-15-0402 
299.  Howell PM, Liu Z, Khong HT. Demethylating agents in the treatment of cancer. 
Pharmaceuticals. 2010;3(7):2022-2044. doi:10.3390/ph3072022 
300.  Gailhouste L, Liew LC, Hatada I, Nakagama H, Ochiya T. Epigenetic 
reprogramming using 5- azacytidine promotes an anti-cancer response in 
pancreatic adenocarcinoma cells. Cell Death Dis. 2018. doi:10.1038/s41419-
018-0487-z 
301.  Moss SF, Krivosheyev V, de Souza A, Chin K, Gaetz HP, Chaudhary N, 
Worman HJ HP. Decreased and aberrant nuclear lamin expression in 
gastrointestinal tract neoplasms. Gut. 1999;45(5):723-729. 
 212 
doi:10.1136/gut.45.5.723 
302.  Foster CR, Przyborski SA, Wilson RG, Hutchison CJ. Lamins as cancer 
biomarkers. Biochem Soc Trans. 2010;38(1):297-300. 
doi:10.1042/BST0380297 
303.  EJT, Belt, Fijneman RJA, Van Den Berg EG, Bril H, Delis-Van Diemen PM, 
Tijssen M, Van Essen HF, De Lange-De Klerk ESM, Beliën JAM, Stockmann 
HBAC, Meijer S MG. Loss of lamin A/C expression in stage II and III colon 
cancer is associated with disease recurrence. Eur J Cancer. 
2011;47(12):1837-1845. doi:10.1016/j.ejca.2011.04.025 
304.  Dittmer TA, Misteli T. The lamin protein family. Genome Biol. 2011;12(5):222. 
doi:10.1186/gb-2011-12-5-222 
305.  Peric-Hupkes D, van Steensel B. Role of the nuclear lamina in genome 
organization and gene expression. Cold Spring Harb Symp Quant Biol. 
2010;75:517-524. doi:10.1101/sqb.2010.75.014 
306.  Akter R, Rivas D, Geneau G, Drissi H, Duque G. Effect of Lamin A/C 
Knockdown on Osteoblast Differentiation and Function. J Bone Miner Res. 
2009;24(2). doi:10.1359/JBMR.081010 
307.  Tkach M, Th??ry C. Communication by Extracellular Vesicles: Where We Are 
and Where We Need to Go. Cell. 2016;164(6):1226-1232. 
doi:10.1016/j.cell.2016.01.043 
308.  De Toro J, Herschlik L, Waldner C, Mongini C. Emerging roles of exosomes in 
normal and pathological conditions: New insights for diagnosis and therapeutic 
applications. Front Immunol. 2015;6(MAY):1-12. 
 213 
doi:10.3389/fimmu.2015.00203 
309.  Malaquin N, Carrier-Leclerc A, Dessureault M, Rodier F. DDR-mediated 
crosstalk between DNA-damaged cells and their microenvironment. Front 
Genet. 2015;5(FEB):1-8. doi:10.3389/fgene.2015.00094 
310.  Little JB, Azzam EI, de Toledo SM, Nagasawa H. Bystander effects: 
Intercellular transmission of radiation damage signals. Radiat Prot Dosimetry. 
2002;99(1-4):159-162. doi:10.1093/oxfordjournals.rpd.a006751 
311.  Shao C, Prise KM, Folkard M. Signaling factors for irradiated glioma cells 
induced bystander responses in fibroblasts. Mutat Res - Fundam Mol Mech 
Mutagen. 2008;638(1-2):139-145. doi:10.1016/j.mrfmmm.2007.09.007 
312.  Marín A, Martín M, Liñán O, Alvarenga F, López M, Fernández L, Büchser D 
CL. Bystander effects and radiotherapy. Reports Pract Oncol Radiother. 
2015;20(1):12-21. doi:10.1016/j.rpor.2014.08.004 
313.  Narayanan PK, Goodwin EH, Lehnert BE. alpha Particles Initiate Biological 
Production of Superoxide Anions and Hydrogen Peroxide in Human Cells. 
Cancer Res. 1997;57(18):3963-3971. 
314.  Wang X, Zhang J, Fu J, Wang J, Ye S, Liu W SC. Role of ROS-mediated 
autophagy in radiation-induced bystander effect of hepatoma cells. Int J Radiat 
Biol. 2015;91(5):452-458. doi:10.3109/09553002.2015.1012308 
315.  Alexandre J, Hu Y, Lu W, Pelicano H, Huang P. Novel action of paclitaxel 
against cancer cells: Bystander effect mediated by reactive oxygen species. 
Cancer Res. 2007;67(8):3512-3517. doi:10.1158/0008-5472.CAN-06-3914 
316.  Arscott WT, Tandle AT, Zhao S, Shabason JE, Gordon IK, Schlaff CD, Zhang 
 214 
G, Tofilon PJ CK. Ionizing radiation and glioblastoma exosomes: implications 
in tumor biology and cell migration. Transl Oncol. 2013;6(6):638-648. 
doi:10.1593/tlo.13640 
317.  Jelonek K, Wojakowska A, Marczak L, Muer A, Tinhofer-Keilholz I, Lysek-
Gladysinska M, Widlak P PM. Ionizing radiation affects protein composition of 
exosomes secreted in vitro from head and neck squamous cell carcinoma. 
Acta Biochim Pol. 2015;62(2):265-272. doi:10.18388/abp.2015_970 
318.  Jelonek K, Widlak P, Pietrowska M. The Influence of Ionizing Radiation on 
Exosome Composition, Secretion and Intercellular Communication. Protein 
Pept Lett. 2016:656-663. http://www.ncbi.nlm.nih.gov/pubmed/27117741. 
319.  Kumar Jella K, Rani S, O’Driscoll L, McClean B, Byrne HJ, Lyng FM. 
Exosomes Are Involved in Mediating Radiation Induced Bystander Signaling in 
Human Keratinocyte Cells. Radiat Res. 2014;181(2):138-145. 
doi:10.1667/rr13337.1 
320.  Al-Mayah A, Bright S, Chapman K, Irons S, Luo P, Carter D, Goodwin E KM. 
The non-targeted effects of radiation are perpetuated by exosomes. Mutat Res 
- Fundam Mol Mech Mutagen. 2015;772:38-45. 
doi:10.1016/j.mrfmmm.2014.12.007 
321.  Jabbari N, Karimipour M, Khaksar M, Akbariazar E, Heidarzadeh M, Mojarad 
B, Aftab H, Rahbarghazi R RJ. Tumor-derived extracellular vesicles: insights 
into bystander effects of exosomes after irradiation. Lasers Med Sci. 2019. 
doi:10.1007/s10103-019-02880-8 
322.  Ward JF, Evans JW, Limoli CL, Calabro-Jones PM. Radiation and hydrogen 
 215 
peroxide induced free radical damage to DNA. Br J Cancer. 1987;55(SUPPL. 
8):105-112. 
323.  Roers A, Hiller B, Hornung V. Recognition of Endogenous Nucleic Acids by 
the Innate Immune System. Immunity. 2016;44(4):739-754. 
doi:10.1016/j.immuni.2016.04.002 
324.  De Leo MG, Staiano L, Vicinanza M, Luciani A, Carissimo A, Mutarelli M, Di 
Campli A, Polishchuk E, Di Tullio G, Morra V, Levtchenko E, Oltrabella F, 
Starborg T, Santoro M, di Bernardo D, Devuyst O, Lowe M, Medina DL, 
Ballabio A DMM. Autophagosome-lysosome fusion triggers a lysosomal 
response mediated by TLR9 and controlled by OCRL. Nat Cell Biol. 
2016;18(8):839-850. doi:10.1038/ncb3386 
325.  Jackson SP, Bartek J. The DNA-damage response in human biology and 
disease. Nature. 2009;461(7267):1071-1078. doi:10.1038/nature08467 
326.  Azzam EI, De Toledo SM, Little JB. Oxidative metabolism, gap junctions and 
the ionizing radiation-induced bystander effect. Oncogene. 2003;22:7050-
7057. doi:10.1038/sj.onc.1206961 
327.  Sigurdson AJ, Jones IM. Second cancers after radiotherapy: any evidence for 
radiation-induced genomic instability? Oncogene. 2003;22(45):7018-7027. 
doi:10.1038/sj.onc.1206989 
328.  Sun Y, Nelson PS. Molecular pathways: Involving microenvironment damage 
responses in cancer therapy resistance. Clin Cancer Res. 2012;18(15):4019-
4025. doi:10.1158/1078-0432.CCR-11-0768 
329.  Kitai Y, Kawasaki T, Sueyoshi T, Kobiyama K, Ishii KJ, Zou J, Akira S, 
 216 
Matsuda T KT. DNA-Containing Exosomes Derived from Cancer Cells Treated 
with Topotecan Activate a STING-Dependent Pathway and Reinforce 
Antitumor Immunity. J Immunol. 2017;198(4):1649-1659. 
doi:10.4049/jimmunol.1601694 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 217 
Vita 
 
Jena Leigh Tavormina was born in Houston, Texas, the daughter of Leslie Jean 
Rohrer and John William Tavormina. After completing her work at Lamar High 
School, Houston, Texas in 2008, she entered Brown University in Providence, 
Rhode Island. She received the degree Bachelor of Science with a concentration in 
Biology from Brown in May, 2012. For the next two years, she worked as a Study 
Coordinator in the Department of Ophthalmology at Boston Children’s Hospital, 
Harvard Medical School. In August of 2014 she entered the University of Texas MD 
Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences. 
 
Permanent Address: 
3060 Locke Lane 
Houston, Texas 77019 
